1 00:00:06,161 --> 00:00:07,829 WELCOME, EVERYONE. 2 00:00:07,829 --> 00:00:10,232 THIS IS THE AIDS RESEARCH 3 00:00:10,232 --> 00:00:12,200 ADVISORY COMMITTEE. 4 00:00:12,200 --> 00:00:12,467 MEETING. 5 00:00:12,467 --> 00:00:14,603 THANK YOU FOR ALL ATTENDING, 6 00:00:14,603 --> 00:00:17,472 INCLUDING THOSE OF YOU ONLINE. 7 00:00:17,472 --> 00:00:20,542 I'M ELAINE ABRAMS, THE CHAIR. 8 00:00:20,542 --> 00:00:24,346 AND WE'RE GOING TO START WITH 9 00:00:24,346 --> 00:00:27,215 APPROVAL OF THE MINUTES FROM THE 10 00:00:27,215 --> 00:00:30,685 JUNE 3RD MEETING. 11 00:00:30,685 --> 00:00:32,254 WHICH YOU SHOULD HAVE REVIEWED 12 00:00:32,254 --> 00:00:33,855 ONLINE. 13 00:00:33,855 --> 00:00:37,025 ANYONE HAVE ANY QUESTIONS OR 14 00:00:37,025 --> 00:00:42,197 COMMENTS ABOUT THE MINUTES? 15 00:00:42,197 --> 00:00:44,699 IF NOT, CAN I SEE A MOVE FOR 16 00:00:44,699 --> 00:00:50,805 APPROVAL? 17 00:00:50,805 --> 00:00:51,373 SECOND? 18 00:00:51,373 --> 00:00:52,574 ALL IN FAVOR? 19 00:00:52,574 --> 00:00:53,108 GREAT. 20 00:00:53,108 --> 00:00:55,510 SO NOW WE CAN GO ON TO THE 21 00:00:55,510 --> 00:00:57,712 IMPORTANT PART, AND THE 22 00:00:57,712 --> 00:01:00,248 DIRECTOR'S REPORT. 23 00:01:00,248 --> 00:01:01,650 >> THANK YOU, ELAINE. 24 00:01:01,650 --> 00:01:02,083 WELCOME, EVERYONE. 25 00:01:02,083 --> 00:01:03,418 IT'S A PLEASURE TO BE HERE WITH 26 00:01:03,418 --> 00:01:04,486 YOU TODAY. 27 00:01:04,486 --> 00:01:10,925 I'D LIKE TO START BY THANKING 28 00:01:10,925 --> 00:01:13,395 THE MEMBERS OF THE COMMITTEE WHO 29 00:01:13,395 --> 00:01:16,197 ARE ROTATING OFF. 30 00:01:16,197 --> 00:01:17,299 REUBEN, IT'S BEEN GREAT HAVING 31 00:01:17,299 --> 00:01:18,333 YOU ON THE COMMITTEE AND WE 32 00:01:18,333 --> 00:01:20,568 THANK YOU FOR YOUR SERVICE. 33 00:01:20,568 --> 00:01:22,337 WE HAVE A -- YOU'VE GOT IT. 34 00:01:22,337 --> 00:01:25,173 THAT'S GREAT. 35 00:01:25,173 --> 00:01:26,241 ADDITIONALLY, KEITH, WHO 36 00:01:26,241 --> 00:01:29,444 RECEIVED HIS PLAQUE FOR BEING A 37 00:01:29,444 --> 00:01:33,281 COUNCILMEMBER FROM JEANIEN 38 00:01:33,281 --> 00:01:34,249 PREVIOUS MEETING, THANK YOU FOR 39 00:01:34,249 --> 00:01:34,783 YOUR SERVICE. 40 00:01:34,783 --> 00:01:35,884 IT'S BEEN REALLY IMPORTANT TO 41 00:01:35,884 --> 00:01:40,021 HAVE THE TWO OF YOU ON THIS 42 00:01:40,021 --> 00:01:42,791 COMMITTEE THROUGH THIS PEER. 43 00:01:42,791 --> 00:01:43,091 PERIOD. 44 00:01:43,091 --> 00:01:44,326 THE SCIENCE THAT WE HAVE BEEN 45 00:01:44,326 --> 00:01:45,493 DEALING WITH HAS BEEN 46 00:01:45,493 --> 00:01:46,928 CHALLENGING, AND YOU DEFINITELY 47 00:01:46,928 --> 00:01:49,130 HELPED US MOVE IT FORWARD. 48 00:01:49,130 --> 00:01:53,368 I'D LIKE TO THANK THIS MOMENT TO 49 00:01:53,368 --> 00:01:57,439 WELCOME CESAR BOGGIANO AS THE 50 00:01:57,439 --> 00:01:58,406 NEW DIRECTOR OF THE VACCINE 51 00:01:58,406 --> 00:02:00,942 RESEARCH PROGRAM. 52 00:02:00,942 --> 00:02:04,112 CESAR HAS OVER 25 YEARS OF 53 00:02:04,112 --> 00:02:06,181 EXPERIENCE IN DRUG DISCOVERY, 54 00:02:06,181 --> 00:02:07,482 VACCINE KE SIGN AND EVALUATION 55 00:02:07,482 --> 00:02:09,150 OF VACCINE CANDIDATES THROUGH 56 00:02:09,150 --> 00:02:10,652 BOTH PRE-CLINICAL AND CLINICAL 57 00:02:10,652 --> 00:02:12,087 STAGES. 58 00:02:12,087 --> 00:02:14,689 CESAR HAD SERVED AS CHIEF OF THE 59 00:02:14,689 --> 00:02:17,659 RP'S PRE-CLINICAL BRANCH SINCE 60 00:02:17,659 --> 00:02:17,859 2020. 61 00:02:17,859 --> 00:02:21,062 PRIOR TO THAT, HE HAD DEDICATED 62 00:02:21,062 --> 00:02:22,063 MORE THAN SEVEN YEARS OF SERVICE 63 00:02:22,063 --> 00:02:25,667 AS A PROGRAM OFFICER IN THE 64 00:02:25,667 --> 00:02:27,168 VACCINE CLINICAL BRANCH. 65 00:02:27,168 --> 00:02:28,837 CESAR HAS A PROVEN TRACK RECORD 66 00:02:28,837 --> 00:02:32,006 OF SUCCESSFULLY LEADING AND 67 00:02:32,006 --> 00:02:33,308 BUILDING DIVERSE 68 00:02:33,308 --> 00:02:34,175 MULTIDISCIPLINARY RESEARCH 69 00:02:34,175 --> 00:02:36,478 PROJECTS, FOCUSED ON HIV/AIDS, 70 00:02:36,478 --> 00:02:39,447 TB AND COVID PREVENTION 71 00:02:39,447 --> 00:02:40,014 STRATEGIES. 72 00:02:40,014 --> 00:02:42,384 HIS COLLABORATIVE EFFORTS SPAN 73 00:02:42,384 --> 00:02:43,918 PARTNERSHIPS WITH NATIONAL AND 74 00:02:43,918 --> 00:02:45,120 INTERNATIONAL ACADEMIC 75 00:02:45,120 --> 00:02:47,422 INSTITUTIONS, BIOTECH, AND 76 00:02:47,422 --> 00:02:48,056 PHARMA. 77 00:02:48,056 --> 00:02:49,724 WE'RE CONFIDENT THAT UNDER HIS 78 00:02:49,724 --> 00:02:51,559 LEADERSHIP, VRP WILL CONTINUE TO 79 00:02:51,559 --> 00:02:53,194 THRIVE AND MAKE SIGNIFICANT 80 00:02:53,194 --> 00:02:54,195 ADVANCES IN THE FIELD. 81 00:02:54,195 --> 00:02:57,465 NO PRESSURE, CESAR. 82 00:02:57,465 --> 00:02:58,900 I WOULD ALSO LIKE TO TAKE A 83 00:02:58,900 --> 00:03:01,536 MOMENT TO DEEPLY THANK JIM LANE 84 00:03:01,536 --> 00:03:03,805 FOR HIS LEADERSHIP AS THE ACTING 85 00:03:03,805 --> 00:03:05,774 DIRECTOR OF VRP. 86 00:03:05,774 --> 00:03:07,976 JIM DID AN OUTSTANDING JOB IN 87 00:03:07,976 --> 00:03:12,680 EXCEL RAACCELERATING THE SCIENCP 88 00:03:12,680 --> 00:03:14,649 AND ALSO HELPING TO GUIDE US 89 00:03:14,649 --> 00:03:16,084 THROUGH SOME VERY CHALLENGING 90 00:03:16,084 --> 00:03:17,152 TIMES OVER THE LAST YEAR. 91 00:03:17,152 --> 00:03:25,693 SO THANK YOU, JIM. 92 00:03:25,693 --> 00:03:27,429 A DEAR FRIEND IS NOW RETIRING AT 93 00:03:27,429 --> 00:03:29,097 THE END OF THE MONTH. 94 00:03:29,097 --> 00:03:32,000 HE WAS RETIRING AFTER NEARLY 20 95 00:03:32,000 --> 00:03:33,368 YEARS AT NIAID. 96 00:03:33,368 --> 00:03:38,373 SO HE STARTED AS A CONTRACTOR AS 97 00:03:38,373 --> 00:03:39,707 THE DIVISION -- AND HE WAS A 98 00:03:39,707 --> 00:03:40,975 CONTRACTOR FOR ABOUT SIX MONTHS 99 00:03:40,975 --> 00:03:42,544 WHILE THEY GOT HIS PAPERWORK 100 00:03:42,544 --> 00:03:43,578 FINISHED. 101 00:03:43,578 --> 00:03:45,280 BUT HE STARTED AT THAT TIME AS 102 00:03:45,280 --> 00:03:49,517 WE WERE IN A VERY DIFFICULT TIME 103 00:03:49,517 --> 00:03:52,053 IN DAIDS WHERE WE HAD RUN A 104 00:03:52,053 --> 00:03:54,522 NETWORK RENEWAL, AND EVERYBODY 105 00:03:54,522 --> 00:03:56,658 WAS UP IN ARMS. 106 00:03:56,658 --> 00:03:59,627 WE HAD MADE SOME DRASTIC CHANGES 107 00:03:59,627 --> 00:04:01,996 INTO THE SITES WE WERE GOING TO 108 00:04:01,996 --> 00:04:04,532 SUPPORT, BASED ON PERFORMANCE, 109 00:04:04,532 --> 00:04:06,167 WHICH WAS A NEW CONCEPT AT THAT 110 00:04:06,167 --> 00:04:07,368 TIME. 111 00:04:07,368 --> 00:04:08,903 WE HAD A SERIES OF SITES THAT 112 00:04:08,903 --> 00:04:12,407 HAD NOT ENROLLED ANYBODY FOR TWO 113 00:04:12,407 --> 00:04:16,344 OR THREE YEARS, AND THEIR 114 00:04:16,344 --> 00:04:18,480 ATTITUDE WAS, I NEVER HAD TO 115 00:04:18,480 --> 00:04:19,747 HAVE ANY SORT OF METRIC BEFORE, 116 00:04:19,747 --> 00:04:21,149 WHY ARE YOU HOLDING ME TO THAT 117 00:04:21,149 --> 00:04:23,885 NOW? 118 00:04:23,885 --> 00:04:25,954 AND WE SPENT TIME IN SENATORS' 119 00:04:25,954 --> 00:04:27,288 OFFICES AND VISITED THE HILL, 120 00:04:27,288 --> 00:04:28,590 AND IT ALL WORKED OUT, BUT 121 00:04:28,590 --> 00:04:31,559 THROUGH THAT, WE FORMED A VERY 122 00:04:31,559 --> 00:04:32,193 STRONG BOND. 123 00:04:32,193 --> 00:04:34,496 THE OTHER PERSON WHO WAS PART OF 124 00:04:34,496 --> 00:04:39,200 THAT WAS JILL HARPER, WHO IS NOW 125 00:04:39,200 --> 00:04:41,236 THE HEAD OF ESSENTIALLY THE 126 00:04:41,236 --> 00:04:41,870 EXECUTIVE OFFICE OF THE 127 00:04:41,870 --> 00:04:42,136 INSTITUTE. 128 00:04:42,136 --> 00:04:44,105 AT THAT TIME SHE WAS OUR LEG 129 00:04:44,105 --> 00:04:44,339 PERSON. 130 00:04:44,339 --> 00:04:46,741 SO HE HAS REALLY PROVIDED 131 00:04:46,741 --> 00:04:50,044 LEADERSHIP THAT WE IN DAIDS 132 00:04:50,044 --> 00:04:54,716 DEEPLY APPRECIATED. 133 00:04:54,716 --> 00:04:57,685 HE'SLED NIAID THROUGH 134 00:04:57,685 --> 00:04:58,686 IMPLEMENTATION AND PLANNING 135 00:04:58,686 --> 00:05:00,054 ACTIVITIES AND HELPED TO REALLY 136 00:05:00,054 --> 00:05:02,490 BUILD STRATEGIC VISION FOR THE 137 00:05:02,490 --> 00:05:03,358 INSTITUTE. 138 00:05:03,358 --> 00:05:05,460 HIS DIFFERENT ROLES AS DEPUTY 139 00:05:05,460 --> 00:05:07,862 AND THEN AS ACTING DIRECTOR, HE 140 00:05:07,862 --> 00:05:09,264 HAS OVERSEEN THIS EXTENSIVE 141 00:05:09,264 --> 00:05:11,900 PORTFOLIO AND HELPED US AS AN 142 00:05:11,900 --> 00:05:17,038 INSTITUTE GROW FOR BIO-D, 143 00:05:17,038 --> 00:05:18,039 HIV/AIDS, INFECTIOUS DISEASES 144 00:05:18,039 --> 00:05:20,308 AND IMMUNE MEDIATED DISORDERS. 145 00:05:20,308 --> 00:05:21,976 THERE'S A PROCESS INTERNAL 146 00:05:21,976 --> 00:05:23,945 CALLED THE RIC THAT HE HAS 147 00:05:23,945 --> 00:05:26,014 CHAIRED FOR YEARS, AND IT HAS 148 00:05:26,014 --> 00:05:27,315 REALLY HELPED TO BRING THE 149 00:05:27,315 --> 00:05:29,617 DIVISIONS TOGETHER AND FOSTER 150 00:05:29,617 --> 00:05:30,285 COLLABORATION. 151 00:05:30,285 --> 00:05:34,222 IN HIS OWN GENTLE WAY, HE LEADS 152 00:05:34,222 --> 00:05:36,824 WITH HUMOR, HUMILITY, AND 153 00:05:36,824 --> 00:05:38,593 OCCASIONALLY HE PUTS HIS FOOT OR 154 00:05:38,593 --> 00:05:40,128 HIS KNEE IN YOUR BACK AND PUSHES 155 00:05:40,128 --> 00:05:41,329 REALLY HARD. 156 00:05:41,329 --> 00:05:44,098 SO HE KNOWS WHEN TO EXERCISE 157 00:05:44,098 --> 00:05:47,702 THAT LEVEL OF INFLUENCE. 158 00:05:47,702 --> 00:05:50,838 HE WILL BE MISSED. 159 00:05:50,838 --> 00:05:53,241 I'D ALSO LIKE TO ANNOUNCE THAT 160 00:05:53,241 --> 00:05:55,209 GERI DONENBERG HAS BEEN 161 00:05:55,209 --> 00:05:56,644 ANNOUNCED BY MONICA BERTAGNOLLI 162 00:05:56,644 --> 00:05:58,713 AS THE NEW DIRECTOR OF THE 163 00:05:58,713 --> 00:05:59,814 OFFICE OF AIDS RESEARCH. 164 00:05:59,814 --> 00:06:02,417 SHE WILL JOIN HIV IN OCTOBER AND 165 00:06:02,417 --> 00:06:03,985 LEAD IN THE ADVANCEMENT AND 166 00:06:03,985 --> 00:06:05,820 COORDINATION OF AIDS RESEARCH AT 167 00:06:05,820 --> 00:06:06,154 NIH. 168 00:06:06,154 --> 00:06:07,822 WE LOOK FORWARD TO WORKING WITH 169 00:06:07,822 --> 00:06:10,325 HER. 170 00:06:10,325 --> 00:06:13,828 DR. DONENBERG EARNED HER B. YOU. 171 00:06:13,828 --> 00:06:17,098 AND PSYCHOLOGY AND POLITICAL 172 00:06:17,098 --> 00:06:19,400 SCIENCE AT ANN ARBOR AND HER 173 00:06:19,400 --> 00:06:21,035 PH.D. MASTERS AND PH.D. IN 174 00:06:21,035 --> 00:06:22,437 PSYCHOLOGY AT UCLA. 175 00:06:22,437 --> 00:06:24,205 SHE COMPLETED A PSYCHOLOGY 176 00:06:24,205 --> 00:06:28,042 INTERNSHIP AT UCLA, AND ACTUALLY 177 00:06:28,042 --> 00:06:32,513 DID A FULBRIGHT, WHICH IS AN 178 00:06:32,513 --> 00:06:33,281 INTERESTING -- YOU DON'T SEE 179 00:06:33,281 --> 00:06:34,482 THOSE VERY OFTEN IN THE 180 00:06:34,482 --> 00:06:36,784 SCIENCES. 181 00:06:36,784 --> 00:06:39,387 SCIENCES, IN CAPETOWN. 182 00:06:39,387 --> 00:06:40,622 DR. DONENBERG HAS BEEN ACTIVE IN 183 00:06:40,622 --> 00:06:43,324 REVIEW FOR NIH AND HAS OVER 170 184 00:06:43,324 --> 00:06:46,060 PUBLICATIONS. 185 00:06:46,060 --> 00:06:47,161 DR. DONENBERG BRINGS OVER 25 186 00:06:47,161 --> 00:06:48,596 YEARS OF AIDS RESEARCH 187 00:06:48,596 --> 00:06:50,798 EXPERIENCE FOCUSING ON THE 188 00:06:50,798 --> 00:06:53,067 UNDERLYING MECHANISMS OF RISKY 189 00:06:53,067 --> 00:06:54,702 SEXUAL BEHAVIOR AND SUBSTANCE 190 00:06:54,702 --> 00:06:57,005 USE IN YOUTH, AND DESIGNING 191 00:06:57,005 --> 00:06:59,540 SPECIALLY TARGETED INTERVENTIONS 192 00:06:59,540 --> 00:07:02,043 TO PREVENT HIV PREVENTION. 193 00:07:02,043 --> 00:07:05,880 SO SHE'S GOING TO BRING A NEW 194 00:07:05,880 --> 00:07:07,281 ENERGY TO AIDS RESEARCH HERE AT 195 00:07:07,281 --> 00:07:10,585 NIH AND THE INSTITUTE LOOKS 196 00:07:10,585 --> 00:07:13,354 FORWARD TO WORKING WITH HER VERY 197 00:07:13,354 --> 00:07:14,288 CLOSELY. 198 00:07:14,288 --> 00:07:16,491 NOW TO THE BEST NEWS OF ALL, THE 199 00:07:16,491 --> 00:07:20,094 BUDGET UPDATE. 200 00:07:20,094 --> 00:07:24,799 THAT WAS SARCASM. 201 00:07:24,799 --> 00:07:29,037 SO TO DATE FOR THE 2025 202 00:07:29,037 --> 00:07:30,805 APPROPRIATIONS, THE PRESIDENT 203 00:07:30,805 --> 00:07:32,206 RELEASED HIS BUDGET ON 204 00:07:32,206 --> 00:07:32,674 MARCH 11TH. 205 00:07:32,674 --> 00:07:34,509 THE HOUSE RELEASED THEIR VERSION 206 00:07:34,509 --> 00:07:35,610 IN JULY. 207 00:07:35,610 --> 00:07:37,512 AND THE SENATE JUST RELEASED 208 00:07:37,512 --> 00:07:38,379 THEIR VERSION AT THE BEGINNING 209 00:07:38,379 --> 00:07:41,616 OF AUGUST. 210 00:07:41,616 --> 00:07:45,019 SO THIS GRAPHIC SHOWS THE 211 00:07:45,019 --> 00:07:48,723 CURVES, AND NOTE FOR 2025 HOUSE, 212 00:07:48,723 --> 00:07:51,492 THERE'S TWO NUMBERS, WITH 213 00:07:51,492 --> 00:07:52,660 BASICALLY CUTTING THE INSTITUTE 214 00:07:52,660 --> 00:07:55,830 IN HALF. 215 00:07:55,830 --> 00:07:57,532 IT SEPARATES THE INFECTIOUS 216 00:07:57,532 --> 00:07:58,700 DISEASE COMPONENT FROM THE 217 00:07:58,700 --> 00:08:01,969 IMMUNOLOGY COMPONENT. 218 00:08:01,969 --> 00:08:05,139 THE QUESTION WAS ASKED IN THE 219 00:08:05,139 --> 00:08:06,007 PREVIOUS SESSION, THE OPEN 220 00:08:06,007 --> 00:08:08,409 SESSION OF COUNCIL, WHAT WAS THE 221 00:08:08,409 --> 00:08:12,613 LOGIC BEHIND THAT? 222 00:08:12,613 --> 00:08:18,653 ANAND YOU SEE THE SENATE PROPOSD 223 00:08:18,653 --> 00:08:20,121 A LITTLE BIT MORE MONEY FOR US 224 00:08:20,121 --> 00:08:25,259 OVERALL. 225 00:08:25,259 --> 00:08:28,229 SO WHAT WE'RE LOOKING AT, IF YOU 226 00:08:28,229 --> 00:08:33,735 INTEGRATE THIS IN, IS NIAID IS 227 00:08:33,735 --> 00:08:34,802 OVERALL SCHEDULED ON THE HOUSE 228 00:08:34,802 --> 00:08:39,907 SIDE TO RECEIVE A VERY SMALL 229 00:08:39,907 --> 00:08:41,242 INCREASE, AND ON THE SENATE SIDE 230 00:08:41,242 --> 00:08:44,412 SHOULD IT BE ENACTED ABOUT A 2% 231 00:08:44,412 --> 00:08:45,813 INCREASE AS OPPOSED TO WHAT THE 232 00:08:45,813 --> 00:08:47,248 PRESIDENT PROPOSED IN HIS BUDGET 233 00:08:47,248 --> 00:08:49,550 WAS NO REAL INCREASE OR A VERY 234 00:08:49,550 --> 00:08:55,356 SMALL INCREASE FOR NIAID. 235 00:08:55,356 --> 00:08:56,457 SUFFICE IT TO SAY, YOU MAY HAVE 236 00:08:56,457 --> 00:08:57,959 NOTICED THERE'S AN ELECTION WITH 237 00:08:57,959 --> 00:09:00,595 CAMPAIGNS GOING ON RIGHT NOW. 238 00:09:00,595 --> 00:09:02,997 THERE'S A VERY GOOD CHANCE THAT 239 00:09:02,997 --> 00:09:04,632 WE WILL BE UNDER A CONTINUING 240 00:09:04,632 --> 00:09:07,468 RESOLUTION UNTIL JANUARY. 241 00:09:07,468 --> 00:09:10,338 AT WHICH POINT, WHOEVER IS THE 242 00:09:10,338 --> 00:09:11,539 PARTY IN CONTROL OF THE HOUSE 243 00:09:11,539 --> 00:09:12,740 AND THE SENATE WILL DETERMINE 244 00:09:12,740 --> 00:09:14,709 WHAT THIS ALL LOOKS LIKE. 245 00:09:14,709 --> 00:09:18,212 SO WE'LL START THE YEAR UNDER A 246 00:09:18,212 --> 00:09:19,413 CONTINUING RESOLUTION. 247 00:09:19,413 --> 00:09:20,848 THIS WILL REQUIRE THAT BETWEEN 248 00:09:20,848 --> 00:09:23,885 SOMETIME IN THE NEXT 21 DAYS, 249 00:09:23,885 --> 00:09:27,054 THERE IS A CR PASSED BY THE 250 00:09:27,054 --> 00:09:28,156 HOUSE AND SENATE TO KEEP US 251 00:09:28,156 --> 00:09:30,792 OPEN. 252 00:09:30,792 --> 00:09:32,093 I DON'T THINK THERE'S ANY DANGER 253 00:09:32,093 --> 00:09:34,495 OF THEM NOT DOING THAT BECAUSE 254 00:09:34,495 --> 00:09:38,099 IT WOULD LOOK BAD FOR THE PARTY 255 00:09:38,099 --> 00:09:40,301 THAT LED TO THAT KIND OF A 256 00:09:40,301 --> 00:09:45,206 SHUTDOWN OR POTENTIAL SHUTDOWN. 257 00:09:45,206 --> 00:09:49,610 BUT THAT MEANS, AS YOU SAW, NRM 258 00:09:49,610 --> 00:09:51,245 PAYLINES ARE QUITE DRACONIAN. 259 00:09:51,245 --> 00:09:54,615 WE'RE AT 8 AND 10% FOR NEW -- 8% 260 00:09:54,615 --> 00:09:58,986 FOR NEW -- REGULAR GRANTS. 261 00:09:58,986 --> 00:10:03,925 10% FOR ESIs, SO THOSE NUMBERS 262 00:10:03,925 --> 00:10:05,226 WILL CHANGE HOPEFULLY IF AND 263 00:10:05,226 --> 00:10:09,163 WHEN WE GET A BUDGET. 264 00:10:09,163 --> 00:10:10,832 SO IN TERMS OF SCIENCE AND 265 00:10:10,832 --> 00:10:12,466 PROGRAMMATIC UPDATES, THIS WAS A 266 00:10:12,466 --> 00:10:13,768 REALLY INTERESTING ONE THAT CAME 267 00:10:13,768 --> 00:10:15,303 OUT IN JUNE. 268 00:10:15,303 --> 00:10:20,208 AND THAT IS THAT THE 269 00:10:20,208 --> 00:10:22,410 CCR5 INHIBITOR ACTUALLY HAS 270 00:10:22,410 --> 00:10:25,146 ADDITIONAL ACTIVITIES, AND IN A 271 00:10:25,146 --> 00:10:32,019 CLINICAL TRIAL, I DWES GUESS WL 272 00:10:32,019 --> 00:10:35,523 IT -- THE BRAND NAME OF THE 273 00:10:35,523 --> 00:10:38,059 DRUG -- WHEN GIVEN TO PEOPLE 274 00:10:38,059 --> 00:10:39,794 WHO'VE UNDERGONE KIDNEY 275 00:10:39,794 --> 00:10:40,661 TRANSPLANTS, IT IMPROVED 276 00:10:40,661 --> 00:10:43,197 FUNCTION AND ACTUALLY THEY 277 00:10:43,197 --> 00:10:44,932 EXPERIENCED LOWER RATES OF 278 00:10:44,932 --> 00:10:48,870 REJECTION COMPARED TO PLACEBO. 279 00:10:48,870 --> 00:10:50,738 AND PART OF THE PROBLEM, LIKE 280 00:10:50,738 --> 00:10:53,241 WITH ALL OF THESE, IT WASN'T 281 00:10:53,241 --> 00:10:54,342 STATISTICALLY SIGNIFICANT 282 00:10:54,342 --> 00:10:55,543 BECAUSE THE CARE YOU RECEIVE IN 283 00:10:55,543 --> 00:10:59,146 A TRIAL TENDS TO BE BETTER THAN 284 00:10:59,146 --> 00:11:01,015 IN A -- WHEN THEY LOOKED AT 285 00:11:01,015 --> 00:11:02,783 REJECTION RATES ACROSS THE 286 00:11:02,783 --> 00:11:04,418 ENTIRE POPULATION. 287 00:11:04,418 --> 00:11:07,021 SUFFICE IT TO SAY IT DIDN'T DO 288 00:11:07,021 --> 00:11:08,990 HARM AND MAY DO SOME GOOD. 289 00:11:08,990 --> 00:11:13,928 BUT THE IDEA THAT BLOCKING 290 00:11:13,928 --> 00:11:17,365 CCR5 AS AN INNATE RESPONSE 291 00:11:17,365 --> 00:11:18,833 COMPONENT RELATIVE TO 292 00:11:18,833 --> 00:11:19,834 INFLAMMATION THAT'S ASSOCIATED 293 00:11:19,834 --> 00:11:21,936 WITH REJECTION MAY BE IMPORTANT. 294 00:11:21,936 --> 00:11:22,136 , 295 00:11:22,136 --> 00:11:23,304 I THINK WAS AN INTERESTING 296 00:11:23,304 --> 00:11:28,910 FINDING. 297 00:11:28,910 --> 00:11:30,978 WE HAVE MADE AS A DIVISION AND 298 00:11:30,978 --> 00:11:32,847 AN INSTITUTE TREMENDOUS PROGRESS 299 00:11:32,847 --> 00:11:35,249 WITH INJECTABLE CABOTEGRAVIR. 300 00:11:35,249 --> 00:11:39,520 NOT ONLY DOES IT PREVENT AN 301 00:11:39,520 --> 00:11:40,721 ACQUISITION IN MEN AND WOMEN, 302 00:11:40,721 --> 00:11:45,960 BUT IT ALSO IS LOOKING SAFE IN 303 00:11:45,960 --> 00:11:47,495 PREGNANCY, AND NOW THE IDEA IS, 304 00:11:47,495 --> 00:11:51,332 CAN WE EXTEND THIS INTO 305 00:11:51,332 --> 00:11:52,900 PREGNANCY TO A POINT WHERE IT 306 00:11:52,900 --> 00:11:56,804 BECOMES A MEANS OF PREVENTING 307 00:11:56,804 --> 00:11:59,407 ACQUISITION DURING THE -- 308 00:11:59,407 --> 00:12:00,741 THROUGHOUT PREGNANCY AND THROUGH 309 00:12:00,741 --> 00:12:03,044 THE BREASTFEEDING PERIOD. 310 00:12:03,044 --> 00:12:12,653 AS WE GO FORWARD, AND WORK UP 311 00:12:12,653 --> 00:12:13,621 CABROPIVARINE, CAN WE USE THAT 312 00:12:13,621 --> 00:12:15,289 PAIR OF DRUGS IN PREGNANT WOMEN 313 00:12:15,289 --> 00:12:17,258 OR PREGNANT PEOPLE THROUGH THE 314 00:12:17,258 --> 00:12:20,328 BREASTFEEDING PERIOD TO HELP 315 00:12:20,328 --> 00:12:20,861 PREVENT ACQUISITION. 316 00:12:20,861 --> 00:12:22,830 SO THERE'S SO MUCH THAT WE CAN 317 00:12:22,830 --> 00:12:30,171 DO WITH THESE NOW THAT I THINK 318 00:12:30,171 --> 00:12:31,572 WILL BE EXCITING AND WE'LL GET 319 00:12:31,572 --> 00:12:32,640 TO THAT DISCUSSION WHEN I TALK 320 00:12:32,640 --> 00:12:34,342 LATER IN THE AFTERNOON ABOUT 321 00:12:34,342 --> 00:12:35,309 FUTURE DIRECTIONS IN THE 322 00:12:35,309 --> 00:12:36,277 NETWORKS, THIS IDEA THAT WE CAN 323 00:12:36,277 --> 00:12:39,280 TAKE THESE NEW AGENTS AND USE 324 00:12:39,280 --> 00:12:41,749 THEM THROUGH AN INTEGRATED SET 325 00:12:41,749 --> 00:12:47,655 OF IMPLEMENTATION SCIENCE 326 00:12:47,655 --> 00:12:48,856 EXPERIMENTS AS WELL AS CLINICAL 327 00:12:48,856 --> 00:12:51,726 RESEARCH TO REALLY HELP US BUILD 328 00:12:51,726 --> 00:12:55,329 A PACKAGE TO HELP TO PREVENT 329 00:12:55,329 --> 00:12:58,265 VERTICAL TRANSMISSION. 330 00:12:58,265 --> 00:12:59,900 SO THIS IS A VERY EXCITING TIME. 331 00:12:59,900 --> 00:13:01,035 AND ALSO THIS IS NOW THE ONE 332 00:13:01,035 --> 00:13:02,737 THAT'S APPROVED, WE STILL HAVE 333 00:13:02,737 --> 00:13:06,240 ANOTHER TRIAL TO COMPLETE FOR 334 00:13:06,240 --> 00:13:10,945 LEN, SO STAY TUNED, FOR NOW RAVI 335 00:13:10,945 --> 00:13:12,279 WILL CONTINUE TO RIDE THIS 336 00:13:12,279 --> 00:13:14,348 HORSE, RIGHT? 337 00:13:14,348 --> 00:13:16,984 YOU'LL HEAR MORE ABOUT THE NIAID 338 00:13:16,984 --> 00:13:18,185 STRATEGIC PLAN LATER THIS 339 00:13:18,185 --> 00:13:19,253 AFTERNOON. 340 00:13:19,253 --> 00:13:23,090 WE'VE BEEN WORKING ON THIS FOR I 341 00:13:23,090 --> 00:13:25,393 GUESS SIX OR EIGHT MONTHS AT 342 00:13:25,393 --> 00:13:25,826 THIS POINT. 343 00:13:25,826 --> 00:13:29,663 ONE OF THE CRITICAL AREAS THAT 344 00:13:29,663 --> 00:13:32,299 IS HELPING TO FEED INTO THE 345 00:13:32,299 --> 00:13:33,734 STRATEGIC PLAN IS STAKEHOLDER 346 00:13:33,734 --> 00:13:34,802 INPUT. 347 00:13:34,802 --> 00:13:38,839 WE HAD AN RFI THAT WENT OUT AND 348 00:13:38,839 --> 00:13:41,142 WE WERE THRILLED BY THE RESPONSE 349 00:13:41,142 --> 00:13:45,746 NUMBERS AND THE QUALITY THAT WE 350 00:13:45,746 --> 00:13:52,553 RECEIVED FROM THE COMMUNITIES 351 00:13:52,553 --> 00:13:53,654 INVESTIGATORS, THROUGH 352 00:13:53,654 --> 00:13:54,755 COMMUNITY, AND INTERESTED 353 00:13:54,755 --> 00:13:57,825 FACULTY AROUND THE COUNTRY. 354 00:13:57,825 --> 00:14:01,662 THAT'S THE REASON NICHOLAS 355 00:14:01,662 --> 00:14:03,064 BESHUR IS ON THE AGENDA TODAY TO 356 00:14:03,064 --> 00:14:04,598 TALK ABOUT THE OUTPUT OF THAT 357 00:14:04,598 --> 00:14:08,102 RFI SO YOU CAN HEAR SOME OF THE 358 00:14:08,102 --> 00:14:10,304 DETAILS AS PART OF OUR PROCESS 359 00:14:10,304 --> 00:14:13,774 AS A DIVISION OF HAVING INPUT 360 00:14:13,774 --> 00:14:18,179 INTO THE INSTITUTE'S STRATEGIC 361 00:14:18,179 --> 00:14:19,146 PLAN. 362 00:14:19,146 --> 00:14:20,915 ADDITIONALLY, ANNE IS HERE FROM 363 00:14:20,915 --> 00:14:25,386 THE OAR TO GIVE A REPORT ABOUT 364 00:14:25,386 --> 00:14:28,889 THE UPDATE OF THE MOST RECENT 365 00:14:28,889 --> 00:14:34,728 OAR MEETING, THE MAJOR AREA OF 366 00:14:34,728 --> 00:14:35,830 THAT, MAJOR TOPIC OF THAT 367 00:14:35,830 --> 00:14:37,398 MEETING WAS THE OAR STRATEGIC 368 00:14:37,398 --> 00:14:37,698 PLAN. 369 00:14:37,698 --> 00:14:39,467 SO I THINK IN THIS RELATIVELY 370 00:14:39,467 --> 00:14:42,503 SHORT PERIOD TODAY, YOU CAN HEAR 371 00:14:42,503 --> 00:14:44,505 FROM ANNE AND NICK SOME ASPECT 372 00:14:44,505 --> 00:14:47,108 OF THE PLANNING PROCESSES FOR 373 00:14:47,108 --> 00:14:48,309 HIV/AIDS THAT ARE GOING ON AT 374 00:14:48,309 --> 00:14:51,312 THE NIH, SO I THINK THAT WILL BE 375 00:14:51,312 --> 00:14:56,717 VERY USEFUL. 376 00:14:56,717 --> 00:14:57,818 SO I'LL CLOSE BY POINTING OUT 377 00:14:57,818 --> 00:15:02,423 THAT THE NEXT MEETING WILL BE 378 00:15:02,423 --> 00:15:03,190 JANUARY 27TH, 2025. 379 00:15:03,190 --> 00:15:06,460 ALWAYS IN THE FUTURE, THE 380 00:15:06,460 --> 00:15:07,661 MEETINGS IN THE DEAD OF WINTER 381 00:15:07,661 --> 00:15:09,964 WILL BE VIRTUAL. 382 00:15:09,964 --> 00:15:11,265 WE'VE HAD -- BEFORE THE 383 00:15:11,265 --> 00:15:12,800 PANDEMIC, WHENEVER WE HAD A 384 00:15:12,800 --> 00:15:15,870 MEETING IN JANUARY, IT SEEMED 385 00:15:15,870 --> 00:15:16,737 LIKE THERE WAS ALWAYS TWO FEET 386 00:15:16,737 --> 00:15:19,707 OF SNOW ON THE GROUND, AND IT 387 00:15:19,707 --> 00:15:22,877 WAS ALWAYS TOUCH AND GO, SO JUST 388 00:15:22,877 --> 00:15:23,978 EASIER TO MAKE THEM VIRTUAL. 389 00:15:23,978 --> 00:15:27,081 SO WITH THAT, I WILL CLOSE, AND 390 00:15:27,081 --> 00:15:35,456 HAPPY TO TAKE QUESTIONS. 391 00:15:35,456 --> 00:15:40,694 SEEING NONE, WE CAN MOVE ON TO 392 00:15:40,694 --> 00:15:40,895 OUR -- 393 00:15:40,895 --> 00:15:42,163 >> ARE THERE ANY QUESTIONS 394 00:15:42,163 --> 00:15:42,997 ONLINE? 395 00:15:42,997 --> 00:15:43,330 OKAY, GREAT. 396 00:15:43,330 --> 00:15:45,399 THANK YOU VERY MUCH. 397 00:15:45,399 --> 00:15:48,669 WE'RE GOING TO TURN NEXT TO THE 398 00:15:48,669 --> 00:15:54,141 ONE CONCEPT THAT WE HAVE, BOB 399 00:15:54,141 --> 00:15:54,575 MAHON. 400 00:15:54,575 --> 00:15:55,676 I'M GOING TO ASK ALL VOTING 401 00:15:55,676 --> 00:16:01,048 MEMBERS TO PLEASE OPEN UP YOUR 402 00:16:01,048 --> 00:16:02,583 ELECTRONIC VOTING SO THAT YOU 403 00:16:02,583 --> 00:16:04,418 CAN VOTE IMMEDIATELY AFTER THE 404 00:16:04,418 --> 00:16:05,419 PRESENTATION. 405 00:16:05,419 --> 00:16:07,588 AND WE'LL HAVE THAT DONE. 406 00:16:07,588 --> 00:16:07,922 OKAY. 407 00:16:07,922 --> 00:16:08,289 OVER TO YOU. 408 00:16:08,289 --> 00:16:11,425 >> SO MY NAME IS ROBERT MAHON. 409 00:16:11,425 --> 00:16:12,526 I WILL BE PRESENTING THIS 410 00:16:12,526 --> 00:16:14,595 CONCEPT FOR APPROVAL ENTITLED 411 00:16:14,595 --> 00:16:15,162 TRANSLATIONAL APPROACHES TO 412 00:16:15,162 --> 00:16:18,332 DEVELOPING NEW TB MENINGITIS, OR 413 00:16:18,332 --> 00:16:19,633 TBM DRUG REGIMENS IN PEOPLE 414 00:16:19,633 --> 00:16:21,168 LIVING WITH AND WITHOUT HIV. 415 00:16:21,168 --> 00:16:23,671 THE OBJECTIVE OF THIS PROPOSED 416 00:16:23,671 --> 00:16:24,872 INITIATIVE WOULD BE TO ADVANCE 417 00:16:24,872 --> 00:16:26,307 RESEARCH TO DEVELOP NOVEL 418 00:16:26,307 --> 00:16:27,942 TREATMENT STRATEGIES THAT 419 00:16:27,942 --> 00:16:29,977 ADDRESS TBM-SPECIFIC NEEDS AS 420 00:16:29,977 --> 00:16:32,546 WELL AS TO ENSURE RECENT 421 00:16:32,546 --> 00:16:34,615 SUCCESSES IN PULMONARY TB 422 00:16:34,615 --> 00:16:35,816 TREATMENT ARE APPROPRIATELY 423 00:16:35,816 --> 00:16:37,785 ADAPTED TO ADVANCE TBM TREATMENT 424 00:16:37,785 --> 00:16:39,987 IN PEOPLE LIVING WITH AND 425 00:16:39,987 --> 00:16:44,592 WITHOUT HIV. 426 00:16:44,592 --> 00:16:45,659 WE'VE PROPOSED THIS AS A 427 00:16:45,659 --> 00:16:47,194 COOPERATIVE AGREEMENT UNDER THE 428 00:16:47,194 --> 00:16:48,829 ACTIVITY CODE OF U19. 429 00:16:48,829 --> 00:16:50,598 PARTICIPATING NUMBER OF 430 00:16:50,598 --> 00:16:51,999 GRANTABLECATIONS TO BE TWO TO 431 00:16:51,999 --> 00:16:52,967 THREE AND THE ABILITY TO MAKE 432 00:16:52,967 --> 00:16:54,068 ONE AWARD AND FINANCIALLY 433 00:16:54,068 --> 00:16:55,402 COMMITTED PARTNERS FROM NINDS 434 00:16:55,402 --> 00:17:00,441 AND NIMH. 435 00:17:00,441 --> 00:17:02,176 SO TB IN GENERAL USING THE MOST 436 00:17:02,176 --> 00:17:03,877 UP TO DATE STATISTICS FROM THE 437 00:17:03,877 --> 00:17:04,578 WORLD HEALTH ORGANIZATION, 438 00:17:04,578 --> 00:17:06,113 THERE'S APPROXIMATELY 439 00:17:06,113 --> 00:17:07,114 10.6 MILLION NEW CASES OF TB 440 00:17:07,114 --> 00:17:09,717 EVERY YEAR, WITH OVER 400,000 OF 441 00:17:09,717 --> 00:17:12,353 THOSE BEING DRUG RESISTANT AND 442 00:17:12,353 --> 00:17:13,988 THERE'S APPROXIMATELY 443 00:17:13,988 --> 00:17:14,989 1.3 MILLION PEOPLE WHO DIE OF 444 00:17:14,989 --> 00:17:15,356 TB. 445 00:17:15,356 --> 00:17:17,458 SO NOW AS WE'RE FURTHER AWAY 446 00:17:17,458 --> 00:17:19,260 FROM THE PART OF THE COVID 447 00:17:19,260 --> 00:17:21,662 PANDEMIC, TB IS ONCE AGAIN 448 00:17:21,662 --> 00:17:23,030 BECOMING THE MOST DEADLY 449 00:17:23,030 --> 00:17:23,831 INFECTIOUS DISEASE IN THE WORLD. 450 00:17:23,831 --> 00:17:25,699 FOR THOSE LIVING WITH HIV, 451 00:17:25,699 --> 00:17:27,468 THEY'RE 18 TIMES MORE LIKELY TO 452 00:17:27,468 --> 00:17:29,303 DEVELOP ACTIVE TB, AND TB IS A 453 00:17:29,303 --> 00:17:31,038 LEADING CAUSE OF DEATH IN PEOPLE 454 00:17:31,038 --> 00:17:32,706 LIVING WITH HIV. 455 00:17:32,706 --> 00:17:36,310 SO TB MENINGITIS OCCURS WHEN TB 456 00:17:36,310 --> 00:17:39,713 DISSEMINATES FROM THE LUNG, 457 00:17:39,713 --> 00:17:41,248 CROSSES THE BLOOD BRAIN BARRIER 458 00:17:41,248 --> 00:17:42,616 AND ESTABLISHES AN INFECTION IN 459 00:17:42,616 --> 00:17:44,285 THE BRAIN AND CNS. 460 00:17:44,285 --> 00:17:46,353 IT'S BELIEVED THAT UP TO .3 TO 461 00:17:46,353 --> 00:17:48,322 5% OF ALL PEOPLE LIVING WITH TB 462 00:17:48,322 --> 00:17:52,326 HAVE TBM, WHICH ROUGHLY ABOUT 30 463 00:17:52,326 --> 00:17:53,894 OF THE 10.6 MILLION NEW CASES 464 00:17:53,894 --> 00:17:56,764 EVERY YEAR, 30,000 TO 490,000 OF 465 00:17:56,764 --> 00:17:59,166 THEM HAVE TBM. 466 00:17:59,166 --> 00:18:00,367 AND FOR CHILDREN AND PEOPLE 467 00:18:00,367 --> 00:18:01,902 LIVING WITH HIV, THERE ARE HIGH 468 00:18:01,902 --> 00:18:04,538 RATES OF MORTALITY. 469 00:18:04,538 --> 00:18:07,808 CHILDREN HAVE UP TO 20% OF THE 470 00:18:07,808 --> 00:18:08,809 MORTALITY RATE FOR PEOPLE LIVING 471 00:18:08,809 --> 00:18:10,644 WITH HIV, IT'S UP TO 40 TO 50%, 472 00:18:10,644 --> 00:18:11,945 SO IT'S A VERY SIGNIFICANT 473 00:18:11,945 --> 00:18:13,213 DISEASE AND DEADLY DISEASE FOR 474 00:18:13,213 --> 00:18:16,550 BOTH POPULATIONS. 475 00:18:16,550 --> 00:18:18,419 AND SURVIVORS HAVE THE RISK OF 476 00:18:18,419 --> 00:18:19,853 SIGNIFICANT LONG-TERM 477 00:18:19,853 --> 00:18:20,721 NEUROLOGICAL DISABILITIES, WHICH 478 00:18:20,721 --> 00:18:23,991 CAN INCLUDE COMA, CRANIAL NERVE 479 00:18:23,991 --> 00:18:26,960 DEFICITS, HEMI AND PARAPRECYST, 480 00:18:26,960 --> 00:18:28,262 MOVEMENT DISORDERS AND VISUAL 481 00:18:28,262 --> 00:18:29,563 AND HEARING DISTURBANCES. 482 00:18:29,563 --> 00:18:31,665 AND WHILE THE MIGRATION OR THE 483 00:18:31,665 --> 00:18:34,935 DISSEMINATION OF TB INTO THE 484 00:18:34,935 --> 00:18:36,236 BRAIN IS A PRIMARY FACTOR IN 485 00:18:36,236 --> 00:18:38,539 DEVELOPING TB MENINGITIS, IT'S 486 00:18:38,539 --> 00:18:40,507 REALLY THE ABERRANT HOST IMMUNE 487 00:18:40,507 --> 00:18:42,476 RESPONSE INDUCED IN THE BRAIN IN 488 00:18:42,476 --> 00:18:43,811 C NS THAT DRIVES THE PATHOLOGY 489 00:18:43,811 --> 00:18:47,281 THAT'S SEEN WITH TB MENINGITIS. 490 00:18:47,281 --> 00:18:48,949 SO THE OVERALL DRUG PIPELINE FOR 491 00:18:48,949 --> 00:18:50,250 TB IS QUITE ROBUST. 492 00:18:50,250 --> 00:18:53,754 WE HAVE MULTIPLE NOW DRUGS BEING 493 00:18:53,754 --> 00:18:55,055 IN CLINICAL DEVELOPMENT IN 494 00:18:55,055 --> 00:18:56,924 VARIOUS PHASES OF CLINICAL 495 00:18:56,924 --> 00:18:58,125 DEVELOPMENT WITH SEVERAL MORE 496 00:18:58,125 --> 00:18:59,660 BEHIND THEM IN PRE-CLINICAL 497 00:18:59,660 --> 00:19:00,961 DEVELOPMENT AND DISCOVERY. 498 00:19:00,961 --> 00:19:03,063 BUT THE BULK OF THESE DRUGS AND 499 00:19:03,063 --> 00:19:05,232 THE REGIMENS THAT ARE BEING 500 00:19:05,232 --> 00:19:06,667 TESTED WITH THEM ARE BEING 501 00:19:06,667 --> 00:19:08,502 STUDIED IN THE CONTEXT OF 502 00:19:08,502 --> 00:19:09,069 PULMONARY TB. 503 00:19:09,069 --> 00:19:11,038 WHEREAS TB MENINGITIS HAS 504 00:19:11,038 --> 00:19:12,005 TREATMENT REQUIREMENTS THAT ARE 505 00:19:12,005 --> 00:19:14,441 DISTINCT FROM PULMONARY TB, MOST 506 00:19:14,441 --> 00:19:16,243 PREVALENT BEING THAT YOU NEED 507 00:19:16,243 --> 00:19:18,479 SUFFICIENT CNS PENETRATION TO 508 00:19:18,479 --> 00:19:19,680 ACHIEVE MTB KILLING IN THE BRAIN 509 00:19:19,680 --> 00:19:21,081 AND CNS. 510 00:19:21,081 --> 00:19:23,617 AND THAT ALSO THE IMMUNE 511 00:19:23,617 --> 00:19:24,818 MODULATION IS A CRITICAL ASPECT 512 00:19:24,818 --> 00:19:26,220 OF TB MENINGITIS TREATMENT. 513 00:19:26,220 --> 00:19:27,554 SO THE DEBILITATING OUTCOMES 514 00:19:27,554 --> 00:19:29,390 THAT ARE ASSOCIATED WITH TBM 515 00:19:29,390 --> 00:19:31,492 REQUIRES THAT NOVEL STRATEGIES 516 00:19:31,492 --> 00:19:34,094 BE EVALUATED VIA ROBUST 517 00:19:34,094 --> 00:19:34,862 PRE-CLINICAL RESEARCH PRIOR TO 518 00:19:34,862 --> 00:19:35,629 CLINICAL TESTING. 519 00:19:35,629 --> 00:19:37,831 WE CAN'T SIMPLY TAKE THESE DRUGS 520 00:19:37,831 --> 00:19:38,932 AND THE REGIMENS WE'RE 521 00:19:38,932 --> 00:19:40,334 DEVELOPING HERE AND SAYING THE 522 00:19:40,334 --> 00:19:42,536 WORKING AND PULMONARY TB, LET'S 523 00:19:42,536 --> 00:19:44,371 SEE IF THEY WORK WITH TB 524 00:19:44,371 --> 00:19:45,372 MENINGITIS WITHOUT DOING 525 00:19:45,372 --> 00:19:46,039 PRE-CLINICAL WORK. 526 00:19:46,039 --> 00:19:49,309 AND WE DO HAVE PRE-CLINICAL 527 00:19:49,309 --> 00:19:51,044 MODELS TO STUDY, PRE-CLINICAL 528 00:19:51,044 --> 00:19:55,115 ANIMAL MODELS TO STUDY TBM. 529 00:19:55,115 --> 00:19:57,518 PRIMARILY THESE ARE RABBITS AND 530 00:19:57,518 --> 00:19:59,586 MICE. 531 00:19:59,586 --> 00:20:01,021 EXAMPLES INCLUDE 532 00:20:01,021 --> 00:20:02,222 INTRAVENTRICULAR INFECTIONS OF 533 00:20:02,222 --> 00:20:12,499 BOTH RABBITS AND -- MICE WITH 534 00:20:12,499 --> 00:20:14,668 VIER LENT MTB STRAINS AND IT'SS 535 00:20:14,668 --> 00:20:16,870 ABOUT LN FOUND NOS TO KNOCKOUT 536 00:20:16,870 --> 00:20:22,443 MICE WHEN INTERFECTED 537 00:20:22,443 --> 00:20:22,976 INTERVENTRICULARLY -- THE 538 00:20:22,976 --> 00:20:24,311 DISEASE SIMILAR IN THE MICE TO 539 00:20:24,311 --> 00:20:25,312 HUMAN TBM. 540 00:20:25,312 --> 00:20:26,613 IN ADDITION TO THIS WORK THERE'S 541 00:20:26,613 --> 00:20:28,015 BEEN BRAIN SCANS USING RADIO 542 00:20:28,015 --> 00:20:29,116 LABELED ABT BIOTICS THAT HAVE 543 00:20:29,116 --> 00:20:31,084 BEEN ABLE TO ESTABLISH DATA ON 544 00:20:31,084 --> 00:20:33,454 DRUG PENETRATION INTO THE BRAIN 545 00:20:33,454 --> 00:20:33,921 AND CNS. 546 00:20:33,921 --> 00:20:36,657 THE MOST PREVALENT SHOWN IN THIS 547 00:20:36,657 --> 00:20:38,325 FIGURE SEEMS TO BE VERY EASILY 548 00:20:38,325 --> 00:20:39,927 AND EFFECTIVELY ENTER THE BRAIN 549 00:20:39,927 --> 00:20:42,996 COMPARED TO OTHER TB DRUGS. 550 00:20:42,996 --> 00:20:47,501 SO THERE IS A ONGOING CLINICAL 551 00:20:47,501 --> 00:20:49,870 TRIAL NETWORK OR THERE ARE 552 00:20:49,870 --> 00:20:50,504 MULTIPLE CLINICAL TRIALS ONGOING 553 00:20:50,504 --> 00:20:54,741 THAT FIT INTO ONE OF ROUGHLY 554 00:20:54,741 --> 00:20:55,676 THREE DIFFERENT TYPES OF 555 00:20:55,676 --> 00:20:55,943 BUCKETS. 556 00:20:55,943 --> 00:20:57,811 THERE ARE THOSE FOCUSED ON 557 00:20:57,811 --> 00:20:59,012 MODIFYING THE STANDARD OF CARE, 558 00:20:59,012 --> 00:21:00,981 THE STANDARD OF THE ANTIBIOTICS 559 00:21:00,981 --> 00:21:03,383 THAT ARE UTILIZED WHICH IS TWO 560 00:21:03,383 --> 00:21:08,956 MONTHS OF INH AND -- FOLLOWED BY 561 00:21:08,956 --> 00:21:14,862 9 TO 12 MONTHS OF IN H&R 562 00:21:14,862 --> 00:21:20,234 IFAMPISI NE. ALONE. 563 00:21:20,234 --> 00:21:23,971 TESTING HIGHER DOSES OF 564 00:21:23,971 --> 00:21:28,342 RIFAMPISIN OR INH, ALSO 565 00:21:28,342 --> 00:21:29,977 INCLUDING -- STANDARD OF CARE. 566 00:21:29,977 --> 00:21:31,545 IN ADDITION TO THESE STUDY, ONE 567 00:21:31,545 --> 00:21:33,881 THAT HAS RECENTLY STARTED WAS 568 00:21:33,881 --> 00:21:36,750 INCLUDED IN THIS FIGURE OR THIS 569 00:21:36,750 --> 00:21:39,152 TABLE IS THE IMAGINE TRIAL 570 00:21:39,152 --> 00:21:42,256 THAT'S -- THE FIRST TRIAL FROM 571 00:21:42,256 --> 00:21:46,293 ACTG LOOKING AT TB MENINGITIS 572 00:21:46,293 --> 00:21:49,796 REGIMEN STUDYING HIGH DOSE RIF, 573 00:21:49,796 --> 00:21:51,765 HIGH DOSE -- AND PZA. 574 00:21:51,765 --> 00:21:54,268 IN ADDITION TO THOSE STUDIES BE, 575 00:21:54,268 --> 00:21:59,206 THERE ARE OTHERS LOOKING AT 576 00:21:59,206 --> 00:21:59,840 DEXAMETHASONE IN ADDITION TO 577 00:21:59,840 --> 00:22:03,677 STANDARD OF CARE, DEATH MEX ZONE 578 00:22:03,677 --> 00:22:08,348 COMMONLYPRESCRIBED WITH THE STAF 579 00:22:08,348 --> 00:22:11,685 CARE ATTEMPTING TO ALLEVIATE THE 580 00:22:11,685 --> 00:22:12,553 INFLAMMATORY CONDITION WITHIN 581 00:22:12,553 --> 00:22:14,621 THE BRAIN OF TBM. 582 00:22:14,621 --> 00:22:16,256 IT HAS BEEN MILDLY EFFECTIVE. 583 00:22:16,256 --> 00:22:17,558 IT'S EFFECTIVE IN SOME PATIENTS 584 00:22:17,558 --> 00:22:19,059 BUT NOT ALL, SO IF SOME TRIALS 585 00:22:19,059 --> 00:22:21,828 ARE TRYING TO BETTER UNDERSTAND 586 00:22:21,828 --> 00:22:23,797 EXACTLY WHO IS BENEFITING AND 587 00:22:23,797 --> 00:22:28,068 WHY SOME BENEFIT MORE THAN 588 00:22:28,068 --> 00:22:29,836 OTHERS, AND THERE'S ALSO WORK 589 00:22:29,836 --> 00:22:31,104 WITH HIV COINFECTED INDIVIDUALS 590 00:22:31,104 --> 00:22:33,206 TO SEE HOW EFFECTIVE DEX MET 591 00:22:33,206 --> 00:22:34,641 ZONE IS IN THOSE POPULATIONS AS 592 00:22:34,641 --> 00:22:35,409 WELL. 593 00:22:35,409 --> 00:22:38,378 IN ADDITION TO THE STUDIES OF 594 00:22:38,378 --> 00:22:39,680 DEXAMETHASONE, ASPIRIN IS BEING 595 00:22:39,680 --> 00:22:40,981 STUDIED IN MULTIPLE STUDIES. 596 00:22:40,981 --> 00:22:43,951 NATIONAL TO HIGHER DOSES OF 597 00:22:43,951 --> 00:22:47,321 RIF -- COMBINING BOTH OF THESE 598 00:22:47,321 --> 00:22:48,322 WHERE YOU'RE COMBINING THE 599 00:22:48,322 --> 00:22:50,057 CHEMOTHERAPY WITH THE ADJUNCTIVE 600 00:22:50,057 --> 00:22:50,390 THERAPY. 601 00:22:50,390 --> 00:22:54,795 NONE HAVE BEEN GANG BUSTERS AT 602 00:22:54,795 --> 00:22:55,862 THIS POINT. 603 00:22:55,862 --> 00:22:57,264 BUT THEY ARE ONGOING CLINICAL 604 00:22:57,264 --> 00:22:57,731 TRIALS. 605 00:22:57,731 --> 00:22:59,166 I WOULD NOTE ALSO THERE ARE 606 00:22:59,166 --> 00:23:02,436 MULTIPLE CASE REPORTS SHOWING 607 00:23:02,436 --> 00:23:05,839 BENEFITS OF ANTI-TNF GIVEN WITH 608 00:23:05,839 --> 00:23:08,342 SOME TBM PATIENTS, BUT THESE 609 00:23:08,342 --> 00:23:10,544 HAVE NOT REACHED THE LEVEL OF 610 00:23:10,544 --> 00:23:11,745 BEING STUDIED WITH CLINICAL 611 00:23:11,745 --> 00:23:13,380 TRIALS BUT THESE ARE ANOTHER 612 00:23:13,380 --> 00:23:15,349 AREA OF HOST-DIRECTED 613 00:23:15,349 --> 00:23:16,350 THERAPEUTICS THAT ARE BEING 614 00:23:16,350 --> 00:23:17,517 STUDIED IN THE CONTEXT, ARE 615 00:23:17,517 --> 00:23:19,052 BEING LOOKED AT IN THE CONTEXT 616 00:23:19,052 --> 00:23:21,722 OF TBM. 617 00:23:21,722 --> 00:23:23,023 BUT THE REAL NEEDS GOING FORWARD 618 00:23:23,023 --> 00:23:24,758 WITH THE CLINICAL TRIALS REALLY 619 00:23:24,758 --> 00:23:27,494 ARE THERAPEUTIC REGIMENS WITH 620 00:23:27,494 --> 00:23:29,029 IMPROVED CNS PENETRATION AND NOW 621 00:23:29,029 --> 00:23:30,664 THE HOST MODULATING 622 00:23:30,664 --> 00:23:32,633 INTERVENTIONS. 623 00:23:32,633 --> 00:23:35,035 SO A REAL GAP WE WANT TO ADDRESS 624 00:23:35,035 --> 00:23:37,104 WITH THIS INITIATIVE IS LACK OF 625 00:23:37,104 --> 00:23:39,206 TRANSLATIONAL MODELS TO 626 00:23:39,206 --> 00:23:40,073 INTEGRATE PRE-CLINICAL AND 627 00:23:40,073 --> 00:23:42,709 CLINICAL STUDIES, PRIMARILY THE 628 00:23:42,709 --> 00:23:44,678 NEED TO DEVELOP COMPUTATIONAL 629 00:23:44,678 --> 00:23:47,314 AND OTHER SILICONE MODELS TO 630 00:23:47,314 --> 00:23:49,149 FORWARD OR REVERSE TRANSLATE TBM 631 00:23:49,149 --> 00:23:51,785 DATA FROM SMALL ANIMAL MODELS 632 00:23:51,785 --> 00:23:52,886 AND CLINICAL TRIALS, KEY 633 00:23:52,886 --> 00:23:54,855 COMPONENTS OF CLINICAL RESULTS 634 00:23:54,855 --> 00:23:56,390 IN SMALL ANIMAL MODEL STUDIES 635 00:23:56,390 --> 00:23:57,924 ARE THE DRUG PENETRATION INTO 636 00:23:57,924 --> 00:23:59,760 THE CNS AND BRAIN, HOW 637 00:23:59,760 --> 00:24:01,061 EFFECTIVELY THE DRUGS ARE 638 00:24:01,061 --> 00:24:04,131 CROSSING THE BLOOD BRAIN 639 00:24:04,131 --> 00:24:10,804 BARRIER, THE PK/B K/PD ANALYSIS. 640 00:24:10,804 --> 00:24:16,076 TO GET THESE MORE IN SYNC, WE 641 00:24:16,076 --> 00:24:17,544 REALLY WANT TO CONNECT THEM SO 642 00:24:17,544 --> 00:24:20,213 WE KNOW WHAT WE NEED TO BE 643 00:24:20,213 --> 00:24:21,314 STUDYING -- NEED TO BE 644 00:24:21,314 --> 00:24:22,315 OPTIMIZING SMALL ANIMAL MODELS 645 00:24:22,315 --> 00:24:24,685 TO BE EFFECTIVE IN CLINICAL 646 00:24:24,685 --> 00:24:25,786 TRIALS IS A GAP AND ONE WE WANT 647 00:24:25,786 --> 00:24:26,353 TO ADDRESS. 648 00:24:26,353 --> 00:24:28,422 SO THIS INITIATIVE WOULD ENABLE 649 00:24:28,422 --> 00:24:29,956 A MULTIDISCIPLINARY APPROACHES 650 00:24:29,956 --> 00:24:31,591 TO INFORM THERAPEUTIC STRATEGIES 651 00:24:31,591 --> 00:24:35,395 FOR TBM UNTIL SCOPE, WOULD 652 00:24:35,395 --> 00:24:37,064 INCLUDE EVALUATIONS OF NOVEL 653 00:24:37,064 --> 00:24:39,900 APPROACHED TO TBM TREATMENTS IN 654 00:24:39,900 --> 00:24:42,602 PRE-CLINICAL MODELS BEING IT 655 00:24:42,602 --> 00:24:45,172 MICE, RABBITS, POTENTIALLY 656 00:24:45,172 --> 00:24:47,340 NHPs AND WE WOULD WANT TO 657 00:24:47,340 --> 00:24:49,543 ENCOURAGE 3D CEREBRAL ORGANOIDS 658 00:24:49,543 --> 00:24:51,178 OF NOVEL AND EXISTING DRUG 659 00:24:51,178 --> 00:24:53,046 FORMULATIONS TO IMPROVE CNS 660 00:24:53,046 --> 00:24:54,014 PENETRATION INCLUDING 661 00:24:54,014 --> 00:24:55,649 ADVANCEMENT OF PEDIATRIC 662 00:24:55,649 --> 00:24:56,983 FORMULATIONS, IDENTIFYING AND 663 00:24:56,983 --> 00:24:58,285 VALIDATING POTENTIAL HOST WIE 664 00:24:58,285 --> 00:24:59,920 OWE MARKERS FOR DIAGNOSIS AND 665 00:24:59,920 --> 00:25:01,455 VSH OR PROGNOSIS, THIS BEING 666 00:25:01,455 --> 00:25:03,223 ADULTS AND CHILDREN AND 667 00:25:03,223 --> 00:25:04,191 DETERMINING -- EXAMPLES BEING 668 00:25:04,191 --> 00:25:05,392 ADULTS AND CHILDREN AND 669 00:25:05,392 --> 00:25:07,461 DETERMINING HOW HIV AND ART 670 00:25:07,461 --> 00:25:11,064 INFLUENCE BIOMARKER AK CASSIE 671 00:25:11,064 --> 00:25:15,001 AND SELECTION, APPLYING 672 00:25:15,001 --> 00:25:18,839 COMPUTATIONAL -- TO DEVELOP 673 00:25:18,839 --> 00:25:20,173 PARTICULAR INSILICO MODELS TO 674 00:25:20,173 --> 00:25:21,007 INFORM REGIMEN SELECTION 675 00:25:21,007 --> 00:25:21,575 GUIDELINES. 676 00:25:21,575 --> 00:25:24,411 THIS IS BEING DONE IN PULMONARY 677 00:25:24,411 --> 00:25:25,746 TB QUITE EFFECTIVELY. 678 00:25:25,746 --> 00:25:26,947 WE'D LIKE TO ENCOURAGE MOWR OF 679 00:25:26,947 --> 00:25:28,248 THIS BEING DONE WITH TB 680 00:25:28,248 --> 00:25:29,449 MENINGITIS AND PERFORMING 681 00:25:29,449 --> 00:25:30,884 CLINICAL RESEARCH INVOLVING 682 00:25:30,884 --> 00:25:32,719 ALREADY COLLECTED HUMAN SAMPLES. 683 00:25:32,719 --> 00:25:33,820 WHAT WOULD BE OUT OF SCOPE WOULD 684 00:25:33,820 --> 00:25:35,255 BE APPLICATIONS THAT DO NOT 685 00:25:35,255 --> 00:25:36,857 INCLUDE A COMPONENT STUDYING TBM 686 00:25:36,857 --> 00:25:40,060 IN THE CONTEXT OF HIV. 687 00:25:40,060 --> 00:25:42,796 IT WOULDN'T BE EXPECTED TO BE 688 00:25:42,796 --> 00:25:43,897 COMPLETELY -- THE PROJECTS WOULD 689 00:25:43,897 --> 00:25:45,432 ALL NEED TO BE INVOLVING 690 00:25:45,432 --> 00:25:46,433 COINFECTION BUT WE WOULD EXPECT 691 00:25:46,433 --> 00:25:48,268 THEM TO HAVE AT LEAST ONE 692 00:25:48,268 --> 00:25:51,104 INVOLVING COINFECTION. 693 00:25:51,104 --> 00:25:56,143 PULMONARY TB AND OTHER NON-TBM 694 00:25:56,143 --> 00:25:57,778 DRUG OR REGIMEN WOULD BE 695 00:25:57,778 --> 00:25:58,979 EXCLUDED AND CLINICAL TRIALS AND 696 00:25:58,979 --> 00:26:03,917 CLINICAL STUDIES OF PULMONARY TB 697 00:26:03,917 --> 00:26:05,452 REGIMENS APPLIED DIRECTLY TO T 698 00:26:05,452 --> 00:26:05,786 BM. 699 00:26:05,786 --> 00:26:08,488 SO AS THIS IS A U19, THE 700 00:26:08,488 --> 00:26:09,689 EXPECTATION WOULD BE AT LEAST TO 701 00:26:09,689 --> 00:26:11,358 HAVE MULTIPLE RESEARCH PROJECTS, 702 00:26:11,358 --> 00:26:13,760 AT LEAST THREE SYNERGISTIC CROSS 703 00:26:13,760 --> 00:26:15,529 DISCIPLINARY HYPOTHESIS-DRIVEN 704 00:26:15,529 --> 00:26:17,798 RESEARCH PROJECTS, ONE BEING 705 00:26:17,798 --> 00:26:18,832 CLINICAL, ONE PRE-CLINICAL AND 706 00:26:18,832 --> 00:26:22,169 ONE TRANSLATIONAL. 707 00:26:22,169 --> 00:26:24,137 FOCUSED ON AREAS THAT WOULD 708 00:26:24,137 --> 00:26:28,074 INCLUDE OPTIMIZING TB DRUG 709 00:26:28,074 --> 00:26:30,477 COMBINATIONS AND REGIMENS, 710 00:26:30,477 --> 00:26:31,344 EXPANDING DRUG FORMULATION 711 00:26:31,344 --> 00:26:33,446 TECHNOLOGIES TO IMPROVE CNS DRUG 712 00:26:33,446 --> 00:26:35,749 EXPOSURE AND ELUCIDATING EFFECT 713 00:26:35,749 --> 00:26:37,617 OF INFLAMMATORY DAMAGE ON BLOOD 714 00:26:37,617 --> 00:26:40,554 BRAIN BARRIER AND NOVEL DRUG 715 00:26:40,554 --> 00:26:41,955 TARGETS AND WE'D STRONGLY 716 00:26:41,955 --> 00:26:43,490 ENCOURAGE THE INTEGRATION OF 717 00:26:43,490 --> 00:26:45,358 EXISTING DATA/SAMPLE COLLECTIONS 718 00:26:45,358 --> 00:26:47,327 STRONGLY ENCOURAGED. 719 00:26:47,327 --> 00:26:48,228 THE EXPECTATION IS EVERYONE 720 00:26:48,228 --> 00:26:49,462 WOULD HAVE AN ADMINISTRATIVE 721 00:26:49,462 --> 00:26:50,597 CORE WITH PROGRAM ORGANIZED 722 00:26:50,597 --> 00:26:52,566 WHERE THE PROGRAM ORGANIZATION 723 00:26:52,566 --> 00:26:53,333 AND MANAGEMENT SUPERVISION 724 00:26:53,333 --> 00:26:54,668 ACTIVITIES WOULD BE FOCUSED ON 725 00:26:54,668 --> 00:26:57,070 AND THERE WOULD BE A CENTRAL 726 00:26:57,070 --> 00:26:58,605 DATA MANAGEMENT CENTER. 727 00:26:58,605 --> 00:27:00,907 MULTIPLE SCIENTIFIC CORES THAT 728 00:27:00,907 --> 00:27:02,108 WOULD UTILIZE TWO OR MORE OF THE 729 00:27:02,108 --> 00:27:04,277 PROJECTS WITHIN THE PROGRAM. 730 00:27:04,277 --> 00:27:05,145 EXAMPLES WOULD INCLUDE 731 00:27:05,145 --> 00:27:06,079 IMMUNOLOGY, PHARMACOLOGY AND 732 00:27:06,079 --> 00:27:08,348 CLINICAL CORES, CLINICAL SITES 733 00:27:08,348 --> 00:27:09,850 AND LABORATORIES THAT WOULD 734 00:27:09,850 --> 00:27:10,517 ESTABLISH INFRASTRUCTURE AND 735 00:27:10,517 --> 00:27:11,818 EXPERTISE TO CONDUCT RESEARCH 736 00:27:11,818 --> 00:27:13,954 AND DEVELOPMENT OF AN EXTERNAL 737 00:27:13,954 --> 00:27:15,322 SCIENTIFIC ADVISORY GROUP 738 00:27:15,322 --> 00:27:16,857 ESTABLISHED AFTER THE AWARD IS 739 00:27:16,857 --> 00:27:18,925 MADE TO EVALUATE AND ADVISE ON 740 00:27:18,925 --> 00:27:19,926 SCIENTIFIC PROGRESS. 741 00:27:19,926 --> 00:27:21,228 AND ONCE AGAIN, WHERE WE SEE 742 00:27:21,228 --> 00:27:22,562 THIS FITTING IS THE 743 00:27:22,562 --> 00:27:24,097 TRANSLATIONAL STUDIES ARE A GAP 744 00:27:24,097 --> 00:27:26,166 IN DAIDS TBM PORTFOLIO. 745 00:27:26,166 --> 00:27:30,437 AND I'LL JUST NOTE ANNIE 746 00:27:30,437 --> 00:27:32,172 BRIDWELL DID THE LIT REVIEW HERE 747 00:27:32,172 --> 00:27:33,373 AND REALLY PUSHED THIS 748 00:27:33,373 --> 00:27:34,374 INITIATIVE FORWARD EARLY IN THE 749 00:27:34,374 --> 00:27:37,210 YEAR BEFORE SHE LEFT FOR OTHER 750 00:27:37,210 --> 00:27:39,379 OPPORTUNITIES OUTSIDE OF DAIDS. 751 00:27:39,379 --> 00:27:41,381 BUT THERE ARE 14 GRANTS 752 00:27:41,381 --> 00:27:43,016 CURRENTLY IN THE PORTFOLIO OF 753 00:27:43,016 --> 00:27:44,651 NIAID, FIVE OF WHICH ARE IN 754 00:27:44,651 --> 00:27:45,085 DAIDS. 755 00:27:45,085 --> 00:27:48,355 THREE OF WHICH ARE THROUGH A 756 00:27:48,355 --> 00:27:52,292 PREVIOUS PAR INITIATIVE THAT TRP 757 00:27:52,292 --> 00:27:56,129 HAD THAT HAS PRODUCED A PRETTY 758 00:27:56,129 --> 00:27:56,796 EFFECTIVE RESPONSE. 759 00:27:56,796 --> 00:27:59,633 AND FROM THE DAIDS STUDIES, THEY 760 00:27:59,633 --> 00:28:04,004 ARE PRIMARILY FOCUSED ON HUMAN 761 00:28:04,004 --> 00:28:06,072 STUDIES, WHEREAS DAIT AND DMID 762 00:28:06,072 --> 00:28:10,343 HAVE STUDIES ON ZEBRAFISH, 763 00:28:10,343 --> 00:28:11,978 RABBITS AND MICE BUT ONLY ONE 764 00:28:11,978 --> 00:28:14,614 STUDY REALLY COMBINING HUMANS -- 765 00:28:14,614 --> 00:28:16,917 AND THIS IS IN OUR PORTFOLIO, 766 00:28:16,917 --> 00:28:18,218 HUMANS AND MICE, SO WHERE WE SEE 767 00:28:18,218 --> 00:28:20,520 THE GAP CURRENTLY IN OUR 768 00:28:20,520 --> 00:28:21,388 PORTFOLIO AND WHERE WE WANT TO 769 00:28:21,388 --> 00:28:23,490 BE TAKING THE TB MENINGITIS 770 00:28:23,490 --> 00:28:25,025 FIELD FORWARD WITH THIS 771 00:28:25,025 --> 00:28:26,993 INITIATIVE IS BUILDING 772 00:28:26,993 --> 00:28:27,861 PRE-CLINICALLING, CLINICAL AND 773 00:28:27,861 --> 00:28:29,729 COMPUTATIONAL TBM COLLABORATIONS 774 00:28:29,729 --> 00:28:31,064 THAT WILL DRIVE MORE PORTABLE 775 00:28:31,064 --> 00:28:32,766 AND THEREFORE MORE TRANSLATABLE 776 00:28:32,766 --> 00:28:33,333 RELEVANT OUTCOMES. 777 00:28:33,333 --> 00:28:36,169 SO OUR REVIEWERS WERE DRS. 778 00:28:36,169 --> 00:28:38,672 ABRAMS AND NDHLOVU. 779 00:28:38,672 --> 00:28:40,974 WE'RE VERY THA THANKFUL FOR YOUR 780 00:28:40,974 --> 00:28:42,943 TIME AND EFFORT IN REVIEWING THE 781 00:28:42,943 --> 00:28:43,376 CONCEPT. 782 00:28:43,376 --> 00:28:44,711 THEY WERE HIGHLY SUPPORTIVE OF 783 00:28:44,711 --> 00:28:45,712 THE RELEVANT AND TIMELY PROPOSE 784 00:28:45,712 --> 00:28:46,112 WILL A. 785 00:28:46,112 --> 00:28:47,547 THEY THOUGHT THE U19 MECHANISM 786 00:28:47,547 --> 00:28:50,050 IS WELL SUITED FOR THE SCOPE OF 787 00:28:50,050 --> 00:28:52,986 WORK ENVISIONED AND COULD 788 00:28:52,986 --> 00:28:53,887 SUCCESSFULLY HARNESS DIVERSE 789 00:28:53,887 --> 00:28:55,188 RESOURCES TO CATALYZE SCIENCE 790 00:28:55,188 --> 00:28:56,523 AND INNOVATION, AND IT WILL 791 00:28:56,523 --> 00:28:58,458 ALLOW FOR TRANSFORMATIONAL 792 00:28:58,458 --> 00:28:59,659 INVESTMENT IN RESEARCH TO FILL A 793 00:28:59,659 --> 00:29:03,396 GAP TOWARDS ADVANCES IN NEW TBM 794 00:29:03,396 --> 00:29:04,397 DRUG REGIMENS. 795 00:29:04,397 --> 00:29:05,231 RECOMMENDATIONS INCLUDE SHOULD 796 00:29:05,231 --> 00:29:06,266 CONSIDER UNDERSCORING THE IMPACT 797 00:29:06,266 --> 00:29:08,301 OF TBM IN PEDIATRIC POPULATIONS 798 00:29:08,301 --> 00:29:10,270 AND THAT CHILDREN ARE A PRIORITY 799 00:29:10,270 --> 00:29:12,138 POPULATION TO INCLUDE. 800 00:29:12,138 --> 00:29:13,773 WE STRONGLY AGREE THAT CHILDREN 801 00:29:13,773 --> 00:29:15,642 ARE AN IMPORTANT POPULATION FOR 802 00:29:15,642 --> 00:29:16,843 TBM RESEARCH AND WILL BE 803 00:29:16,843 --> 00:29:18,078 PRIORITIZING THE INITIATIVE. 804 00:29:18,078 --> 00:29:20,146 I ATTEMPTED TO HIGHLIGHT THEM 805 00:29:20,146 --> 00:29:22,115 MORE IN TODAY'S PRESENTATION. 806 00:29:22,115 --> 00:29:23,216 AND OPPORTUNITIES TO LEVERAGE 807 00:29:23,216 --> 00:29:24,718 NEW INNOVATIONS AND ADVANCES IN 808 00:29:24,718 --> 00:29:28,455 THE USE OF 3D CEREBRAL ORGANOID 809 00:29:28,455 --> 00:29:29,889 MODELS AND OTHER ANIMAL MODELS 810 00:29:29,889 --> 00:29:31,958 SUCH AS NHPs THAT COULD 811 00:29:31,958 --> 00:29:32,659 STRENGTHEN TRANSLATIONAL 812 00:29:32,659 --> 00:29:34,294 COMPONENTS OF THE PROPOSAL. 813 00:29:34,294 --> 00:29:35,462 WE ARE THANKFUL FOR THE 814 00:29:35,462 --> 00:29:36,663 RECOMMENDATION AND AGREE IN 815 00:29:36,663 --> 00:29:38,298 PARTICULAR THAT CEREBRAL 816 00:29:38,298 --> 00:29:40,266 ORGANOID MODELS WOULD STRENGTHEN 817 00:29:40,266 --> 00:29:41,234 THE TRANSLATIONAL COMPONENT OF 818 00:29:41,234 --> 00:29:42,469 THE PROPOSAL AND WILL BE 819 00:29:42,469 --> 00:29:43,336 INCLUDED IN THE INITIATIVE. 820 00:29:43,336 --> 00:29:45,205 SO FOR THAT, I WILL JUST LEAVE 821 00:29:45,205 --> 00:29:47,507 IT HERE AND TAKE ANYBODY'S 822 00:29:47,507 --> 00:29:52,312 QUESTIONS. 823 00:29:52,312 --> 00:29:53,747 THANK YOU FOR YOUR TIME. 824 00:29:53,747 --> 00:29:54,848 HOPE I DIDN'T RUSH TOO FAST 825 00:29:54,848 --> 00:29:55,181 THROUGH THAT. 826 00:29:55,181 --> 00:29:56,149 >> NO, IT WAS GREAT. 827 00:29:56,149 --> 00:29:56,583 STAY UP THERE. 828 00:29:56,583 --> 00:29:57,884 LET'S SEE IF WE HAVE ANY 829 00:29:57,884 --> 00:29:58,151 QUESTIONS. 830 00:29:58,151 --> 00:30:00,353 >> I SAW NOTES BEING TAKEN IN 831 00:30:00,353 --> 00:30:01,588 THE PERIPHERY, SO -- 832 00:30:01,588 --> 00:30:04,357 >> WELL, I HAVE A QUESTION ABOUT 833 00:30:04,357 --> 00:30:08,495 WHETHER A DEVICE MIGHT BE 834 00:30:08,495 --> 00:30:11,031 CONSIDERED RESPONSIVE. 835 00:30:11,031 --> 00:30:12,565 IN CANCER, THERE'S A LOT OF 836 00:30:12,565 --> 00:30:15,935 DEVELOPMENT OF AN ULTRASOUND 837 00:30:15,935 --> 00:30:18,038 DEVICE THAT CAN OPEN THE BLOOD 838 00:30:18,038 --> 00:30:20,140 BRAIN BARRIER TRANSIENTLY. 839 00:30:20,140 --> 00:30:22,108 I DON'T KNOW -- I CAN'T SPEAK 840 00:30:22,108 --> 00:30:25,478 FOR IMPLEMENTATION OF SUCH A 841 00:30:25,478 --> 00:30:27,647 THING FOR TB. 842 00:30:27,647 --> 00:30:32,719 BUT WOULD IT BE USEFUL TO KIND 843 00:30:32,719 --> 00:30:34,454 OF AT THIS STAGE IN PRE-CLINICAL 844 00:30:34,454 --> 00:30:39,192 MODELS INCLUDING MICE AND 845 00:30:39,192 --> 00:30:39,826 ORGANOIDS TEST SOMETHING LIKE 846 00:30:39,826 --> 00:30:40,493 THAT? 847 00:30:40,493 --> 00:30:42,762 >> I'M NOT AWARE OF THEM DOING 848 00:30:42,762 --> 00:30:45,732 THAT CURRENTLY. 849 00:30:45,732 --> 00:30:47,167 A LOT OF WHAT I'M KNOWING FROM 850 00:30:47,167 --> 00:30:48,568 THE ANIMAL MODELS RIGHT NOW IS 851 00:30:48,568 --> 00:30:50,303 THE IMAGING, JUST BEING ABLE TO 852 00:30:50,303 --> 00:30:57,210 IMAGE THE BRAIN, BUT I KNOW WE 853 00:30:57,210 --> 00:30:58,511 WOULD CERTAINLY NOT SAY NO TO 854 00:30:58,511 --> 00:30:58,845 THAT. 855 00:30:58,845 --> 00:31:01,414 THE QUESTION OF COST WOULD BE 856 00:31:01,414 --> 00:31:03,116 ONE THAT WOULD NEED TO REALLY BE 857 00:31:03,116 --> 00:31:09,689 SERIOUSLY CONSIDERED. 858 00:31:09,689 --> 00:31:10,990 ANYONE ONLINE? 859 00:31:10,990 --> 00:31:12,759 SORRY. 860 00:31:12,759 --> 00:31:14,961 >> THERE'S NO ONE ONLINE WHO'S 861 00:31:14,961 --> 00:31:20,066 JOINING US BY ZOOM. 862 00:31:20,066 --> 00:31:20,934 NOPE. 863 00:31:20,934 --> 00:31:21,601 WELL, THANK YOU SO MUCH. 864 00:31:21,601 --> 00:31:22,402 >> THANK YOU. 865 00:31:22,402 --> 00:31:25,038 >> OKAY. 866 00:31:25,038 --> 00:31:27,107 YES, AND PAM IS REMINDING ME TO 867 00:31:27,107 --> 00:31:29,609 REMIND YOU TO PLEASE VOTE IN THE 868 00:31:29,609 --> 00:31:31,244 ELECTRONIC COUNCIL BOOK. 869 00:31:31,244 --> 00:31:34,948 AND YOU COULD DO THAT AS I 870 00:31:34,948 --> 00:31:37,917 INTRODUCE ANNE NEILAN FROM THE 871 00:31:37,917 --> 00:31:44,958 OFFICE OF AIDS RESEARCH ADVISORY 872 00:31:44,958 --> 00:31:48,228 COUNCIL BRIEFING. 873 00:31:48,228 --> 00:31:49,863 >> GOOD AFTERNOON, EVERYONE. 874 00:31:49,863 --> 00:31:52,599 I'M PLEASED TO SERVE AS THE 875 00:31:52,599 --> 00:31:54,234 LIAISON TO ARAC FOR THE OFFICE 876 00:31:54,234 --> 00:31:57,403 OF AIDS RESEARCH ADVISORY 877 00:31:57,403 --> 00:31:58,938 COUNCIL OR OARAC. 878 00:31:58,938 --> 00:31:59,606 THANKS FOR THE OPPORTUNITY TO 879 00:31:59,606 --> 00:32:05,478 PROVIDE A SUMMARY OF THE 66TH 6H 880 00:32:05,478 --> 00:32:06,179 OARAC MEETING. 881 00:32:06,179 --> 00:32:08,948 SO THE 66TH OARAC MEETING WAS 882 00:32:08,948 --> 00:32:13,186 HELD VIRTUALLY ON JUNE 20TH 883 00:32:13,186 --> 00:32:15,755 CHAIRED BY DR. IVY TURNBULL, 884 00:32:15,755 --> 00:32:16,956 DEPUTY EXECUTIVE DIRECTOR OF THE 885 00:32:16,956 --> 00:32:18,358 AIDS ALLIANCE FOR WOMEN, 886 00:32:18,358 --> 00:32:19,359 INFANTS, CHILDREN YOUTH AND 887 00:32:19,359 --> 00:32:21,194 FAMILIES, AND THAT INCLUDED A 888 00:32:21,194 --> 00:32:23,730 REPORT FROM OUR ACTING DIRECTOR. 889 00:32:23,730 --> 00:32:26,900 UPDATES ON THE 2026 TO 2030 NIH 890 00:32:26,900 --> 00:32:28,735 STRATEGIC PLAN FOR HIV AND 891 00:32:28,735 --> 00:32:29,502 HIV-RELATED RESEARCH. 892 00:32:29,502 --> 00:32:30,703 A PRESENTATION BY WHITE HOUSE 893 00:32:30,703 --> 00:32:32,906 OFFICE OF NATIONAL AIDS POLICY 894 00:32:32,906 --> 00:32:35,842 DIRECTOR FRANCISCO RUIZ, TWO 895 00:32:35,842 --> 00:32:37,810 PRESENTATIONS ON PERINATAL HIV 896 00:32:37,810 --> 00:32:39,012 RESEARCH AND RESPONSE, AS WELL 897 00:32:39,012 --> 00:32:46,052 AS UPDATES FROM ARAC AND THE NIH 898 00:32:46,052 --> 00:32:47,020 HIV/AIDS EXECUTIVE COMMITTEE AND 899 00:32:47,020 --> 00:32:50,523 ALL OF THE HIV CLINICAL 900 00:32:50,523 --> 00:32:57,864 GUIDELINES GROUPS. 901 00:32:57,864 --> 00:33:00,033 2026 NIH HIV/AIDS PROFESSIONAL 902 00:33:00,033 --> 00:33:00,900 JUDGMENT BUDGET WHICH WAS 903 00:33:00,900 --> 00:33:02,235 RELEASED IN JULY 2024. 904 00:33:02,235 --> 00:33:07,574 FOR EACH FISCAL YEAR, OAR 905 00:33:07,574 --> 00:33:09,542 PREPARES -- WHICH IS A DOCUMENT 906 00:33:09,542 --> 00:33:11,110 THAT SYMPTOMS THE AMOUNT OF 907 00:33:11,110 --> 00:33:12,745 FUNDING NEEDED TO FULLY PURSUE 908 00:33:12,745 --> 00:33:14,614 THE GOALS OF THE RESEARCH AGENDA 909 00:33:14,614 --> 00:33:17,116 ABOVE CURRENT FUNDING LEVELS. 910 00:33:17,116 --> 00:33:18,184 AND IT'S STRUCTURED TO ALIGN 911 00:33:18,184 --> 00:33:20,053 WITH THE STRATEGIC GOALS 912 00:33:20,053 --> 00:33:21,087 BULLETED ON THAT SLIDE, WHICH 913 00:33:21,087 --> 00:33:23,356 ARE FEATURED IN THE NEXT 914 00:33:23,356 --> 00:33:25,091 PROPOSED ITERATION OF THE NIH 915 00:33:25,091 --> 00:33:27,527 STRATEGIC PLAN FOR HIV AND 916 00:33:27,527 --> 00:33:28,728 HIV-RELATED RESEARCH. 917 00:33:28,728 --> 00:33:30,230 AND THE QR CODE ON THE SLIDE 918 00:33:30,230 --> 00:33:31,798 LINKS TO THAT PROFESSIONAL 919 00:33:31,798 --> 00:33:32,565 JUDGMENT BUDGET IF YOU ARE 920 00:33:32,565 --> 00:33:33,533 INTERESTED IN LEARNING MORE 921 00:33:33,533 --> 00:33:41,074 DETAILS ABOUT IT. 922 00:33:41,074 --> 00:33:43,042 DR. FINZI ALSO HIGHLIGHTED 923 00:33:43,042 --> 00:33:44,877 UPCOMING OAR ENGAGEMENT WHICH 924 00:33:44,877 --> 00:33:46,879 INCLUDED IN JUNE THE 925 00:33:46,879 --> 00:33:48,848 MULTIPURPOSE PREVENTION 926 00:33:48,848 --> 00:33:50,917 TECHNOLOGY OR NPT SUMMIT ON 927 00:33:50,917 --> 00:33:56,155 ENVISIONING THE FUTURE OF 928 00:33:56,155 --> 00:33:57,690 HIV/STI PREVENTION AND 929 00:33:57,690 --> 00:33:58,791 CONTRACEPTION. 930 00:33:58,791 --> 00:34:00,660 THE 25TH INTERNATIONAL AIDS 931 00:34:00,660 --> 00:34:04,130 CONFERENCE WAS HELD IN GERMANY, 932 00:34:04,130 --> 00:34:05,698 SESSIONS ON AGING, STIGMA AND 933 00:34:05,698 --> 00:34:06,899 GLOBAL HEALTH RECIPROCAL 934 00:34:06,899 --> 00:34:08,735 INNOVATION. 935 00:34:08,735 --> 00:34:11,271 IN LATE JULY, OAR PARTICIPATED 936 00:34:11,271 --> 00:34:13,239 ON A PANEL AT THE AFRICAN 937 00:34:13,239 --> 00:34:14,774 IMMIGRANT HEALTH RESEARCH 938 00:34:14,774 --> 00:34:15,541 COLLABORATIVE CONFERENCE WHICH 939 00:34:15,541 --> 00:34:17,010 WAS IN BOSTON, MASSACHUSETTS, 940 00:34:17,010 --> 00:34:21,514 AND THAT PANEL BROUGHT TOGETHER 941 00:34:21,514 --> 00:34:22,982 NATIONAL STRATEGIES FOR 942 00:34:22,982 --> 00:34:24,384 SUPPORTING COMMUNITY AND 943 00:34:24,384 --> 00:34:26,252 ACADEMIC PARTNERSHIPS FOCUSED ON 944 00:34:26,252 --> 00:34:27,353 AFRICAN IMMIGRANT HEALTH. 945 00:34:27,353 --> 00:34:29,555 LAST WEEK, AT THE GLOBAL BLACK 946 00:34:29,555 --> 00:34:31,491 PRIDE CONFERENCE IN ATLANTA, OAR 947 00:34:31,491 --> 00:34:33,926 AND THE NIH SEXUAL AND GENDER 948 00:34:33,926 --> 00:34:34,994 MINORITY RESEARCH OFFICE 949 00:34:34,994 --> 00:34:36,863 PRESENTED ON COMMUNITY 950 00:34:36,863 --> 00:34:38,965 PARTNERSHIPS IN THE CONTEXT OF 951 00:34:38,965 --> 00:34:40,600 NIH HIV RESEARCH AND ON 952 00:34:40,600 --> 00:34:42,001 ADVANCING HIV RESEARCH AT NIH 953 00:34:42,001 --> 00:34:43,636 FOR SEXUAL AND GENDER MINORITY 954 00:34:43,636 --> 00:34:45,071 PEOPLE. 955 00:34:45,071 --> 00:34:47,040 AND LASTLY IN A FEW DAYS, THE 956 00:34:47,040 --> 00:34:48,241 U.S. CONFERENCE ON HIV/AIDS WILL 957 00:34:48,241 --> 00:34:49,709 BE HELD IN NEW ORLEANS, 958 00:34:49,709 --> 00:34:51,344 LOUISIANA. 959 00:34:51,344 --> 00:34:53,379 THAT WILL BE IN COLLABORATION 960 00:34:53,379 --> 00:34:55,014 WITH THE NIH TRIBAL HEALTH 961 00:34:55,014 --> 00:34:57,283 RESEARCH OFFICE AND THE INDIAN 962 00:34:57,283 --> 00:34:59,285 HEALTH SERVICE, OAR WILL HOST A 963 00:34:59,285 --> 00:35:01,354 WORKSHOP FOCUSED ON EMERGING 964 00:35:01,354 --> 00:35:03,456 SCIENTIFIC AREAS THAT GUIDE 965 00:35:03,456 --> 00:35:04,457 NIH'S HIV RESEARCH PROGRAM AND 966 00:35:04,457 --> 00:35:05,558 THE IMPACTS ON TRIBAL 967 00:35:05,558 --> 00:35:10,363 COMMUNITIES. 968 00:35:10,363 --> 00:35:13,966 SO AT THAT 66TH OARAC MEETING AS 969 00:35:13,966 --> 00:35:14,534 DR. DIEFFENBACH ALLUDED TO, 970 00:35:14,534 --> 00:35:15,935 THERE WAS A LOT OF DISCUSSION 971 00:35:15,935 --> 00:35:18,905 ABOUT THE 2026 TO 2030 NIH 972 00:35:18,905 --> 00:35:21,107 STRATEGIC PLAN, AND OAR SENIOR 973 00:35:21,107 --> 00:35:22,642 POLICY ADVISOR DR. RACHEL 974 00:35:22,642 --> 00:35:25,011 ANDERSON REPORTED ON THE PROCESS 975 00:35:25,011 --> 00:35:26,612 TO DEVELOP THAT PLAN, INCLUDING 976 00:35:26,612 --> 00:35:29,482 THE REQUEST FOR INFORMATION FOR 977 00:35:29,482 --> 00:35:30,850 THAT PLAN DISTINCT FROM THE 978 00:35:30,850 --> 00:35:32,352 NIAID ONE THAT GENERATED OVER 979 00:35:32,352 --> 00:35:35,655 200 RESPONSES, AND DR. ANDERSON 980 00:35:35,655 --> 00:35:36,789 DISCUSSED HOW THE SOURCES WHICH 981 00:35:36,789 --> 00:35:38,858 ARE DEPICTED ON THE SLIDE ARE 982 00:35:38,858 --> 00:35:40,126 GOING TO INFORM THE DEVELOPMENT 983 00:35:40,126 --> 00:35:41,060 OF THE NEW PLAN WHICH IS 984 00:35:41,060 --> 00:35:42,128 EXPECTED TO LAUNCH DURING THE 985 00:35:42,128 --> 00:35:52,405 SUMMER OF 2025. 986 00:35:52,705 --> 00:35:54,073 DO YOU MIND ADVANCING THE SLIDE 987 00:35:54,073 --> 00:35:54,774 MAYBE ALL THE WAY THROUGH. 988 00:35:54,774 --> 00:35:55,174 THANK YOU. 989 00:35:55,174 --> 00:35:57,243 SO THE NEW PLAN PROPOSES A 990 00:35:57,243 --> 00:35:58,344 FRAMEWORK OF THREE BROAD 991 00:35:58,344 --> 00:35:59,645 RESEARCH GOALS AND ONE CAPACITY 992 00:35:59,645 --> 00:36:00,980 GOAL WITH CORRESPONDING 993 00:36:00,980 --> 00:36:02,081 OBJECTIVES. 994 00:36:02,081 --> 00:36:05,685 SO FOR GOAL ONE, IT IS TO 995 00:36:05,685 --> 00:36:07,120 ENHANCE THE DISCOVERY AND 996 00:36:07,120 --> 00:36:08,755 ADVANCE HIV SCIENCE THROUGH 997 00:36:08,755 --> 00:36:09,622 FUNDAMENTAL RESEARCH AND I'LL 998 00:36:09,622 --> 00:36:10,723 READ OUT THE OBJECTIVES AS I'VE 999 00:36:10,723 --> 00:36:11,491 BEEN ASKED TO DO. 1000 00:36:11,491 --> 00:36:13,659 THERE ARE A LOT OF BIG WORDS ON 1001 00:36:13,659 --> 00:36:14,794 HERE MEANT TO TOUCH ON THE 1002 00:36:14,794 --> 00:36:15,862 SCIENTIFIC AREAS ENCOMPASSED 1003 00:36:15,862 --> 00:36:16,529 UNDER EACH ONE. 1004 00:36:16,529 --> 00:36:19,098 SO THE OBJECTIVES UNDER GOAL ONE 1005 00:36:19,098 --> 00:36:21,367 ARE TO ENHANCE DISCOVERY AND 1006 00:36:21,367 --> 00:36:23,102 ADVANCE HIV SCIENCE THROUGH 1007 00:36:23,102 --> 00:36:24,871 FUNDAMENTAL RESEARCH, 1008 00:36:24,871 --> 00:36:26,072 COMORBIDITIES, COINFECTIONS AND 1009 00:36:26,072 --> 00:36:27,106 COMPLICATIONS. 1010 00:36:27,106 --> 00:36:29,275 EPIDEMIOLOGIC ASPECTS OF HIV 1011 00:36:29,275 --> 00:36:31,010 INFECTION, COINFECTIONS AND 1012 00:36:31,010 --> 00:36:31,677 COMORBIDITIES, BEHAVIORAL AND 1013 00:36:31,677 --> 00:36:34,313 SOCIAL FACTORS AND PROCESSES. 1014 00:36:34,313 --> 00:36:35,948 GOAL TWO IS TO ADVANCE THE 1015 00:36:35,948 --> 00:36:37,350 DEVELOPMENT AND ASSESSMENT OF 1016 00:36:37,350 --> 00:36:38,918 NOVEL INTERVENTIONS FOR HIV 1017 00:36:38,918 --> 00:36:41,287 PREVENTION, TREATMENT, AND CURE. 1018 00:36:41,287 --> 00:36:44,056 AND THE OBJECTIVES THERE INCLUDE 1019 00:36:44,056 --> 00:36:47,093 PRE-CLINICAL AND TRANSLATIONAL 1020 00:36:47,093 --> 00:36:48,661 RESEARCH, CLINICAL TRIALS AND 1021 00:36:48,661 --> 00:36:49,862 OTHER INTERVENTION STUDIES OF 1022 00:36:49,862 --> 00:36:51,931 PROMISING HIV PREVENTION, 1023 00:36:51,931 --> 00:36:53,232 TREATMENT, COMORBIDITIES AND 1024 00:36:53,232 --> 00:36:54,801 CURE STRATEGIES, NEW AND 1025 00:36:54,801 --> 00:36:56,002 INTEGRATED MODELS OF HIV 1026 00:36:56,002 --> 00:36:57,870 PREVENTION, TREATMENT, CARE, 1027 00:36:57,870 --> 00:36:58,971 COMORBIDITIES AND CURE RESEARCH 1028 00:36:58,971 --> 00:37:03,776 AND SERVICES. 1029 00:37:03,776 --> 00:37:05,878 THE THIRD RESEARCH GOAL IS TO 1030 00:37:05,878 --> 00:37:09,015 OPT MICE PUBLIC HEALTH IMPACT OF 1031 00:37:09,015 --> 00:37:11,784 HIV DISCOVERIES THROUGH 1032 00:37:11,784 --> 00:37:12,552 DISSEMINATION, IMPLEMENTATION OF 1033 00:37:12,552 --> 00:37:14,086 RESEARCH FINDINGS. 1034 00:37:14,086 --> 00:37:15,855 THE CORRESPONDING GOALS ARE 1035 00:37:15,855 --> 00:37:16,622 IMPLEMENTATION SCIENCE AND 1036 00:37:16,622 --> 00:37:17,590 TRANSLATIONAL RESEARCH, 1037 00:37:17,590 --> 00:37:19,225 COMMUNITY ENGAGED AND COMMUNITY 1038 00:37:19,225 --> 00:37:20,860 LED HIV RESEARCH, DISSEMINATION 1039 00:37:20,860 --> 00:37:21,861 AND COMMUNICATION OF HIV 1040 00:37:21,861 --> 00:37:22,195 SCIENCE. 1041 00:37:22,195 --> 00:37:24,297 AND THEN THE FOURTH CAPACITY 1042 00:37:24,297 --> 00:37:25,832 BUILDING GOAL IS TO BUILD 1043 00:37:25,832 --> 00:37:26,466 RESEARCH WORKFORCE AND 1044 00:37:26,466 --> 00:37:27,800 INFRASTRUCTURE CAPACITY TO 1045 00:37:27,800 --> 00:37:30,002 ENHANCE SUSTAINABILITY OF HIV 1046 00:37:30,002 --> 00:37:31,938 SCIENTIFIC DISCOVERY. 1047 00:37:31,938 --> 00:37:33,606 WITH OBJECTIVES OF WORKFORCE 1048 00:37:33,606 --> 00:37:35,508 CAPACITY STRENGTHENING, RESEARCH 1049 00:37:35,508 --> 00:37:36,642 INFRASTRUCTURE AND CAPACITY AND 1050 00:37:36,642 --> 00:37:41,581 METHODS AND TECHNOLOGIES. 1051 00:37:41,581 --> 00:37:45,318 THREE OAR TASK FORCES WERE 1052 00:37:45,318 --> 00:37:46,853 FORMED IN THE SUMMER OF 2024 1053 00:37:46,853 --> 00:37:49,589 BASED ON FUNCTIONAL SCIENCE 1054 00:37:49,589 --> 00:37:51,557 AREAS, PRE-CLINICAL RESEARCH, 1055 00:37:51,557 --> 00:37:52,391 INTERVENTION RESEARCH AND 1056 00:37:52,391 --> 00:37:53,759 BEHAVIORAL AND SOCIAL SCIENCES 1057 00:37:53,759 --> 00:37:54,227 RESEARCH. 1058 00:37:54,227 --> 00:37:56,229 EACH TASK FORCE INCLUDES OARAC 1059 00:37:56,229 --> 00:37:57,063 MEMBERS AS WELL AS OTHER 1060 00:37:57,063 --> 00:37:58,931 EXTERNAL SUBJECT MATTER EXPERTS 1061 00:37:58,931 --> 00:38:00,600 MEANT TO REFLECT A BROAD RANGE 1062 00:38:00,600 --> 00:38:04,003 OF EXPERTISE IN HIV SCIENCE, IN 1063 00:38:04,003 --> 00:38:05,505 CLINICAL EXPERIENCE, AND IN 1064 00:38:05,505 --> 00:38:07,607 LIVED EXPERIENCE WITH HIV. 1065 00:38:07,607 --> 00:38:09,108 AND THANKS TO THOSE OF YOU TODAY 1066 00:38:09,108 --> 00:38:10,510 WHO ARE -- MANY OF YOU HERE WHO 1067 00:38:10,510 --> 00:38:12,211 ARE SERVING ON THOSE TASK FORCE 1068 00:38:12,211 --> 00:38:12,879 COMMITTEES. 1069 00:38:12,879 --> 00:38:15,314 THE TASK FORCES ARE THEN CHARGED 1070 00:38:15,314 --> 00:38:16,749 WITH DEVELOPING RECOMMENDATIONS 1071 00:38:16,749 --> 00:38:21,287 FOR FUNDING PRIORITIES UNDER 1072 00:38:21,287 --> 00:38:22,955 THOSE BROAD CATEGORIES THAT ARE 1073 00:38:22,955 --> 00:38:24,323 THEN GOING TO BE SHARED AT THE 1074 00:38:24,323 --> 00:38:30,496 NEXT ORAC MEETING IN OCTOBER. 1075 00:38:30,496 --> 00:38:33,466 SO IN THE NEXT PART OF THAT # 1076 00:38:33,466 --> 00:38:36,402 6TH OARAC MEETING, FRANCISCO 1077 00:38:36,402 --> 00:38:38,905 RUIZ, NAMED DIRECTOR OF THE 1078 00:38:38,905 --> 00:38:39,939 WHITE HOUSE OFFICE OF NATIONAL 1079 00:38:39,939 --> 00:38:41,707 AIDS POLICY IN 2024 THEN GAVE A 1080 00:38:41,707 --> 00:38:42,909 PRESENTATION IN WHICH HE 1081 00:38:42,909 --> 00:38:47,413 DISCUSSED HOW ONAP'S VALUES, 1082 00:38:47,413 --> 00:38:48,581 EQUITY, ACCOUNTABILITY, 1083 00:38:48,581 --> 00:38:50,483 INNOVATION, INCLUSIVITY, 1084 00:38:50,483 --> 00:38:51,484 ACCESSIBILITY, ADAPTABILITY AND 1085 00:38:51,484 --> 00:38:52,685 COLLABORATION GUIDE THE OFFICE'S 1086 00:38:52,685 --> 00:38:54,954 EFFORTS TO IMPLEMENT THE WHITE 1087 00:38:54,954 --> 00:38:56,422 HOUSE'S NATIONAL HIV/AIDS 1088 00:38:56,422 --> 00:38:57,056 STRATEGY, DISTINCT FROM THE 1089 00:38:57,056 --> 00:38:59,125 OTHER STRATEGIES. 1090 00:38:59,125 --> 00:39:01,127 MR. RUIZ PRESENTED NEW CDC DATA 1091 00:39:01,127 --> 00:39:02,995 REPORTING AN OVERALL 12% DECLINE 1092 00:39:02,995 --> 00:39:05,531 IN NEW HIV INFECTIONS IN THE 1093 00:39:05,531 --> 00:39:08,167 U.S. FROM 2018 TO 2 2022. 1094 00:39:08,167 --> 00:39:09,769 HE CONTEXTUALIZED THOSE FINDINGS 1095 00:39:09,769 --> 00:39:11,070 BY NOTING THE SUCCESS OF 1096 00:39:11,070 --> 00:39:12,438 PREVENTION STRATEGIES. 1097 00:39:12,438 --> 00:39:14,640 HE ALSO ACKNOWLEDGED PERSISTENT 1098 00:39:14,640 --> 00:39:17,743 DISPARITIES BY RACE/ETHNICITY 1099 00:39:17,743 --> 00:39:20,346 AND SEX WITH 37% OF NEW HIF 1100 00:39:20,346 --> 00:39:21,447 INFECTIONS IN BLACK AFRICAN 1101 00:39:21,447 --> 00:39:22,982 AMERICAN PEOPLE, AND 81% IN 1102 00:39:22,982 --> 00:39:25,217 PEOPLE ASSIGNED MALE AT BIRTH IN 1103 00:39:25,217 --> 00:39:26,452 2022. 1104 00:39:26,452 --> 00:39:29,388 HE ALSO PRESENTED DATA SHOWING 1105 00:39:29,388 --> 00:39:30,156 SIGNIFICANT GEOGRAPHIC 1106 00:39:30,156 --> 00:39:31,691 DISPARITIES WITH 49% OF NEW 1107 00:39:31,691 --> 00:39:33,793 INFECTIONS OCCURRING IN THE U.S. 1108 00:39:33,793 --> 00:39:36,395 SOUTH IN 2022, AND MR. RUIZ ALSO 1109 00:39:36,395 --> 00:39:37,363 TOOK THE OPPORTUNITY TO 1110 00:39:37,363 --> 00:39:40,466 HIGHLIGHT THE OFFICE OF NATIONAL 1111 00:39:40,466 --> 00:39:41,901 AIDS POLICY, THE EFFORTS OF THAT 1112 00:39:41,901 --> 00:39:44,637 OFFICE TO OUTREACH TO GROUPS 1113 00:39:44,637 --> 00:39:45,838 EXPERIENCING HIGHER RATES OF HIV 1114 00:39:45,838 --> 00:39:47,707 OR ADAPTING HIV PREVENTION 1115 00:39:47,707 --> 00:39:49,108 PROGRAMS FOR RURAL AREAS IN THE 1116 00:39:49,108 --> 00:39:51,544 SOUTH, FOR EXAMPLE. 1117 00:39:51,544 --> 00:39:57,883 HE ALSO FLAGGED THE ONAPS' 2024 1118 00:39:57,883 --> 00:39:59,218 PRIORITIES WHICH ARE TO 1119 00:39:59,218 --> 00:40:00,419 MODERNIZE POLICIES TO ENSURE 1120 00:40:00,419 --> 00:40:03,155 THEY'RE BASED ON CURRENT 1121 00:40:03,155 --> 00:40:04,490 SCIENTIFIC KNOWLEDGE, TO 1122 00:40:04,490 --> 00:40:05,658 ACCELERATE PROGRESS IN THE 1123 00:40:05,658 --> 00:40:06,892 FEDERAL HIV RESPONSE AND TO 1124 00:40:06,892 --> 00:40:07,860 ADVANCE EQUITY AND ACCESS. 1125 00:40:07,860 --> 00:40:09,629 HE ENDED HIS REMARKS WITH A CALL 1126 00:40:09,629 --> 00:40:11,931 TO ACTION ENCOURAGING MEETING 1127 00:40:11,931 --> 00:40:13,599 ATTENDEES TO RECOMMIT EFFORTS TO 1128 00:40:13,599 --> 00:40:15,067 ENDING THE HIV EPIDEMIC. 1129 00:40:15,067 --> 00:40:17,770 AT THE END OF JULY, THEY HELD A 1130 00:40:17,770 --> 00:40:19,171 SUMMIT THAT FEATURED RISING 1131 00:40:19,171 --> 00:40:19,905 LEADERS IN COMMUNITIES THAT 1132 00:40:19,905 --> 00:40:21,841 CONTINUE TO BE MOST IMPACTED BY 1133 00:40:21,841 --> 00:40:23,242 THE RACIAL INEQUITIES DRIVING 1134 00:40:23,242 --> 00:40:26,846 THE HIV EPIDEMIC. 1135 00:40:26,846 --> 00:40:28,881 IN THE NEXT PART OF THE MEETING, 1136 00:40:28,881 --> 00:40:30,916 THERE WERE PRESENTATIONS ON 1137 00:40:30,916 --> 00:40:32,118 PERINATAL HIV RESEARCH AND 1138 00:40:32,118 --> 00:40:35,187 RESPONSE. 1139 00:40:35,187 --> 00:40:41,994 DR. PLEASE MARTINS PRESENTED BD 1140 00:40:41,994 --> 00:40:42,662 TRANSLATIONAL RESEARCH ON THE 1141 00:40:42,662 --> 00:40:46,599 USE OF IMMUNOGLOBULIN-BASED HIV 1142 00:40:46,599 --> 00:40:48,200 BIOLOGICS TO PREVENT PERINATAL 1143 00:40:48,200 --> 00:40:50,002 TRANSMISSION AND THEN 1144 00:40:50,002 --> 00:40:52,438 MS. KIMBERLY KENNEDY, BORN WITH 1145 00:40:52,438 --> 00:40:54,073 HIV IN THE 1980s, PROVIDED A 1146 00:40:54,073 --> 00:40:55,508 VERY MOVING PERSONAL AND 1147 00:40:55,508 --> 00:40:58,811 COMMUNITY PERSPECTIVE. 1148 00:40:58,811 --> 00:41:04,717 SO DR. MARTINS DISCUSSED HOW HOW 1149 00:41:04,717 --> 00:41:06,085 ANTIRETROVIRAL THERAPY OR ART IS 1150 00:41:06,085 --> 00:41:07,486 EFFECTIVE IN PREVENTING 1151 00:41:07,486 --> 00:41:08,688 PERINATAL TRANSMISSION, ISSUES 1152 00:41:08,688 --> 00:41:11,657 SUCH AS UNDIAGNOSED HIV AND 1153 00:41:11,657 --> 00:41:13,325 PREGNANT PEOPLE, DRUG TOXICITY 1154 00:41:13,325 --> 00:41:15,594 AND RESISTANCE, POOR ADHERENCE 1155 00:41:15,594 --> 00:41:17,897 AND STIGMA MAKE IT UNLIKELY IT 1156 00:41:17,897 --> 00:41:19,699 ALONE WILL STOP PERINATAL 1157 00:41:19,699 --> 00:41:20,533 TRANSMISSION. 1158 00:41:20,533 --> 00:41:21,734 HIS TEAM INVESTIGATES DELIVERING 1159 00:41:21,734 --> 00:41:23,736 HIV BROADLY NEUTRALIZING 1160 00:41:23,736 --> 00:41:25,571 ANTIBODIES TO BOTH PREVENT HIV 1161 00:41:25,571 --> 00:41:26,338 TRANSMISSION IN INFANTS AND 1162 00:41:26,338 --> 00:41:30,076 CHILDREN AS WELL AS TO PROMOTE 1163 00:41:30,076 --> 00:41:32,278 SUSTAINED BIOLOGIC RESPONSE. 1164 00:41:32,278 --> 00:41:34,680 SO HE SHOWED DATA SHOWING A 1165 00:41:34,680 --> 00:41:35,648 SUBSTANTIAL DELAY IN VIRAL 1166 00:41:35,648 --> 00:41:37,083 REBOUND WITH EARLY ART 1167 00:41:37,083 --> 00:41:39,752 INITIATION, PROVIDED IN 1168 00:41:39,752 --> 00:41:41,487 COMBINATION WITH B NAPS. 1169 00:41:41,487 --> 00:41:43,789 WITH CONTINUED RESEARCH, MARTINS 1170 00:41:43,789 --> 00:41:46,025 SUGGESTED THE DELIVERY COULD BE 1171 00:41:46,025 --> 00:41:47,660 KEY TO SUSTAINED BUY LODGE 1172 00:41:47,660 --> 00:41:50,930 REMISSION WITH CHILDREN WITH 1173 00:41:50,930 --> 00:41:51,897 HIV -- SO CALLED FUNCTIONAL 1174 00:41:51,897 --> 00:41:52,998 CURE. 1175 00:41:52,998 --> 00:41:55,568 HE ALSO -- THROUGH 1176 00:41:55,568 --> 00:41:56,669 ADENOASSOCIATED VIRUS RISK 1177 00:41:56,669 --> 00:41:58,504 FACTORS COULD THEORETICALLY 1178 00:41:58,504 --> 00:42:02,675 PROVIDE IMMUNITY THROUGHOUT 1179 00:42:02,675 --> 00:42:05,211 INFANCY, WITH DURABILITY PERHAPS 1180 00:42:05,211 --> 00:42:07,279 LASTING MANY YEARS THROUGH EARLY 1181 00:42:07,279 --> 00:42:08,247 ADULTHOOD. 1182 00:42:08,247 --> 00:42:10,483 THEN MS. CANADY WHO I MENTIONED 1183 00:42:10,483 --> 00:42:13,552 BORN WITH HIV IN 1986 DESCRIBED 1184 00:42:13,552 --> 00:42:14,520 HER EXPERIENCE GROWING UP IN THE 1185 00:42:14,520 --> 00:42:16,222 EARLY STAGES OF THE HIV 1186 00:42:16,222 --> 00:42:17,523 EPIDEMIC, BEFORE ART WAS 1187 00:42:17,523 --> 00:42:19,158 AVAILABLE, SHE NOTED THAT TODAY 1188 00:42:19,158 --> 00:42:21,227 THERE ARE 13,000 PEOPLE IN THE 1189 00:42:21,227 --> 00:42:24,196 U.S. WITH HIV-ACQUIRED PERINAY 1190 00:42:24,196 --> 00:42:25,631 NATELY, MANY NOW IN THEIR 30s 1191 00:42:25,631 --> 00:42:27,533 AND 40s, AND SHE NOTED THIS 1192 00:42:27,533 --> 00:42:28,834 POPULATION WILL CONTINUE TO AGE 1193 00:42:28,834 --> 00:42:31,036 AND EXPERIENCE HIV AND 1194 00:42:31,036 --> 00:42:31,637 AGE-RELATED COMPLICATIONS AND 1195 00:42:31,637 --> 00:42:33,906 SHE CALLED ON MEETING ATTENDEES 1196 00:42:33,906 --> 00:42:36,509 VERY SPECIFICALLY TO PRIORITIZE 1197 00:42:36,509 --> 00:42:38,544 RESEARCH TO ADDRESS THE MEDICAL, 1198 00:42:38,544 --> 00:42:40,179 MENTAL HEALTH AND SOCIAL NEEDS 1199 00:42:40,179 --> 00:42:42,381 OF LONG-TERM SURVIVORS WITH HIV, 1200 00:42:42,381 --> 00:42:43,449 PARTICULARLY THAT WAS BORN WITH 1201 00:42:43,449 --> 00:42:50,389 HIV. 1202 00:42:50,389 --> 00:42:51,757 THE 66TH OARAC MEETING CLOSED 1203 00:42:51,757 --> 00:42:54,794 THEN WITH UPDATES FROM ARAC 1204 00:42:54,794 --> 00:42:56,328 PROVIDED BY DR. ABRAMS AND FROM 1205 00:42:56,328 --> 00:42:57,997 THE NIH AIDS EXECUTIVE 1206 00:42:57,997 --> 00:42:59,431 COMMITTEE, AS WELL AS UPDATES 1207 00:42:59,431 --> 00:43:01,267 FROM THE HIV CLINICAL GUIDELINES 1208 00:43:01,267 --> 00:43:03,369 WORKING GROUPS OF OARAC AND FOR 1209 00:43:03,369 --> 00:43:04,603 THOSE WHO ARE NOT FAMILIAR WITH 1210 00:43:04,603 --> 00:43:05,905 THEM, THOSE ARE THE GROUPS WHICH 1211 00:43:05,905 --> 00:43:07,540 DEVELOP THE HIV CLINICAL 1212 00:43:07,540 --> 00:43:09,842 PRACTICE GUIDELINES THAT INFORM 1213 00:43:09,842 --> 00:43:11,177 CLINICAL PRACTICE IN THE U.S. 1214 00:43:11,177 --> 00:43:17,616 AND AROUND THE WORLD. 1215 00:43:17,616 --> 00:43:21,687 AS A REMINDER, RECORDINGS OF -- 1216 00:43:21,687 --> 00:43:22,721 MEETINGS MINUTES AND SUMMARIES 1217 00:43:22,721 --> 00:43:24,557 OF THE OARAC MEETINGS ARE 1218 00:43:24,557 --> 00:43:25,524 AVAILABLE ON OUR WEBSITE. 1219 00:43:25,524 --> 00:43:27,092 THE NEXT MEETING WILL BE 1220 00:43:27,092 --> 00:43:31,497 VIRTUAL, THURSDAY, OCTOBER 24TH, 1221 00:43:31,497 --> 00:43:31,697 2024. 1222 00:43:31,697 --> 00:43:32,898 AS MENTIONED THAT MEETING WILL 1223 00:43:32,898 --> 00:43:34,700 FEATURE REPORT OUTS FROM THE HIV 1224 00:43:34,700 --> 00:43:36,535 STRATEGIC PLANNING TASK FORCES. 1225 00:43:36,535 --> 00:43:40,573 AS WELL AS A REVIEW OF THE 1226 00:43:40,573 --> 00:43:43,876 ORIGINS OF --CAPAVIR, AS USUAL 1227 00:43:43,876 --> 00:43:45,311 THE MEETING WILL BE VIDEOCAST 1228 00:43:45,311 --> 00:43:45,911 FOR PUBLIC VIEWING. 1229 00:43:45,911 --> 00:43:46,745 THANK YOU. 1230 00:43:46,745 --> 00:43:51,984 ANY QUESTIONS? 1231 00:43:51,984 --> 00:43:52,685 IF THERE'S TIME? 1232 00:43:52,685 --> 00:43:54,220 >> THERE'S PLENTY OF TIME. 1233 00:43:54,220 --> 00:43:58,357 ANY QUESTION FORCE ANNE? 1234 00:43:58,357 --> 00:43:58,924 NO? 1235 00:43:58,924 --> 00:44:00,226 I DON'T SEE ANY. 1236 00:44:00,226 --> 00:44:01,694 THANK YOU VERY MUCH. 1237 00:44:01,694 --> 00:44:04,296 WE ARE WAY AHEAD OF TIME. 1238 00:44:04,296 --> 00:44:05,598 EVERYONE HAS VOTED, BY THE WAY. 1239 00:44:05,598 --> 00:44:06,365 THANK YOU FOR THAT. 1240 00:44:06,365 --> 00:44:12,238 WE CAN TAKE A BREAK NOW, AND 1241 00:44:12,238 --> 00:44:15,608 RECONVENE AT THE TOP OF THE 1242 00:44:15,608 --> 00:44:21,489 HOUR. 2:00 EASTERN. 1243 00:44:21,489 --> 00:44:23,992 WELCOME BACK, EVERYONE. 1244 00:44:23,992 --> 00:44:27,028 NICK BUSHAR WILL NOW GIVE US AN 1245 00:44:27,028 --> 00:44:28,763 UPDATE ON THE NIAID STRATEGIC 1246 00:44:28,763 --> 00:44:32,300 PLAN, THE RFI RESPONSES, 1247 00:44:32,300 --> 00:44:34,469 RESPONSES TO THE RFI. 1248 00:44:34,469 --> 00:44:35,603 >> GREAT, THANK YOU VERY MUCH. 1249 00:44:35,603 --> 00:44:37,472 AND THANK YOU VERY MUCH FOR THE 1250 00:44:37,472 --> 00:44:41,075 OPPORTUNITY TO COME TODAY. 1251 00:44:41,075 --> 00:44:42,844 I PUT ON A SUIT SO THE KIDS CAN 1252 00:44:42,844 --> 00:44:44,212 FEEL LIKE DAD IS DOING SOMETHING 1253 00:44:44,212 --> 00:44:45,313 IMPORTANT AT WORK. 1254 00:44:45,313 --> 00:44:46,748 THEY WERE QUITE SURPRISED TO SAY 1255 00:44:46,748 --> 00:44:48,483 THE LEAST THAT DAD HAD A TIE ON 1256 00:44:48,483 --> 00:44:48,917 THIS MORNING. 1257 00:44:48,917 --> 00:44:49,918 TODAY I'M GOING TO BE TALKING A 1258 00:44:49,918 --> 00:44:51,352 LITTLE BIT ABOUT THE NIAID 1259 00:44:51,352 --> 00:44:52,654 STRATEGIC PLAN, IN PARTICULAR, 1260 00:44:52,654 --> 00:44:54,456 THE RESPONSES TO THE RFI. 1261 00:44:54,456 --> 00:44:56,424 AS CARL MENTIONED EARLIER, THE 1262 00:44:56,424 --> 00:44:57,959 STRATEGIC PLAN IS MEANT TO BE 1263 00:44:57,959 --> 00:44:59,461 BOTH AN ORGANIZATIONAL EXERCISE 1264 00:44:59,461 --> 00:45:01,463 AND ALSO AN OPPORTUNITY TO KIND 1265 00:45:01,463 --> 00:45:02,564 OF PARTNER WITH THE PUBLIC AND 1266 00:45:02,564 --> 00:45:05,767 GET A LOT OF INPUT SO THAT WE 1267 00:45:05,767 --> 00:45:06,768 CAN CREATE THE PLAN MOVING 1268 00:45:06,768 --> 00:45:07,101 FORWARD. 1269 00:45:07,101 --> 00:45:10,371 SO I'M GOING TO START A LITTLE 1270 00:45:10,371 --> 00:45:11,473 BIT ON WHAT I THINK IS 1271 00:45:11,473 --> 00:45:13,608 EVERYBODY'S MOST EXCITING TOPIC 1272 00:45:13,608 --> 00:45:16,311 OF THE DAY, THE STRATEGIC PLAN. 1273 00:45:16,311 --> 00:45:17,745 I WILL KEEP THIS BRIEF AND 1274 00:45:17,745 --> 00:45:18,947 ORGANIZED FOR EVERYBODY, BUT 1275 00:45:18,947 --> 00:45:20,715 SUFFICE IT TO SAY, IT IS 1276 00:45:20,715 --> 00:45:21,583 IMPORTANT BECAUSE IT GIVES A 1277 00:45:21,583 --> 00:45:23,017 LITTLE BIT OF CONTEXT INTO WHEN 1278 00:45:23,017 --> 00:45:25,186 WE START GOING THROUGH SOME OF 1279 00:45:25,186 --> 00:45:27,422 THE RFI RESPONSES, A BIT OF THE 1280 00:45:27,422 --> 00:45:28,389 ORIGIN, WHERE THEY CAME FROM, 1281 00:45:28,389 --> 00:45:29,491 AND IN PARTICULAR, WHAT THEY SAW 1282 00:45:29,491 --> 00:45:30,725 WHEN THEY WERE RESPONNING IN 1283 00:45:30,725 --> 00:45:32,460 PARTICULAR. 1284 00:45:32,460 --> 00:45:32,927 RESPONDING IN 1285 00:45:32,927 --> 00:45:33,228 PARTICULAR. 1286 00:45:33,228 --> 00:45:35,463 SO THE PREVIOUS STRATEGIC PLAN 1287 00:45:35,463 --> 00:45:38,766 WAS LAST UPDATED IN 2 2017 AND 1288 00:45:38,766 --> 00:45:39,767 OBVIOUSLY WITH SOME CHANGES IN 1289 00:45:39,767 --> 00:45:40,835 THE GLOBAL LANDSCAPE OF 1290 00:45:40,835 --> 00:45:42,270 INFECTIOUS DISEASES SINCE THEN, 1291 00:45:42,270 --> 00:45:43,738 AS WELL AS THE INTRODUCTION OF A 1292 00:45:43,738 --> 00:45:44,973 NEW DIRECTOR TO NIAID, IT WAS 1293 00:45:44,973 --> 00:45:46,608 REALLY TIME FOR AN UPDATE. 1294 00:45:46,608 --> 00:45:49,344 AND I DO MENTION THIS BECAUSE 1295 00:45:49,344 --> 00:45:53,748 REALLY WHEN YOU LOOK THE A STWRA 1296 00:45:53,748 --> 00:45:56,384 STRATEGIC PLAN, ONE OF THE KEY 1297 00:45:56,384 --> 00:45:57,719 THINGS IS ENGAGING IN FORWARD 1298 00:45:57,719 --> 00:45:57,986 THINKING. 1299 00:45:57,986 --> 00:45:59,487 I KNOW THAT SOUNDS VERY SIMPLE, 1300 00:45:59,487 --> 00:46:01,656 ENOUGH TO SAY, HOWEVER, YOU'D BE 1301 00:46:01,656 --> 00:46:02,690 AMAZED HOW OFTEN WHEN YOU START 1302 00:46:02,690 --> 00:46:04,325 IN THESE PROCESSES, YOU OFTEN 1303 00:46:04,325 --> 00:46:05,393 KIND OF LEAN BACK ON YOUR HEELS 1304 00:46:05,393 --> 00:46:06,761 AND SAY, WELL, WE'VE BEEN DOING 1305 00:46:06,761 --> 00:46:08,730 THIS, WE SHOULD JUST KEEP DOING 1306 00:46:08,730 --> 00:46:09,531 WHAT WE'RE DOING. 1307 00:46:09,531 --> 00:46:10,598 HOWEVER, THIS IS REALLY AN 1308 00:46:10,598 --> 00:46:11,432 OPPORTUNITY FOR US TO LOOK AT 1309 00:46:11,432 --> 00:46:14,369 THE NEXT FIVE YEARS OF NIAID IN 1310 00:46:14,369 --> 00:46:14,702 PARTICULAR. 1311 00:46:14,702 --> 00:46:15,803 WHAT I'M GOING TO REVIEW TODAY 1312 00:46:15,803 --> 00:46:17,238 IS THE NEXT FIVE YEARS OF HIV 1313 00:46:17,238 --> 00:46:21,943 RESEARCH AS WELL. 1314 00:46:21,943 --> 00:46:25,113 SO I'M GOING TO REMARKABLY 1315 00:46:25,113 --> 00:46:26,981 OVERSIMPLIFY THE STRATEGIC 1316 00:46:26,981 --> 00:46:28,049 PLANNING PROCESS INTO THREE 1317 00:46:28,049 --> 00:46:30,184 STEPS SO YOU GET A LITTLE 1318 00:46:30,184 --> 00:46:32,420 PERSPECTIVE ON THE RFI ITSELF. 1319 00:46:32,420 --> 00:46:33,721 SO THE WAY WE STARTED WAS REALLY 1320 00:46:33,721 --> 00:46:34,489 TO ESTABLISH THE INITIAL 1321 00:46:34,489 --> 00:46:35,790 PRIORITIES FOR THE INSTITUTE, AS 1322 00:46:35,790 --> 00:46:37,258 WELL AS START TO UNDERSTAND A 1323 00:46:37,258 --> 00:46:38,893 LITTLE BIT OF THE OBJECTIVES. 1324 00:46:38,893 --> 00:46:42,730 SO NOT TO DIG TOO MUCH INTO 1325 00:46:42,730 --> 00:46:44,499 TERMINOLOGY, HOWEVER WE START 1326 00:46:44,499 --> 00:46:45,833 OUR TOP TIER IS REALLY THE 1327 00:46:45,833 --> 00:46:47,035 INSTITUTE PRIORITIES AND THERE 1328 00:46:47,035 --> 00:46:47,802 ARE FIVE OF THOSE. 1329 00:46:47,802 --> 00:46:49,103 THEN WE TALK ABOUT OBJECTIVES. 1330 00:46:49,103 --> 00:46:50,438 SO WHAT ARE WE TRYING TO DO IN 1331 00:46:50,438 --> 00:46:51,639 EACH OF THOSE PRIORITIES. 1332 00:46:51,639 --> 00:46:53,508 THEN WE KIND OF WORK OUR WAY 1333 00:46:53,508 --> 00:46:55,410 DOWN INTO FOCUS AREAS AND THEN 1334 00:46:55,410 --> 00:46:55,610 GOALS. 1335 00:46:55,610 --> 00:46:57,145 FOR THE SAKE OF TODAY, WE'LL 1336 00:46:57,145 --> 00:46:58,146 REALLY KEEP IT HIGH LEVEL AT 1337 00:46:58,146 --> 00:47:01,215 BOTH THE PRIORITY LEVEL AND THE 1338 00:47:01,215 --> 00:47:01,583 OBJECTIVE LEVEL. 1339 00:47:01,583 --> 00:47:02,784 NOW THIS IS IMPORTANT BECAUSE 1340 00:47:02,784 --> 00:47:04,619 WHEN WE SENT OUT THE RFI, SO THE 1341 00:47:04,619 --> 00:47:06,421 FIRST STEP WAS TO ESTABLISH THE 1342 00:47:06,421 --> 00:47:08,389 PRIMARY INSTITUTE PRIORITIES, 1343 00:47:08,389 --> 00:47:09,591 AND AS YOU CAN SEE HERE, THEY 1344 00:47:09,591 --> 00:47:11,025 ARE BASICALLY THE BREAD AND BUT 1345 00:47:11,025 --> 00:47:15,863 ERT OFBUTTER OF THE INSTITUTE, H 1346 00:47:15,863 --> 00:47:17,565 IMMUNOLOGY AND PATHOGEN BIOLOGY, 1347 00:47:17,565 --> 00:47:18,533 THEN PRIORITY TWO STARTS GETTING 1348 00:47:18,533 --> 00:47:20,468 INTO APPLYING THAT RESEARCH TO 1349 00:47:20,468 --> 00:47:22,971 INFECTIOUS DISEASES OUTSIDE OF 1350 00:47:22,971 --> 00:47:23,838 HIV/AIDS. 1351 00:47:23,838 --> 00:47:24,739 THE THIRD PRIORITY WHICH I'LL 1352 00:47:24,739 --> 00:47:27,875 FOCUS ON TODAY ARE HIV 1353 00:47:27,875 --> 00:47:28,876 PORTFOLIO. 1354 00:47:28,876 --> 00:47:30,244 OUR FOURTH PRIORITY IS APPLIED 1355 00:47:30,244 --> 00:47:31,646 RESEARCH IN IMMUNOLOGICAL 1356 00:47:31,646 --> 00:47:33,948 DISEASES AND TRANSPLANTATION, 1357 00:47:33,948 --> 00:47:36,517 AND THEN OUR FIFTH PRIORITY IS 1358 00:47:36,517 --> 00:47:37,051 BIOPREPAREDNESS, REALLY 1359 00:47:37,051 --> 00:47:39,120 PREPARING FOR AND RESPONDING TO 1360 00:47:39,120 --> 00:47:43,024 BIOLOGICAL INCIDENTS THAT AFFECT 1361 00:47:43,024 --> 00:47:43,825 PUBLIC HEALTH. 1362 00:47:43,825 --> 00:47:45,026 FLAD TO THESE, WE ALSO HAVE -- 1363 00:47:45,026 --> 00:47:47,295 THE PLAN REALLY EXPANDS INTO 1364 00:47:47,295 --> 00:47:48,563 BOTH OPERATIONAL CAPACITY 1365 00:47:48,563 --> 00:47:49,230 PRIORITIES, CROSS-CUTTING 1366 00:47:49,230 --> 00:47:50,131 THEMES, A NUMBER OF DIFFERENT 1367 00:47:50,131 --> 00:47:51,299 THINGS THAT REALLY GET 1368 00:47:51,299 --> 00:47:52,567 INTEGRATED THROUGHOUT THE PLAN. 1369 00:47:52,567 --> 00:47:54,969 AND I SAY THIS BECAUSE I THINK 1370 00:47:54,969 --> 00:47:58,039 SOMETIMES WHEN WE LOOK AT SOME 1371 00:47:58,039 --> 00:48:02,010 THINGS, EVEN THE RFI AND 1372 00:48:02,010 --> 00:48:04,979 RESPONSES, WE GET FOCUSED TO SAY 1373 00:48:04,979 --> 00:48:06,814 IT'S NOT WORD FOR WORD, THAT 1374 00:48:06,814 --> 00:48:07,849 MUST MEAN THEY'RE EITHER NOT 1375 00:48:07,849 --> 00:48:09,283 DOING IT OR REALLY NEED TO 1376 00:48:09,283 --> 00:48:10,051 EXPAND. 1377 00:48:10,051 --> 00:48:13,154 SO IN SOME CASES I THINK THE 1378 00:48:13,154 --> 00:48:14,589 GREATER HOLISTIC PLAN OF SOME OF 1379 00:48:14,589 --> 00:48:15,790 THESE THINGS WILL BE ADDRESSED. 1380 00:48:15,790 --> 00:48:16,991 HOWEVER, FOR THE SAKE OF THIS 1381 00:48:16,991 --> 00:48:18,693 WHEN WE SENT OUT THE RFI, PEOPLE 1382 00:48:18,693 --> 00:48:20,428 REALLY WENT DOWN THE LIST AND 1383 00:48:20,428 --> 00:48:21,829 RESPONDED JUST WITHIN EACH 1384 00:48:21,829 --> 00:48:23,631 PRIORITY. 1385 00:48:23,631 --> 00:48:26,134 WE'RE GOING TO FOCUS EXCLUSIVELY 1386 00:48:26,134 --> 00:48:29,704 ON THE THIRD PRIORITY, HIV/AIDS. 1387 00:48:29,704 --> 00:48:30,805 SO THAT IS THE FIRST STEP, IS 1388 00:48:30,805 --> 00:48:32,874 ONCE WE ESTABLISH THE RESEARCH 1389 00:48:32,874 --> 00:48:34,942 PRIORITIES, WE THEN SENT OUT AN 1390 00:48:34,942 --> 00:48:36,644 RFI IN ORDER TO GARNER INBUT 1391 00:48:36,644 --> 00:48:38,946 THAT REALLY -- THAT ROUGH CUT 1392 00:48:38,946 --> 00:48:39,247 BASICALLY. 1393 00:48:39,247 --> 00:48:40,481 WE STARTED WITH INSTITUTE 1394 00:48:40,481 --> 00:48:42,717 PRIORITIES AND OBJECTIVES, THEN 1395 00:48:42,717 --> 00:48:44,352 AN TO SAY OKAY, WHERE DO YOU 1396 00:48:44,352 --> 00:48:45,586 THINK THINGS NEED TO GO, WHERE 1397 00:48:45,586 --> 00:48:46,521 DO WE THINK THE RESEARCH NEEDS 1398 00:48:46,521 --> 00:48:50,525 TO BE. 1399 00:48:50,525 --> 00:48:52,493 THEN AFTER THAT, WE ARE IN THE 1400 00:48:52,493 --> 00:48:54,162 PROCESS, CARL SHOWED A SLIDE OF 1401 00:48:54,162 --> 00:48:55,163 THE TIMELINE, WE'RE IN THE 1402 00:48:55,163 --> 00:48:56,464 PROCESS OF BOTH INTEGRATING THAT 1403 00:48:56,464 --> 00:49:00,134 INPUT AND THEN WORKING WITH THE 1404 00:49:00,134 --> 00:49:01,369 DIVISION AND PROGRAMS TO DEVELOP 1405 00:49:01,369 --> 00:49:02,970 THE PLAN ITSELF. 1406 00:49:02,970 --> 00:49:06,207 SO SPECIFICALLY FOR PRIORITY 1407 00:49:06,207 --> 00:49:07,742 THREE, THIS IS THE ADVANCE AND 1408 00:49:07,742 --> 00:49:08,943 APPLY KNOWLEDGE OF HIV/AIDS TO 1409 00:49:08,943 --> 00:49:12,313 END THE HIV EPIDEMIC THROUGH THE 1410 00:49:12,313 --> 00:49:13,314 DEVELOPMENT OF SAFE AND 1411 00:49:13,314 --> 00:49:14,449 EFFECTIVE PREVENTION, TREATMENT 1412 00:49:14,449 --> 00:49:15,283 AND CURE STRATEGIES. 1413 00:49:15,283 --> 00:49:16,184 AND FOR THE SAKE OF THE 1414 00:49:16,184 --> 00:49:17,618 DISCUSSION TODAY, THESE ARE THE 1415 00:49:17,618 --> 00:49:19,954 PRIMARY OBJECTIVES WITHIN THE 1416 00:49:19,954 --> 00:49:20,354 HIV/AIDS PRIORITY. 1417 00:49:20,354 --> 00:49:22,824 THIS IS REALLY NOT ALL THAT 1418 00:49:22,824 --> 00:49:24,125 DIFFERENT FROM OAR, WHICH I'LL 1419 00:49:24,125 --> 00:49:26,060 TALK ABOUT IN A LITTLE BIT. 1420 00:49:26,060 --> 00:49:27,795 ADVANCING HIV PREVENTION 1421 00:49:27,795 --> 00:49:28,996 STRATEGIES, AND THEN THIS WILL 1422 00:49:28,996 --> 00:49:31,299 BE DEVELOPING AND ASSESSING HIV 1423 00:49:31,299 --> 00:49:34,502 PREVENTION APPROACHES. 1424 00:49:34,502 --> 00:49:37,805 THEN HERE YOU HAVE YOUR 1425 00:49:37,805 --> 00:49:38,339 COINFECTIONS/COMORBIDITIES 1426 00:49:38,339 --> 00:49:39,607 ASSOCIATED WITH HIV AND THEN A 1427 00:49:39,607 --> 00:49:40,675 VERY IMPORTANT FOSTERING 1428 00:49:40,675 --> 00:49:41,676 COMMUNITY INVOLVEMENT IN ALL 1429 00:49:41,676 --> 00:49:42,977 STAGES OF THE RESEARCH PLANNING 1430 00:49:42,977 --> 00:49:48,049 AND IMPLEMENTATION. 1431 00:49:48,049 --> 00:49:49,717 SO WITH THAT PRIORITY AND THAT 1432 00:49:49,717 --> 00:49:51,119 KIND OF SKELETON DRAFT IN MIND, 1433 00:49:51,119 --> 00:49:53,421 WE WENT OUT WITH AN RFI. 1434 00:49:53,421 --> 00:49:55,556 THIS RFI WAS OPEN FOR 90 DAYS 1435 00:49:55,556 --> 00:49:57,959 FROM FEBRUARY 26TH THROUGH MAY 1436 00:49:57,959 --> 00:49:58,926 27TH. 1437 00:49:58,926 --> 00:50:00,228 AND IT INCLUDED BASICALLY EACH 1438 00:50:00,228 --> 00:50:01,596 OF THE PRIORITIES AND A LITTLE 1439 00:50:01,596 --> 00:50:03,264 BIT ABOUT THEM TO THE PUBLIC SO 1440 00:50:03,264 --> 00:50:06,434 THAT THEY COULD THEN RESPOND. 1441 00:50:06,434 --> 00:50:07,702 AS CARL MENTIONED, WE WERE 1442 00:50:07,702 --> 00:50:08,903 THRILLED WITH THE NUMBER OF 1443 00:50:08,903 --> 00:50:10,638 RESPONSES WE GOT FROM THE RFI. 1444 00:50:10,638 --> 00:50:14,075 THEY WERE REMARKABLY THOUGHTFUL, 1445 00:50:14,075 --> 00:50:16,477 THEY WERE WELL ARTICULATED AND 1446 00:50:16,477 --> 00:50:19,113 THEY BOTH -- SO WHEN I SAY 1447 00:50:19,113 --> 00:50:20,114 THERE'S 63 TOTAL RESPONSES, 1448 00:50:20,114 --> 00:50:21,215 PLEASE KEEP IN MIND, THIS IS 1449 00:50:21,215 --> 00:50:23,551 OFTEN A CONGLOMERATE OF AN 1450 00:50:23,551 --> 00:50:24,852 ENTIRE ORGANIZATION RESPONDING 1451 00:50:24,852 --> 00:50:26,087 TO EACH INDIVIDUAL PRIORITY. 1452 00:50:26,087 --> 00:50:28,289 SO APPROXIMATELY 200 PAGES WORTH 1453 00:50:28,289 --> 00:50:29,724 OF RESPONSES TO THE RFI THAT WE 1454 00:50:29,724 --> 00:50:30,625 WENT THROUGH. 1455 00:50:30,625 --> 00:50:33,027 AND AGAIN, THEY WERE ALL VERY, 1456 00:50:33,027 --> 00:50:34,228 VERY WELL WRITTEN AND 1457 00:50:34,228 --> 00:50:35,763 ARTICULATE. 1458 00:50:35,763 --> 00:50:37,665 AND ACTUALLY A LITTLE SHOUT OUT 1459 00:50:37,665 --> 00:50:39,200 TO THE POLICY PLANNING AND 1460 00:50:39,200 --> 00:50:39,867 EVALUATION OFFICE WHO WENT 1461 00:50:39,867 --> 00:50:41,068 THROUGH IT, AND KIND OF 1462 00:50:41,068 --> 00:50:42,103 CONDENSED IT SO THAT WE COULD 1463 00:50:42,103 --> 00:50:44,272 HAVE A HALF-DAY RETREAT AS AN 1464 00:50:44,272 --> 00:50:45,273 INSTITUTE, WHERE WE PROVIDED 1465 00:50:45,273 --> 00:50:47,642 BOTH NIAID LEADERSHIP, THE 1466 00:50:47,642 --> 00:50:48,709 ENTIRETY OF THE RESPONSES, AND 1467 00:50:48,709 --> 00:50:50,044 THEN WE PROVIDED A BIT OF AN 1468 00:50:50,044 --> 00:50:51,579 OVERVIEW SO WE COULD DISCUSS 1469 00:50:51,579 --> 00:50:52,814 THEM AS AN INSTITUTE ALL 1470 00:50:52,814 --> 00:50:53,614 TOGETHER. 1471 00:50:53,614 --> 00:50:56,217 AND I WOULD SAY THE OUTCOME OF 1472 00:50:56,217 --> 00:50:58,119 THAT RETREAT IS ACTUALLY BEING 1473 00:50:58,119 --> 00:50:59,120 INCORPORATED INTO THE PLAN AS WE 1474 00:50:59,120 --> 00:51:06,127 SPEAK. 1475 00:51:06,127 --> 00:51:07,428 SO I'M GOING TO FOCUS ON A 1476 00:51:07,428 --> 00:51:08,663 COUPLE OF THE MAIN TOPICS THAT 1477 00:51:08,663 --> 00:51:11,199 CAME OUT OF THE RFI FOR HIV 1478 00:51:11,199 --> 00:51:11,532 RESEARCH. 1479 00:51:11,532 --> 00:51:12,733 SO A COUPLE THINGS ABOUT IT 1480 00:51:12,733 --> 00:51:14,535 BEFORE I ACTUALLY GET INTO IT. 1481 00:51:14,535 --> 00:51:15,736 I'LL ACTUALLY SHOW SOME OF THEM 1482 00:51:15,736 --> 00:51:16,938 RIGHT HERE. 1483 00:51:16,938 --> 00:51:18,306 SO FOR SAKE OF TODAY OBVIOUSLY 1484 00:51:18,306 --> 00:51:19,841 I'M NOT GOING TO FOCUS ON THE 1485 00:51:19,841 --> 00:51:21,843 ENTIRE NIAID PORTFOLIO, HOWEVER, 1486 00:51:21,843 --> 00:51:22,677 I SHOULD SAY A LOT OF WHAT 1487 00:51:22,677 --> 00:51:24,745 YOU'RE GOING TO HEAR FOR 1488 00:51:24,745 --> 00:51:25,780 HIV/AIDS WERE PRETTY COMMON 1489 00:51:25,780 --> 00:51:26,881 ACROSS THE SPECTRUM. 1490 00:51:26,881 --> 00:51:29,951 NOT SURPRISINGLY, I WOULD SAY. 1491 00:51:29,951 --> 00:51:31,285 SO I THINK WHEN YOU'RE LOOKING 1492 00:51:31,285 --> 00:51:32,620 FORWARD, FORWARD THINKING FOR AN 1493 00:51:32,620 --> 00:51:34,689 INSTITUTE, IT REALLY COMES DOWN 1494 00:51:34,689 --> 00:51:37,058 TO EXPANDING, GROWING, THINGS OF 1495 00:51:37,058 --> 00:51:38,359 THAT NATURE. 1496 00:51:38,359 --> 00:51:39,994 I SHOULD MENTION IN ALMOST EVERY 1497 00:51:39,994 --> 00:51:41,729 SINGLE ONE, PARTICULARLY FOR 1498 00:51:41,729 --> 00:51:44,832 HIV, IT WAS STARTED WITH REALLY 1499 00:51:44,832 --> 00:51:45,833 LAUDING THE WORK OF THE DIVISION 1500 00:51:45,833 --> 00:51:47,635 OF AIDS AND HOW MUCH PROGRESS 1501 00:51:47,635 --> 00:51:48,569 HAS BEEN MADE SO FAR. 1502 00:51:48,569 --> 00:51:53,641 SO I WANTED TO START WITH THAT 1503 00:51:53,641 --> 00:51:54,642 BECAUSE DON'T WORRY, WE SHARED 1504 00:51:54,642 --> 00:51:56,043 THE GOOD THINGS AS WELL AND ALL 1505 00:51:56,043 --> 00:51:57,311 THE POSITIVES BEFOREHAND, BUT I 1506 00:51:57,311 --> 00:51:59,714 WOULD SA SAY THAT A LOT OF WHAT 1507 00:51:59,714 --> 00:52:01,182 CAME IN REALLY LOOKED TOWARDS 1508 00:52:01,182 --> 00:52:02,717 THE FUTURE AND HOW TO BUILD ON 1509 00:52:02,717 --> 00:52:05,553 THE HIV PORTFOLIO. 1510 00:52:05,553 --> 00:52:06,420 THESE ARE SOME OF THE MAIN 1511 00:52:06,420 --> 00:52:07,655 TOPICS THAT REALLY CAME IN FROM 1512 00:52:07,655 --> 00:52:08,256 THE RFI. 1513 00:52:08,256 --> 00:52:11,325 THIS INCLUDED EXPANDING HIV/AIDS 1514 00:52:11,325 --> 00:52:13,060 RESEARCH, CLEARLY COMORBIDITIES 1515 00:52:13,060 --> 00:52:14,662 AND COINFECTION, THERE WAS A BIG 1516 00:52:14,662 --> 00:52:17,098 FOCUS ON IMPLEMENTATION SCIENCE, 1517 00:52:17,098 --> 00:52:17,832 INCLUDING BEHAVIORAL AND A 1518 00:52:17,832 --> 00:52:20,067 SOCIAL RESEARCH, AND THEN HEALTH 1519 00:52:20,067 --> 00:52:21,502 DISPARITIES, INCLUSION, WOMEN'S 1520 00:52:21,502 --> 00:52:25,539 HEALTH AND GLOBAL HEALTH. 1521 00:52:25,539 --> 00:52:28,009 THIS IS BY NO MEANS I WOULD SAY 1522 00:52:28,009 --> 00:52:28,676 ENTIRELY COMPREHENSIVE. 1523 00:52:28,676 --> 00:52:29,777 THIS IS A SUMMARY OF A LOT OF 1524 00:52:29,777 --> 00:52:36,617 WHAT WE FOUND IN THE RFI. 1525 00:52:36,617 --> 00:52:38,252 SO THE WAY WE APPROACHED KIND OF 1526 00:52:38,252 --> 00:52:39,220 DIGESTING THIS AMOUNT OF 1527 00:52:39,220 --> 00:52:40,554 INFORMATION IS WE ACTUALLY TRIED 1528 00:52:40,554 --> 00:52:42,256 A FEW DIFFERENT WAYS OF LOOKING 1529 00:52:42,256 --> 00:52:43,691 HOLISTICALLY AT THAT MANY 1530 00:52:43,691 --> 00:52:45,760 DIFFERENT INDIVIDUAL RESPONSES 1531 00:52:45,760 --> 00:52:46,861 AND WE FOUND THAT NO MATTER HOW 1532 00:52:46,861 --> 00:52:50,731 WE REALLY BROKE IT DOWN INTO, 1533 00:52:50,731 --> 00:52:51,732 SAY, OUTLINES OR BULLET POINTS, 1534 00:52:51,732 --> 00:52:56,070 YOU REALLY DESTROYED THE CONTENT 1535 00:52:56,070 --> 00:52:57,271 OR REALLY THE TONE OR 1536 00:52:57,271 --> 00:52:57,571 CONNOTATION. 1537 00:52:57,571 --> 00:52:59,006 SO WE FOUND THAT QUOTES AND 1538 00:52:59,006 --> 00:53:00,574 PROVIDING THOSE DIRECTLY WAS 1539 00:53:00,574 --> 00:53:03,878 OFTENTIMES THE BEST WAY TO 1540 00:53:03,878 --> 00:53:05,513 REALLY CONVEY WHAT THE MESSAGE 1541 00:53:05,513 --> 00:53:08,115 WAS OF THE RESPONSE. 1542 00:53:08,115 --> 00:53:09,216 SO AS I MENTIONED ONE OF THE 1543 00:53:09,216 --> 00:53:10,384 FIRST KIND OF MORE HOLISTIC 1544 00:53:10,384 --> 00:53:11,485 COMMENTS THAT WE GOT IN WAS 1545 00:53:11,485 --> 00:53:13,120 LOOKING AT EXPANDING THE 1546 00:53:13,120 --> 00:53:15,256 HIV/AIDS PORTFOLIO. 1547 00:53:15,256 --> 00:53:16,991 AND SOME OF THESE REALLY BUILT 1548 00:53:16,991 --> 00:53:19,860 ON A LOT OF THE SUCCESSES THAT 1549 00:53:19,860 --> 00:53:21,295 WERE THEN ATTRIBUTED TO THE 1550 00:53:21,295 --> 00:53:23,064 PORTFOLIO. 1551 00:53:23,064 --> 00:53:24,732 SO ESSENTIALLY HOW CAN WE APPLY 1552 00:53:24,732 --> 00:53:29,537 THAT TO OTHER AREAS OF NIAID IN 1553 00:53:29,537 --> 00:53:33,140 GENERAL. 1554 00:53:33,140 --> 00:53:35,676 SOME OF THIS CAME -- I SHOULD 1555 00:53:35,676 --> 00:53:37,411 MENTION THAT NOT ONLY WAS IT 1556 00:53:37,411 --> 00:53:38,579 JUST BUILDING ON THE RESOURCES 1557 00:53:38,579 --> 00:53:40,181 THAT WE HAD, BUT ALSO LOOKING AT 1558 00:53:40,181 --> 00:53:42,350 THINGS LIKE COMORBIDITIES AND 1559 00:53:42,350 --> 00:53:43,451 COINFECTIONS. 1560 00:53:43,451 --> 00:53:45,086 AND THIS IS ONE OF THE PRIMARY 1561 00:53:45,086 --> 00:53:46,253 TOPICS. 1562 00:53:46,253 --> 00:53:47,989 SO WE RECEIVED A NUMBER OF 1563 00:53:47,989 --> 00:53:50,624 DIFFERENT TOPICS HERE LOOKING 1564 00:53:50,624 --> 00:53:52,560 AT, SO AS HIV RESEARCH HAS 1565 00:53:52,560 --> 00:53:54,095 ENABLED PEOPLE TO LIVE LONGER 1566 00:53:54,095 --> 00:53:55,529 LIVES, SO HAS THE INDUCTION AND 1567 00:53:55,529 --> 00:53:57,999 I WOULD SAY THE FOCUS ON MORE 1568 00:53:57,999 --> 00:53:59,033 COMORBIDITIES AND COMORTALITIES 1569 00:53:59,033 --> 00:54:00,568 THAT OCCUR ACROSS THE LIFESPAN, 1570 00:54:00,568 --> 00:54:02,103 AND WE RECEIVED A NUMBER OF 1571 00:54:02,103 --> 00:54:03,838 DIFFERENT RESPONSES LOOKING AT 1572 00:54:03,838 --> 00:54:07,008 BOTH AUTOIMMUNITY, OTHER IMMUNE 1573 00:54:07,008 --> 00:54:09,010 BIOLOGICAL EFFECTS AND IMPACTS. 1574 00:54:09,010 --> 00:54:12,546 THIS INCLUDED OTHER THINGS LIKE 1575 00:54:12,546 --> 00:54:13,614 CARDIOVASCULAR DISEASE, 1576 00:54:13,614 --> 00:54:14,749 METABOLIC DISEASES, DIABETES AND 1577 00:54:14,749 --> 00:54:16,517 BEAST. 1578 00:54:16,517 --> 00:54:17,118 OBESITY. 1579 00:54:17,118 --> 00:54:19,320 THE TERM SYNDEMIC COME UP A LOT, 1580 00:54:19,320 --> 00:54:21,822 LOOKING AT OTHER RELATED 1581 00:54:21,822 --> 00:54:23,324 INFECTIONS. 1582 00:54:23,324 --> 00:54:24,525 STIs, HEPATITIS, THINGS LIKE 1583 00:54:24,525 --> 00:54:26,394 THAT, VIRAL HEPATITIS. 1584 00:54:26,394 --> 00:54:28,129 AND THESE ARE LISTED HERE UNDER 1585 00:54:28,129 --> 00:54:30,498 THE COINFECTIONS AS WELL. 1586 00:54:30,498 --> 00:54:32,800 IN ADDITION TO PROVIDING MORE OR 1587 00:54:32,800 --> 00:54:34,235 LESS THE BREADTH OF WHAT 1588 00:54:34,235 --> 00:54:35,302 NIAID -- THE NIAID PORTFOLIO 1589 00:54:35,302 --> 00:54:37,238 THEY WERE LOOKING TO SAY COULD 1590 00:54:37,238 --> 00:54:38,672 BE COVERED HERE, THEY ALSO 1591 00:54:38,672 --> 00:54:40,741 TALKED ABOUT POINT OF CARE 1592 00:54:40,741 --> 00:54:41,909 DIAGNOSTICS, AND PARTICULARLY 1593 00:54:41,909 --> 00:54:44,311 FOR COINFECTIONS. 1594 00:54:44,311 --> 00:54:45,179 NOT SURPRISINGLY, THERE WAS A 1595 00:54:45,179 --> 00:54:48,516 LOT OF TALK ABOUT TUBERCULOSIS 1596 00:54:48,516 --> 00:54:50,284 AND INCREASED INVESTMENT IN TB 1597 00:54:50,284 --> 00:54:50,718 VACCINE. 1598 00:54:50,718 --> 00:54:53,020 AND ALSO INCLUDING PARTICULAR 1599 00:54:53,020 --> 00:55:01,829 POPULATIONS IN TB STUDIES. 1600 00:55:01,829 --> 00:55:06,300 IN ADDITION, THEY TALKED ABOUT 1601 00:55:06,300 --> 00:55:07,735 CLINICAL TRIAL CAPACITY TO 1602 00:55:07,735 --> 00:55:09,870 ADDRESS TB AND COINFECTIONS AND 1603 00:55:09,870 --> 00:55:10,204 CO-MORBIDITY. 1604 00:55:10,204 --> 00:55:12,373 SO I DO LIKE TO STOP AT THIS 1605 00:55:12,373 --> 00:55:13,707 POINT TO SAY THESE ARE THE 1606 00:55:13,707 --> 00:55:14,842 COMMENTS THAT CAME IN. 1607 00:55:14,842 --> 00:55:16,043 A LOT ARE ALREADY BEING 1608 00:55:16,043 --> 00:55:17,378 ADDRESSED IN THE PLAN OR ALREADY 1609 00:55:17,378 --> 00:55:18,145 INCLUDED IN THE PLAN. 1610 00:55:18,145 --> 00:55:19,113 SO I SHOULD SAY THAT EVEN SINCE 1611 00:55:19,113 --> 00:55:20,514 SOME OF THE LANGUAGE HAS BEEN 1612 00:55:20,514 --> 00:55:21,148 MODIFIED OR SOME OF THE 1613 00:55:21,148 --> 00:55:22,383 SPECIFICS THAT WE GATHERED FROM 1614 00:55:22,383 --> 00:55:23,984 THE RFI WERE ALREADY INCLUDED IN 1615 00:55:23,984 --> 00:55:29,190 THE PLAN. 1616 00:55:29,190 --> 00:55:30,324 IN ADDITION, ONE OF THE COMMENTS 1617 00:55:30,324 --> 00:55:32,259 THAT WE GOT IN WAS ON 1618 00:55:32,259 --> 00:55:34,128 IMPLEMENTATION SCIENCE, 1619 00:55:34,128 --> 00:55:35,396 INCLUDING BEHAVIORAL AND SOCIAL 1620 00:55:35,396 --> 00:55:35,663 RESEARCH. 1621 00:55:35,663 --> 00:55:39,467 AS I MENTIONED BEFORE, THE TONE 1622 00:55:39,467 --> 00:55:41,102 OF SYNDEMIC FOCUSED CARE 1623 00:55:41,102 --> 00:55:42,203 INCLUDING MENTAL HEALTH, 1624 00:55:42,203 --> 00:55:43,137 SUBSTANCE DISORDER TREATMENT AND 1625 00:55:43,137 --> 00:55:44,338 MANAGEMENT CAME IN. 1626 00:55:44,338 --> 00:55:46,674 AND EXPANDING ENGAGEMENT OF 1627 00:55:46,674 --> 00:55:50,744 COMMUNITIES IN HIV PREVENTION. 1628 00:55:50,744 --> 00:55:52,713 ?AD, THIN ADDITION THERE WAS A E 1629 00:55:52,713 --> 00:55:53,914 FOCUS ON THE SOCIAL ASPECT AND 1630 00:55:53,914 --> 00:55:54,849 SOCIAL RESEARCH AND REALLY THIS 1631 00:55:54,849 --> 00:55:56,484 INCLUDED THE POPULATION-LEVEL 1632 00:55:56,484 --> 00:55:59,019 IMPACT OF BIOMEDICAL ADVANCES. 1633 00:55:59,019 --> 00:56:02,690 SO HOW CAN WE REALLY TURN THE -- 1634 00:56:02,690 --> 00:56:07,294 I WOULD SAY THE SPECIFIC ADVANCE 1635 00:56:07,294 --> 00:56:09,497 INTO MORE PUBLIC SUPPORT, I 1636 00:56:09,497 --> 00:56:14,802 WOULD SAY, FOR THE DISEASE. 1637 00:56:14,802 --> 00:56:16,237 AND THEN IMPLEMENTATION SCIENCE 1638 00:56:16,237 --> 00:56:17,705 BASICALLY ENSURING THAT THIS R & 1639 00:56:17,705 --> 00:56:19,073 D IS TRANSLATED INTO A PUBLIC 1640 00:56:19,073 --> 00:56:20,207 HEALTH IMPACT AND REALLY 1641 00:56:20,207 --> 00:56:21,308 STUDYING HOW BEST TO IMPLEMENT 1642 00:56:21,308 --> 00:56:22,543 THESE INTERVENTIONS. 1643 00:56:22,543 --> 00:56:23,477 LET ME PAUSE THERE. 1644 00:56:23,477 --> 00:56:24,879 ARE THERE ANY QUESTIONS? 1645 00:56:24,879 --> 00:56:27,948 GENERALLY I KNOW WE WAIT UNTIL 1646 00:56:27,948 --> 00:56:29,483 THE END, IS IT OKAY IF WE STOP 1647 00:56:29,483 --> 00:56:30,384 TO GO THROUGH SOME QUESTIONS 1648 00:56:30,384 --> 00:56:30,751 NOW? 1649 00:56:30,751 --> 00:56:31,085 OKAY. 1650 00:56:31,085 --> 00:56:32,153 ARE THERE ANY QUESTIONS AT THIS 1651 00:56:32,153 --> 00:56:32,520 POINT? 1652 00:56:32,520 --> 00:56:33,387 BECAUSE THERE'S A COUPLE MORE 1653 00:56:33,387 --> 00:56:34,555 SLIDES BUT I KNOW THERE'S A LOT 1654 00:56:34,555 --> 00:56:35,990 OF MATERIAL TO GO THROUGH IF 1655 00:56:35,990 --> 00:56:41,028 ANYBODY HAD ANY -- PLEASE. 1656 00:56:41,028 --> 00:56:43,430 >> THANKS. 1657 00:56:43,430 --> 00:56:44,832 I APPRECIATE THE OPPORTUNITY TO 1658 00:56:44,832 --> 00:56:46,200 ASK THE QUESTION NOW. 1659 00:56:46,200 --> 00:56:49,170 SO I WAS WONDERING ABOUT 1660 00:56:49,170 --> 00:56:50,137 INVESTIGATING VACCINE AND 1661 00:56:50,137 --> 00:56:51,672 TREATMENT HESITANCY TO MAXIMIZE 1662 00:56:51,672 --> 00:56:52,072 UPTAKE. 1663 00:56:52,072 --> 00:56:54,208 I THINK IT'S A REALLY IMPORTANT 1664 00:56:54,208 --> 00:56:55,075 ISSUE AND I HAVE TWO QUESTIONS 1665 00:56:55,075 --> 00:56:56,177 ABOUT IT. 1666 00:56:56,177 --> 00:56:59,013 ONE IS I'VE ALWAYS BEEN CURIOUS 1667 00:56:59,013 --> 00:57:00,781 ABOUT MONOCLONAL ANTIBODIES AND 1668 00:57:00,781 --> 00:57:01,882 WHETHER THERE IS A DIFFERENT 1669 00:57:01,882 --> 00:57:03,584 KIND OF HESITANCY THAT COULD BE 1670 00:57:03,584 --> 00:57:06,120 AT PLAY OR NOT. 1671 00:57:06,120 --> 00:57:07,521 AND I DON'T KNOW HOW MUCH 1672 00:57:07,521 --> 00:57:09,156 RESEARCH THERE IS ABOUT THAT. 1673 00:57:09,156 --> 00:57:10,324 I'VE SORT OF STRUGGLED TO FIND 1674 00:57:10,324 --> 00:57:10,758 IT. 1675 00:57:10,758 --> 00:57:13,928 AND THEN THE SECOND THING IS, I 1676 00:57:13,928 --> 00:57:15,996 WAS WONDERING IF THINGS LIKE 1677 00:57:15,996 --> 00:57:19,900 COMMUNICATION SCIENCE ARE PART 1678 00:57:19,900 --> 00:57:21,335 OF HOW YOU MIGHT DO THAT, OR IF 1679 00:57:21,335 --> 00:57:22,970 THAT'S NOT REALLY SOMETHING THAT 1680 00:57:22,970 --> 00:57:27,241 FITS INTO DAIDS' PORTFOLIO. 1681 00:57:27,241 --> 00:57:30,144 >> I'D DEFER TO EITHER CARL 1682 00:57:30,144 --> 00:57:30,344 OR -- 1683 00:57:30,344 --> 00:57:31,779 >> SO I THINK WHEN WE LOOK AT A 1684 00:57:31,779 --> 00:57:32,913 LOT OF THESE COMMENTS, WE HAVE 1685 00:57:32,913 --> 00:57:34,448 TO THINK ABOUT AIDS RESEARCH 1686 00:57:34,448 --> 00:57:36,116 WRIT LARGE. 1687 00:57:36,116 --> 00:57:39,019 AND THAT WE ARE 27 INSTITUTES 1688 00:57:39,019 --> 00:57:42,189 AND CENTERS AT THE NIH, AND FOR 1689 00:57:42,189 --> 00:57:45,826 SOME OF THESE ACTIVITIES, LIKE 1690 00:57:45,826 --> 00:57:50,164 STUDYING SUBSTANCE USE, 1691 00:57:50,164 --> 00:57:50,898 SIGNIFICANT BEHAVIORAL RESEARCH, 1692 00:57:50,898 --> 00:57:52,199 THERE ARE ENTIRE INSTITUTES 1693 00:57:52,199 --> 00:57:53,400 DEVOTED TO THOSE ACTIVITIES. 1694 00:57:53,400 --> 00:58:00,407 AND WE HAVE WORKED CLOSELY WITH 1695 00:58:00,407 --> 00:58:02,243 NIDA AND NIMH TO BUILD THOSE 1696 00:58:02,243 --> 00:58:04,445 BRIDGES. 1697 00:58:04,445 --> 00:58:06,947 SO I WANT TO JUST REMIND PEOPLE 1698 00:58:06,947 --> 00:58:10,017 THAT WE ARE NOT THE SOLE ARBITER 1699 00:58:10,017 --> 00:58:11,285 OF ALL AIDS RESEARCH HERE. 1700 00:58:11,285 --> 00:58:13,587 SO I THINK THAT THERE IS THAT 1701 00:58:13,587 --> 00:58:14,788 ASPECT THAT WE NEED TO DEAL 1702 00:58:14,788 --> 00:58:15,556 WITH. 1703 00:58:15,556 --> 00:58:19,226 ALSO WE HAVE TO THINK ABOUT -- 1704 00:58:19,226 --> 00:58:20,661 WE'RE ALSO NOT SOCIAL SCIENTISTS 1705 00:58:20,661 --> 00:58:22,196 THAT DEAL IN COMMUNICATION. 1706 00:58:22,196 --> 00:58:25,633 SO I DON'T KNOW HOW -- I THINK 1707 00:58:25,633 --> 00:58:27,601 THERE ARE PARTNERSHIPS THAT WILL 1708 00:58:27,601 --> 00:58:28,836 NEED TO BE FORMED FOR THAT. 1709 00:58:28,836 --> 00:58:32,606 FOR EXAMPLE, DURING COVID, WE 1710 00:58:32,606 --> 00:58:35,576 BUILT COLLABORATIONS WITH -- 1711 00:58:35,576 --> 00:58:40,247 THROUGH THE HANK, HIV/AIDS 1712 00:58:40,247 --> 00:58:42,783 COORDINATING ACTIVITIES, TO 1713 00:58:42,783 --> 00:58:47,354 REALLY TAKE ADVANTAGE OF PEOPLE 1714 00:58:47,354 --> 00:58:49,623 LIKE MICHELLE ANDRESAK AND 1715 00:58:49,623 --> 00:58:50,958 OTHERS AND THEIR COMMUNICATION 1716 00:58:50,958 --> 00:58:51,258 SKILLS. 1717 00:58:51,258 --> 00:58:55,829 SO I THINK STUDYING THAT, THOSE 1718 00:58:55,829 --> 00:58:56,930 ASPECTS, DOESN'T NECESSARILY 1719 00:58:56,930 --> 00:58:58,565 HAVE A HOME HERE. 1720 00:58:58,565 --> 00:59:00,434 THAT DOESN'T MEAN IT'S NOT 1721 00:59:00,434 --> 00:59:00,701 IMPORTANT. 1722 00:59:00,701 --> 00:59:04,004 WE DID NOT -- TO OUR CREDIT, WE 1723 00:59:04,004 --> 00:59:05,873 ASKED FOR HIV WRIT LARGE. 1724 00:59:05,873 --> 00:59:08,275 BECAUSE WHAT THAT HELPS US DO IS 1725 00:59:08,275 --> 00:59:11,011 BUILD OUT THE COLLABORATIONS WE 1726 00:59:11,011 --> 00:59:14,114 NEED TO CREATE IN ORDER TO 1727 00:59:14,114 --> 00:59:16,216 ADDRESS THE FULL SCOPE OF WHAT 1728 00:59:16,216 --> 00:59:23,891 IS BEING ASKED FOR HERE. 1729 00:59:23,891 --> 00:59:25,025 >> THANKS. 1730 00:59:25,025 --> 00:59:26,093 IT SOUNDS LIKE MAYBE FOR THAT 1731 00:59:26,093 --> 00:59:27,428 COMMENT, IT'S A COMMENT TAKEN 1732 00:59:27,428 --> 00:59:28,529 UNDER ADVISEMENT FOR THE FUTURE 1733 00:59:28,529 --> 00:59:29,697 BUT MAYBE NOT DIRECTLY MAKING 1734 00:59:29,697 --> 00:59:36,904 ITS WAY INTO THE PLAN. 1735 00:59:36,904 --> 00:59:38,539 >> I JUST AM CURIOUS ABOUT 1736 00:59:38,539 --> 00:59:42,443 CALLING POPULATION LEVEL IMPACT 1737 00:59:42,443 --> 00:59:49,216 SOCIAL RESEARCH. 1738 00:59:49,216 --> 00:59:50,651 AND WHAT THE THINKING IS TO 1739 00:59:50,651 --> 00:59:53,153 CLASSIFY IT AS SOCIAL RESEARCH. 1740 00:59:53,153 --> 00:59:55,022 I THINK POPULATION LEVEL IMPACT 1741 00:59:55,022 --> 00:59:59,593 WOULD BE MORE EPIDEMIOLOGIC. 1742 00:59:59,593 --> 01:00:01,762 UNLESS I'M MISUNDERSTANDING 1743 01:00:01,762 --> 01:00:02,296 WHAT'S MEANT. 1744 01:00:02,296 --> 01:00:03,097 >> I'D HAVE TO LOOK AT THE 1745 01:00:03,097 --> 01:00:03,931 COMMENT AT LARGE WHEN WE WENT 1746 01:00:03,931 --> 01:00:05,265 THROUGH IT. 1747 01:00:05,265 --> 01:00:06,967 PERHAPS IT WAS IN THE CONTEXT OF 1748 01:00:06,967 --> 01:00:09,269 A MORE SOCIAL DIRECTED COMMENT, 1749 01:00:09,269 --> 01:00:09,470 BUT -- 1750 01:00:09,470 --> 01:00:18,479 >> OKAY. 1751 01:00:18,479 --> 01:00:20,247 >> I CAN'T HELP BUT COMMENT ON 1752 01:00:20,247 --> 01:00:21,181 THE PREVIOUS SLIDE, THE TWO 1753 01:00:21,181 --> 01:00:25,219 COMMENTS ABOUT REDISTRIBUTING 1754 01:00:25,219 --> 01:00:26,520 THE BUDGET. 1755 01:00:26,520 --> 01:00:29,690 I MEAN, THIS IS JUST A PERSONAL 1756 01:00:29,690 --> 01:00:30,858 OPINION, BUT I THINK THAT'S WHAT 1757 01:00:30,858 --> 01:00:32,393 I'M SUPPOSED TO DO. 1758 01:00:32,393 --> 01:00:35,662 WE STILL HAVE ISSUES AND A LOT 1759 01:00:35,662 --> 01:00:38,198 OF WORK TO DO. 1760 01:00:38,198 --> 01:00:39,700 YOU KNOW, THE EPIDEMIC IS NOT 1761 01:00:39,700 --> 01:00:43,637 THE SAME AS IT WAS IN THE PAST. 1762 01:00:43,637 --> 01:00:44,705 WE HEARD SOME OF THAT EARLIER 1763 01:00:44,705 --> 01:00:49,076 TODAY. 1764 01:00:49,076 --> 01:00:51,044 SO I GUESS I WOULD JUST LOBBY 1765 01:00:51,044 --> 01:00:55,516 FOR MORE COLLABORATION WITH 1766 01:00:55,516 --> 01:00:56,717 OTHER SCIENTISTS OUTSIDE OF 1767 01:00:56,717 --> 01:01:00,821 DAIDS, BUT ON BRINGING EXPERTISE 1768 01:01:00,821 --> 01:01:03,791 THAT'S OUTSIDE OF HIV RESEARCH 1769 01:01:03,791 --> 01:01:08,328 TO BEAR ON HIV RESEARCH QUEST 1770 01:01:08,328 --> 01:01:09,496 QUESTIONS MIGHT BE A REALLY GOOD 1771 01:01:09,496 --> 01:01:14,935 WAY TO SHARE THE BUDGET. 1772 01:01:14,935 --> 01:01:16,470 >> SO THESE REPRESENTED -- SO 1773 01:01:16,470 --> 01:01:17,704 IT'S INTERESTING THAT THERE'S A 1774 01:01:17,704 --> 01:01:20,274 NUMBER OUT THERE, EIGHT 1775 01:01:20,274 --> 01:01:20,541 RESPONSES. 1776 01:01:20,541 --> 01:01:24,578 SO THIS REPRESENTED A MINORITY 1777 01:01:24,578 --> 01:01:24,778 VIEW. 1778 01:01:24,778 --> 01:01:26,547 IT WASN'T LIKE 60 OUT OF 60 SAID 1779 01:01:26,547 --> 01:01:28,949 TAKE THE AIDS BUDGET AND BUST IT 1780 01:01:28,949 --> 01:01:30,350 APART, SPREAD IT OUT LIKE 1781 01:01:30,350 --> 01:01:31,652 FERTILIZER ALL OVER THE NIH 1782 01:01:31,652 --> 01:01:34,621 LAWN. 1783 01:01:34,621 --> 01:01:36,123 BUT REALLY, THERE IS -- THIS 1784 01:01:36,123 --> 01:01:38,959 GETS BACK TO THE LATENT JEALOUSY 1785 01:01:38,959 --> 01:01:40,727 THAT THERE IS A SETASIDE FOR 1786 01:01:40,727 --> 01:01:43,664 HIV, AND THAT TO A CERTAIN 1787 01:01:43,664 --> 01:01:47,167 EXTENT THROUGH THE COLLECTIVE 1788 01:01:47,167 --> 01:01:48,469 ACTIVITIES AT THE NIH, IT IS 1789 01:01:48,469 --> 01:01:50,304 PRETTY WELL ORGANIZED COMPARED 1790 01:01:50,304 --> 01:01:51,305 TO OTHER FIELDS. 1791 01:01:51,305 --> 01:01:54,141 AND SO I THINK THERE IS A LOT OF 1792 01:01:54,141 --> 01:01:57,744 THOSE KINDS OF ACTIVITIES, BUT I 1793 01:01:57,744 --> 01:02:02,216 AGREE THAT WHERE WE WILL NEED TO 1794 01:02:02,216 --> 01:02:06,687 GO AS DRUGS GET BETTER, 1795 01:02:06,687 --> 01:02:08,121 ANTIRETROVIRALS GET BETTER, IS 1796 01:02:08,121 --> 01:02:09,823 TO BROADEN OUT AND BRING IN 1797 01:02:09,823 --> 01:02:11,792 ADDITIONAL COLLABORATORS AS WE 1798 01:02:11,792 --> 01:02:13,694 DEAL WITH AGING, AS WE DEAL WITH 1799 01:02:13,694 --> 01:02:16,230 BONE DISEASE, AS WE DEAL WITH 1800 01:02:16,230 --> 01:02:20,267 OARL OTHER -- THE COMORBIDITIES 1801 01:02:20,267 --> 01:02:21,568 ASSOCIATED WITH HIV THAT ARE 1802 01:02:21,568 --> 01:02:27,908 MOST EXACERBATED BY LONG-TERM 1803 01:02:27,908 --> 01:02:29,109 ANTIRETROVIRAL TREATMENT IS 1804 01:02:29,109 --> 01:02:30,410 BUILDING THOSE PARTNERSHIPS. 1805 01:02:30,410 --> 01:02:36,350 SO I AGREE WITH YOU, RICH. 1806 01:02:36,350 --> 01:02:37,117 >> QUICK QUESTION. 1807 01:02:37,117 --> 01:02:37,818 >> BY ALL MEANS. 1808 01:02:37,818 --> 01:02:39,586 >> I DON'T KNOW IF YOU HAD 1809 01:02:39,586 --> 01:02:40,554 THIS -- YOU SHOWED IT ON THE 1810 01:02:40,554 --> 01:02:41,889 SLIDE BUT I DON'T KNOW IF IT 1811 01:02:41,889 --> 01:02:43,056 CAME UP IN TERMS OF THE REVIEW 1812 01:02:43,056 --> 01:02:43,924 CYCLE AND THAT'S ONE OF THE 1813 01:02:43,924 --> 01:02:45,025 THINGS WE OFTEN HERE, IS THAT 1814 01:02:45,025 --> 01:02:46,426 THERE'S A DIFFERENT REVIEW CYCLE 1815 01:02:46,426 --> 01:02:47,961 FOR HIV. 1816 01:02:47,961 --> 01:02:49,296 AND I ALWAYS STRESS THAT IT 1817 01:02:49,296 --> 01:02:52,432 SEEMS TO ENCOURAGE MORE CROSS 1818 01:02:52,432 --> 01:02:53,100 COLLABORATION SO THAT THERE'S 1819 01:02:53,100 --> 01:02:55,035 PEOPLE WHO MIGHT NOT CONSIDER 1820 01:02:55,035 --> 01:02:56,136 HIV AS PART OF THEIR RESEARCH 1821 01:02:56,136 --> 01:02:57,538 BUT TRY TO FIGURE OUT A WAY TO 1822 01:02:57,538 --> 01:03:01,909 DO SO BECAUSE IT HAS AN ENHANCED 1823 01:03:01,909 --> 01:03:02,242 CYCLE. 1824 01:03:02,242 --> 01:03:03,644 I WAS WONDERING IF THAT CAME UP 1825 01:03:03,644 --> 01:03:05,078 IN ANY OF THE COMMENTS YOU GOT. 1826 01:03:05,078 --> 01:03:06,146 >> I DON'T BELIEVE SO 1827 01:03:06,146 --> 01:03:08,115 SPECIFICALLY. 1828 01:03:08,115 --> 01:03:10,417 THE UNIQUE REVIEW CYCLE OF HIV. 1829 01:03:10,417 --> 01:03:12,386 I THINK DEPENDING ON OBVIOUSLY 1830 01:03:12,386 --> 01:03:14,521 AS CARL MENTIONED THE TYPES OF 1831 01:03:14,521 --> 01:03:15,856 RESPONSES FROM A MORE GLOBAL 1832 01:03:15,856 --> 01:03:17,257 LEVEL BECAUSE IT WASN'T AS 1833 01:03:17,257 --> 01:03:19,660 FOCUSED ON HIV, PERHAPS 1834 01:03:19,660 --> 01:03:21,395 DIDN'T -- IT DIDN'T REACH THAT 1835 01:03:21,395 --> 01:03:23,830 MARK. 1836 01:03:23,830 --> 01:03:25,999 >> WE HAVE A QUESTION ONLINE, 1837 01:03:25,999 --> 01:03:30,470 AND I WILL ASK YOU TO -- 1838 01:03:30,470 --> 01:03:33,874 >> HI. 1839 01:03:33,874 --> 01:03:35,475 SO -- I'M IN SAN FRANCISCO, I 1840 01:03:35,475 --> 01:03:36,276 CAN'T BE THERE IN PERSON. 1841 01:03:36,276 --> 01:03:38,679 I WANTED TO ECHO BOTH WITH CARL 1842 01:03:38,679 --> 01:03:40,280 AND DR. D'AQUILA MENTIONED AS 1843 01:03:40,280 --> 01:03:43,116 WELL BUT ALSO INCREASING 1844 01:03:43,116 --> 01:03:44,551 COLLABORATIONS ACROSS 1845 01:03:44,551 --> 01:03:46,153 INSTITUTES, OBVIOUSLY THIS IS A 1846 01:03:46,153 --> 01:03:48,121 MULTI-INSTITUTE APPROACH TO HIV 1847 01:03:48,121 --> 01:03:49,656 AND A LOT OF THE SUCCESSES ARE 1848 01:03:49,656 --> 01:03:51,925 BECAUSE OF THESE COLLABORATIONS, 1849 01:03:51,925 --> 01:03:53,460 AND ALSO WONDERING IF THERE'S 1850 01:03:53,460 --> 01:03:55,429 FURTHER DISCUSSION OF EVEN TO 1851 01:03:55,429 --> 01:03:57,297 IMPROVE OR ENHANCE SOME OF THE 1852 01:03:57,297 --> 01:03:58,198 EXISTING COLLABORATIONS WHICH I 1853 01:03:58,198 --> 01:04:01,401 KNOW ARE QUITE STRONG BEING WITH 1854 01:04:01,401 --> 01:04:03,270 EITHER COST SHARING ACROSS 1855 01:04:03,270 --> 01:04:04,771 DIFFERENT -- STRUCTURES, 1856 01:04:04,771 --> 01:04:05,939 MULTI-INSTITUTE CONTRIBUTIONS, 1857 01:04:05,939 --> 01:04:08,075 THINGS LIKE THAT. 1858 01:04:08,075 --> 01:04:09,276 AND COULD SEE THIS AS A 1859 01:04:09,276 --> 01:04:10,143 POTENTIAL OPPORTUNITY TO KIND OF 1860 01:04:10,143 --> 01:04:11,545 STREAMLINE SOME OF THOSE 1861 01:04:11,545 --> 01:04:13,080 PROCESS, ESPECIALLY WHEN 1862 01:04:13,080 --> 01:04:15,015 COMORBIDITIES SUCH AS HEART, 1863 01:04:15,015 --> 01:04:16,583 LUNG OR SUBSTANCE USE HAVE 1864 01:04:16,583 --> 01:04:19,386 DIRECT INTERACTION WITH VIRAL 1865 01:04:19,386 --> 01:04:21,355 PERSISTENCE OR IMMUNOLOGICAL 1866 01:04:21,355 --> 01:04:21,955 FACTORS AS WELL. 1867 01:04:21,955 --> 01:04:23,690 SO I THINK SOMETIMES FOR 1868 01:04:23,690 --> 01:04:26,526 INVESTIGATORS, IT CAN BE A BIT 1869 01:04:26,526 --> 01:04:30,864 CONFUSING TO NAVIGATE WHICH ENS 1870 01:04:30,864 --> 01:04:36,770 INSTITUTE TO APPLY, DIFFERENT 1871 01:04:36,770 --> 01:04:37,871 RFAs COMING FROM DIFFERENT 1872 01:04:37,871 --> 01:04:39,172 REGIONS SO THIS IS A GREAT 1873 01:04:39,172 --> 01:04:41,375 OPPORTUNITY TO REALLY SOLIDIFY 1874 01:04:41,375 --> 01:04:42,275 THESE AMAZING COLLABORATIONS 1875 01:04:42,275 --> 01:04:43,243 THAT HAVE ALREADY BEEN FORMED. 1876 01:04:43,243 --> 01:04:44,111 >> ABSOLUTELY. 1877 01:04:44,111 --> 01:04:46,346 I THINK AS PART OF THE HOLISTIC 1878 01:04:46,346 --> 01:04:47,581 PART, I WAS TRYING TO GIVE 1879 01:04:47,581 --> 01:04:49,316 ENOUGH WARNINGS WHEN YOU'RE 1880 01:04:49,316 --> 01:04:54,121 TAKING A SMALLER SN SNIPPET THAT 1881 01:04:54,121 --> 01:04:55,522 SOME OF THESE THINGS WILL BE 1882 01:04:55,522 --> 01:04:56,990 INCLUDED IN THE MORE HOLISTIC 1883 01:04:56,990 --> 01:04:58,692 PLAN ITSELF, INCLUDING 1884 01:04:58,692 --> 01:04:59,292 COLLABORATION. 1885 01:04:59,292 --> 01:05:00,427 THAT CAME UP AS ONE OF THE KEY 1886 01:05:00,427 --> 01:05:00,761 THINGS. 1887 01:05:00,761 --> 01:05:02,029 I'M ACTUALLY REALLY GLAD YOU 1888 01:05:02,029 --> 01:05:03,230 BROUGHT THAT UP AS WELL. 1889 01:05:03,230 --> 01:05:04,564 PERHAPS I SHOULD HAVE LEFT THAT 1890 01:05:04,564 --> 01:05:06,466 QUOTE TO THE END, BECAUSE PART 1891 01:05:06,466 --> 01:05:08,702 OF THE REASON OF ACTUALLY SAYING 1892 01:05:08,702 --> 01:05:09,870 SOMETHING AND ACTUALLY PUTTING 1893 01:05:09,870 --> 01:05:13,373 THAT UP IS THAT WHAT WE DO WITH 1894 01:05:13,373 --> 01:05:15,242 THESE RFI RESPONSES VARIES. 1895 01:05:15,242 --> 01:05:18,612 SO WHAT I MEAN BY THAT IS THAT 1896 01:05:18,612 --> 01:05:20,147 WHERE RELEVANT AND WHERE 1897 01:05:20,147 --> 01:05:21,915 SPECIFIC, WE CAN INCORPORATE 1898 01:05:21,915 --> 01:05:23,283 THIS INTO WHAT WE DO AS A 1899 01:05:23,283 --> 01:05:23,717 MISSION. 1900 01:05:23,717 --> 01:05:25,819 IN SOME CASES, I THINK IT REALLY 1901 01:05:25,819 --> 01:05:27,654 REQUIRES JUST A BETTER 1902 01:05:27,654 --> 01:05:28,288 ARTICULATION OF WHAT WE'RE 1903 01:05:28,288 --> 01:05:29,056 ALREADY DOING. 1904 01:05:29,056 --> 01:05:30,624 AND IN SOME CASES LIKE THAT, I 1905 01:05:30,624 --> 01:05:32,192 WAS GOING TO GET TO THAT PUNCH 1906 01:05:32,192 --> 01:05:33,527 LINE AT THE END BUT I DIDN'T 1907 01:05:33,527 --> 01:05:34,961 MEAN TO INSTILL A BIG FEAR IN 1908 01:05:34,961 --> 01:05:36,263 FOLKS THAT THAT WAS WHERE WE 1909 01:05:36,263 --> 01:05:39,299 WERE GOING, BUT IN SOME CASES I 1910 01:05:39,299 --> 01:05:40,834 AGREE, A LOT OF IT COMES DOWN 1911 01:05:40,834 --> 01:05:42,869 TO, AS CARL MENTIONED, HOW WE 1912 01:05:42,869 --> 01:05:43,203 COLLABORATE. 1913 01:05:43,203 --> 01:05:44,838 WE ARE NOT THE SOLE HIV -- YOU 1914 01:05:44,838 --> 01:05:46,039 KNOW, THERE ARE DIFFERENT PARTS 1915 01:05:46,039 --> 01:05:47,474 OF THIS WHOLE THAT I THINK A LOT 1916 01:05:47,474 --> 01:05:49,743 OF PEOPLE DON'T RECOGNIZE. 1917 01:05:49,743 --> 01:05:51,511 AND BOTH BEING CLEAR IN WHERE 1918 01:05:51,511 --> 01:05:53,046 OUR SWIM LANE IS BUT ALSO HOW WE 1919 01:05:53,046 --> 01:05:55,949 PARTNER WITH OTHERS IS CRITICAL. 1920 01:05:55,949 --> 01:05:59,553 AND AS FARTH PART OF THAT AS FAS 1921 01:05:59,553 --> 01:06:00,821 PART OF OUR HIV PORTFOLIO 1922 01:06:00,821 --> 01:06:02,055 DOESN'T HAVE TO JUST STAY 1923 01:06:02,055 --> 01:06:03,924 FINITE, WE ARE NOT THE ENTIRETY 1924 01:06:03,924 --> 01:06:04,357 OF IT. 1925 01:06:04,357 --> 01:06:07,627 WE CAN PARTNER WITH OTHERS TO DO 1926 01:06:07,627 --> 01:06:08,395 THAT, AS WELL AS TO ADDRESS SOME 1927 01:06:08,395 --> 01:06:09,696 OF THESE WHERE YOU SAY WE'VE 1928 01:06:09,696 --> 01:06:11,998 MADE SO MANY SUCCESS, IT SHOULD 1929 01:06:11,998 --> 01:06:13,300 BE REDISTRIBUTED, NOT 1930 01:06:13,300 --> 01:06:13,734 NECESSARILY. 1931 01:06:13,734 --> 01:06:15,268 IT COULD ALSO BE A BETTER 1932 01:06:15,268 --> 01:06:16,369 ARTICULATION OF WHAT OUR 1933 01:06:16,369 --> 01:06:17,337 PRIORITIES ARE AND WHAT WE'RE 1934 01:06:17,337 --> 01:06:18,505 DOING AND HOW WE'RE PARTNERING 1935 01:06:18,505 --> 01:06:19,639 WITH OTHERS, AND WE ARE TAKING 1936 01:06:19,639 --> 01:06:20,607 THAT INTO CONSIDERATION AS WE 1937 01:06:20,607 --> 01:06:24,111 DEVELOP THE STRATEGIC PLAN. 1938 01:06:24,111 --> 01:06:25,746 >> I ALSO WANTED TO MENTION 1939 01:06:25,746 --> 01:06:26,947 BRIEFLY TOO ABOUT THE REVIEW 1940 01:06:26,947 --> 01:06:28,648 CYCLE AND HOW HIV HAS A SEPARATE 1941 01:06:28,648 --> 01:06:33,687 REVIEW CYCLE. 1942 01:06:33,687 --> 01:06:36,089 I DO FEEL THERE IS SOME -- I 1943 01:06:36,089 --> 01:06:38,191 WANT TO SAY JEALOUSY FROM PEOPLE 1944 01:06:38,191 --> 01:06:40,026 WHO ARE NOT APPLYING TO THE HIV 1945 01:06:40,026 --> 01:06:40,994 CYCLE ON THE STREAMLINE PROCESS 1946 01:06:40,994 --> 01:06:42,229 WHERE YOU GET REVIEWED WITHIN 1947 01:06:42,229 --> 01:06:43,396 FOUR OR FIVE MONTHS, FUNDING 1948 01:06:43,396 --> 01:06:44,498 DECISIONS COULD BE MADE 1949 01:06:44,498 --> 01:06:45,932 RELATIVELY QUICKLY, AND I'M JUST 1950 01:06:45,932 --> 01:06:46,967 WONDERING, IS THERE A PLAN TO 1951 01:06:46,967 --> 01:06:48,869 EXPAND THAT OUTSIDE AIDS 1952 01:06:48,869 --> 01:06:49,536 RESEARCH CLEARLY CAN BE DONE IN 1953 01:06:49,536 --> 01:06:51,271 THE SETTING OF THE AIDS RESEARCH 1954 01:06:51,271 --> 01:06:52,773 CYCLE AND WHETHER STREAMLINING 1955 01:06:52,773 --> 01:06:55,742 OTHER PARTS OF THE NIAID TO DO A 1956 01:06:55,742 --> 01:06:59,546 SIMILAR TYPE OF PROCESS PROCESO 1957 01:06:59,546 --> 01:07:00,147 ADDRESS SOME OF THE CONCERNS 1958 01:07:00,147 --> 01:07:02,282 THAT SOME OF THESE PEOPLE MAY BE 1959 01:07:02,282 --> 01:07:03,350 FEELING WHO ARE OUTSIDE OF THE 1960 01:07:03,350 --> 01:07:06,987 HIV RESEARCH. 1961 01:07:06,987 --> 01:07:08,722 >> I DON'T MEAN TO BUST YOUR 1962 01:07:08,722 --> 01:07:11,458 BUBBLE THERE, TIM. 1963 01:07:11,458 --> 01:07:13,860 BUT THERE'S BEEN AN ONGOING 1964 01:07:13,860 --> 01:07:16,062 PRESSURE FROM THE AIDS COMMUNITY 1965 01:07:16,062 --> 01:07:18,198 TO TAKE WHAT WE DO AND 1966 01:07:18,198 --> 01:07:20,167 STREAMLINE IT ACROSS THE 1967 01:07:20,167 --> 01:07:23,770 INSTITUTES FOR ALL RESEARCH. 1968 01:07:23,770 --> 01:07:26,173 THE PUSHBACK IS TAKE THE 1969 01:07:26,173 --> 01:07:27,941 AIDS-RELATED REVIEW AWAY AND 1970 01:07:27,941 --> 01:07:31,545 FOLD US INTO THE EXISTING 1971 01:07:31,545 --> 01:07:33,180 STRUCTURES. 1972 01:07:33,180 --> 01:07:35,115 THAT HAS BEEN TRIED A COUPLE OF 1973 01:07:35,115 --> 01:07:36,983 TIMES, AND ONE OF THE GREAT 1974 01:07:36,983 --> 01:07:38,852 THINGS ABOUT THE HIV RESEARCH 1975 01:07:38,852 --> 01:07:40,921 COMMUNITY IS YOU TAKE THEM OFF 1976 01:07:40,921 --> 01:07:45,392 AND THEY GET REALLY AGGRESSIVE. 1977 01:07:45,392 --> 01:07:47,160 AND WE'VE BEEN ABLE TO BEAT IT 1978 01:07:47,160 --> 01:07:50,096 DOWN EVERY TIME IT'S COME UP. 1979 01:07:50,096 --> 01:07:52,699 SO CONTINUE TO HOLD THE THOUGHT 1980 01:07:52,699 --> 01:07:53,800 THAT -- I MEAN, IF YOU THINK 1981 01:07:53,800 --> 01:07:56,102 ABOUT BACK IN THE DAY, LIKE WHEN 1982 01:07:56,102 --> 01:07:58,071 I WROTE MY FIRST GRANT, I GOT -- 1983 01:07:58,071 --> 01:07:59,940 I HAD TO MAIL IT IN, I GOT A 1984 01:07:59,940 --> 01:08:02,209 PIECE OF PAPERBACK CALLED A PINK 1985 01:08:02,209 --> 01:08:04,311 SHEET BECAUSE IT WAS PRINTED ON 1986 01:08:04,311 --> 01:08:04,611 PINK PAPER. 1987 01:08:04,611 --> 01:08:05,946 ALL OF US HAVE LIVED THROUGH 1988 01:08:05,946 --> 01:08:06,246 THAT. 1989 01:08:06,246 --> 01:08:07,781 AND IT TOOK TIME TO MAKE THESE 1990 01:08:07,781 --> 01:08:09,282 AND YOU NEEDED THAT TIME. 1991 01:08:09,282 --> 01:08:10,951 BUT WITH COMPUTERS AND 1992 01:08:10,951 --> 01:08:12,085 EVERYTHING ELSE, EVERYTHING HAS 1993 01:08:12,085 --> 01:08:14,421 BEEN SHRUNK, AND THERE'S NO -- 1994 01:08:14,421 --> 01:08:15,722 I'M GOING TO GO OUT ON A LIMB 1995 01:08:15,722 --> 01:08:18,391 HERE AND AS A PERSONAL OPINION, 1996 01:08:18,391 --> 01:08:19,659 NOT AS DIRECTOR OF DAIDS, 1997 01:08:19,659 --> 01:08:23,196 THERE'S NO REASON WE CAN'T GO TO 1998 01:08:23,196 --> 01:08:24,798 THREE YEAR SEAT DATES A YEAR 1999 01:08:24,798 --> 01:08:25,332 ACROSS THE NIH. 2000 01:08:25,332 --> 01:08:27,634 BUT I DON'T THINK THAT VIEW IS 2001 01:08:27,634 --> 01:08:30,237 WIDELY HELD IN THE OFFICE OF 2002 01:08:30,237 --> 01:08:31,872 EXTRAMURAL RESEARCH OR AT CSR. 2003 01:08:31,872 --> 01:08:34,741 I'LL JUST LEAVE IT AT THAT. 2004 01:08:34,741 --> 01:08:36,576 >> SO JUST TO BE CLEAR, I WAS 2005 01:08:36,576 --> 01:08:38,545 NOT ARGUING AGAINST THE HIV/AIDS 2006 01:08:38,545 --> 01:08:38,812 DEADLINE. 2007 01:08:38,812 --> 01:08:40,981 I WAS SORT OF JUST ASKING ABOUT 2008 01:08:40,981 --> 01:08:42,716 THE -- I THINK IT'S INCREASED 2009 01:08:42,716 --> 01:08:43,817 COLLABORATION WHERE PEOPLE 2010 01:08:43,817 --> 01:08:47,087 POTENTIALLY HAVE INCORPORATED 2011 01:08:47,087 --> 01:08:50,991 HIF IHIV INTO THEIR GRANT. 2012 01:08:50,991 --> 01:08:52,192 SO I'M FOR IT, I WAS NOT 2013 01:08:52,192 --> 01:08:54,127 SPEAKING AGAINST IT. 2014 01:08:54,127 --> 01:08:56,229 >> SO IN ADDITION -- BY THE WAY, 2015 01:08:56,229 --> 01:08:56,563 THANK YOU. 2016 01:08:56,563 --> 01:08:57,764 THOSE ARE ACTUALLY EXCELLENT 2017 01:08:57,764 --> 01:08:59,299 QUESTIONS AND DISCUSSION POINTS. 2018 01:08:59,299 --> 01:09:01,268 SO THE FINAL TOPIC THAT REALLY 2019 01:09:01,268 --> 01:09:03,570 CAME UP AS A LARGE SYNOPSIS IS 2020 01:09:03,570 --> 01:09:04,971 ADDRESSING HEALTH DISPARITIES, 2021 01:09:04,971 --> 01:09:06,139 INCLUSION, WOMEN'S HEALTH AND 2022 01:09:06,139 --> 01:09:07,173 GLOBAL HEALTH. 2023 01:09:07,173 --> 01:09:08,375 AND WE RECEIVED A NUMBER OF 2024 01:09:08,375 --> 01:09:11,111 DIFFERENT RESPONSES HERE LOOKING 2025 01:09:11,111 --> 01:09:12,746 AT SPECIFICALLY PARTICULAR 2026 01:09:12,746 --> 01:09:14,381 POPULATIONS, PREGNANT PEOPLE, 2027 01:09:14,381 --> 01:09:15,682 BREASTFEEDING POPULATIONS, 2028 01:09:15,682 --> 01:09:18,885 MATERNAL HEALTH, NEONATES, WE 2029 01:09:18,885 --> 01:09:21,488 TOUCHED ON THAT EARLIER, 2030 01:09:21,488 --> 01:09:25,759 INFANTS, CHILDREN, ADD LESSONS, 2031 01:09:25,759 --> 01:09:27,160 ADDRESSING HIV IN CERTAIN 2032 01:09:27,160 --> 01:09:28,795 POPULATIONS, MAKING SURE THERE'S 2033 01:09:28,795 --> 01:09:29,896 INCLUSION IN THE STUDIES THAT 2034 01:09:29,896 --> 01:09:30,897 WE'RE DOING. 2035 01:09:30,897 --> 01:09:32,165 IN ADDITION TO ADDRESSING 2036 01:09:32,165 --> 01:09:34,034 WOMEN'S HEALTH, WHICH INCLUDES 2037 01:09:34,034 --> 01:09:36,002 STIGMA, AND ENSURING ACCESS TO 2038 01:09:36,002 --> 01:09:37,304 TREATMENT AND EFFICACY. 2039 01:09:37,304 --> 01:09:39,706 IN ADDITION, OBVIOUSLY WE HAVE 2040 01:09:39,706 --> 01:09:41,808 AN ENTIRELY SEPARATE 2041 01:09:41,808 --> 01:09:42,776 CROSS-CUTTING THEME ON GLOBAL 2042 01:09:42,776 --> 01:09:44,311 HEALTH, SO THAT WILL BE A LOT 2043 01:09:44,311 --> 01:09:45,745 OF -- SOME OF THIS WILL I 2044 01:09:45,745 --> 01:09:52,953 ADDRESSEI BEADDRESSED IN THERE , 2045 01:09:52,953 --> 01:09:55,956 UPTAKE BARRIERS ESPECIALLY IN 2046 01:09:55,956 --> 01:09:56,890 LMICs AND UNDERSERVED 2047 01:09:56,890 --> 01:09:57,190 POPULATIONS. 2048 01:09:57,190 --> 01:10:01,061 ANY QUESTIONS ON THIS SLIDE? 2049 01:10:01,061 --> 01:10:01,895 MORE COMMENTS? 2050 01:10:01,895 --> 01:10:03,029 OKAY. 2051 01:10:03,029 --> 01:10:04,164 WITH THAT, AND AS I MENTIONED, 2052 01:10:04,164 --> 01:10:05,165 THIS IS WHERE I WAS GOING TO 2053 01:10:05,165 --> 01:10:06,466 KIND OF GET TO THE PUNCH LINE OF 2054 01:10:06,466 --> 01:10:08,768 WHAT WE DO WITH THESE THINGS. 2055 01:10:08,768 --> 01:10:09,536 ESSENTIALLY, SO RIGHT NOW WE'RE 2056 01:10:09,536 --> 01:10:12,305 IN THE PROCESS OF BOTH PUTTING 2057 01:10:12,305 --> 01:10:14,007 THE PLAN TOGETHER, ORGANIZING IT 2058 01:10:14,007 --> 01:10:15,475 WITH OUR PROGRAM STAFF AS WELL 2059 01:10:15,475 --> 01:10:17,177 AS TAKING A LOOK AT THE RFI 2060 01:10:17,177 --> 01:10:18,378 RESPONSES AND INCORPORATING IT 2061 01:10:18,378 --> 01:10:19,212 WHERE APPROPRIATE. 2062 01:10:19,212 --> 01:10:22,515 AS I MENTIONED, THAT IS LEFT, I 2063 01:10:22,515 --> 01:10:25,418 WOULD SAY, SPECIFICALLY NEBULOUS 2064 01:10:25,418 --> 01:10:26,586 BECAUSE WHAT WE DO NEXT WITH 2065 01:10:26,586 --> 01:10:29,856 THIS REALLY VARIES ON -- IT 2066 01:10:29,856 --> 01:10:30,957 COULD EITHER COME DOWN TO 2067 01:10:30,957 --> 01:10:32,258 INCLUDING IT AS SOMETHING THAT 2068 01:10:32,258 --> 01:10:34,661 WE THINK WOULD BE RELEVANT OR 2069 01:10:34,661 --> 01:10:36,196 PERHAPS JUST BETTER ARTICULATING 2070 01:10:36,196 --> 01:10:37,497 WHAT WE'RE ALREADY DOING OR HOW 2071 01:10:37,497 --> 01:10:39,299 WE CAN BETTER COLLABORATE TO 2072 01:10:39,299 --> 01:10:40,533 ANSWER SOME OF THESE QUESTIONS, 2073 01:10:40,533 --> 01:10:41,534 EVEN IF THEY'RE NOT SPECIFICALLY 2074 01:10:41,534 --> 01:10:43,503 IN OUR SWIM LANE OR IN OUR 2075 01:10:43,503 --> 01:10:43,937 PURVIEW. 2076 01:10:43,937 --> 01:10:45,472 I THINK AS AN INSTITUTE, ONE OF 2077 01:10:45,472 --> 01:10:46,139 THE OPPORTUNITIES OF THE 2078 01:10:46,139 --> 01:10:47,574 STRATEGIC PLAN IS TO REALLY 2079 01:10:47,574 --> 01:10:50,076 BETTER ORGANIZE OURSELVES AND 2080 01:10:50,076 --> 01:10:51,044 BETTER ARTICULATE ESSENTIALLY 2081 01:10:51,044 --> 01:10:52,479 WHAT WE DO AND IN ADDITION THEN 2082 01:10:52,479 --> 01:10:54,781 HOW WE CAN PARTNER WITH OTHERS 2083 01:10:54,781 --> 01:10:56,549 TO THEN ADDRESS THE ISSUES AS A 2084 01:10:56,549 --> 01:10:57,183 WHOLE. 2085 01:10:57,183 --> 01:10:59,753 I SHOULD ALSO MENTION THAT THE 2086 01:10:59,753 --> 01:11:03,089 ENTIRETY OF THE RFI RESULTS WILL 2087 01:11:03,089 --> 01:11:04,824 ALSO BE INCLUDED AS PART OF THE 2088 01:11:04,824 --> 01:11:05,925 PLAN PUBLICATION, WE'LL BE DOING 2089 01:11:05,925 --> 01:11:08,461 A SUMMARY OF THE RESULTS THERE. 2090 01:11:08,461 --> 01:11:09,462 CARL ALREADY SHOWED THIS SLIDE, 2091 01:11:09,462 --> 01:11:12,298 BUT WHERE WE ARE RIGHT NOW IS 2092 01:11:12,298 --> 01:11:14,667 THAT MY TEAM IS WORKING ON 2093 01:11:14,667 --> 01:11:17,103 DRAFTING THE PLAN AND WORKING TO 2094 01:11:17,103 --> 01:11:17,637 INCORPORATE EVERYTHING. 2095 01:11:17,637 --> 01:11:22,342 THE GOAL IS TO HOPEFULLY PUBLISH 2096 01:11:22,342 --> 01:11:22,876 EARLY NEXT YEAR. 2097 01:11:22,876 --> 01:11:24,310 SO WITH THAT, I WILL SAY THANK 2098 01:11:24,310 --> 01:11:25,712 YOU FOR YOUR TIME AND ASK IF 2099 01:11:25,712 --> 01:11:33,920 THERE ARE ANY QUESTIONS. 2100 01:11:33,920 --> 01:11:35,922 >> I'D LIKE TO GO ALL THE WAY 2101 01:11:35,922 --> 01:11:36,790 BACK TO THE VERY BEGINNING OF 2102 01:11:36,790 --> 01:11:37,223 YOUR TALK. 2103 01:11:37,223 --> 01:11:39,292 SO YOU START OFF I THINK WITH 2104 01:11:39,292 --> 01:11:40,293 ACTUALLY THAT VERY LAST SLIDE 2105 01:11:40,293 --> 01:11:42,462 AND THE PROCESS GOING THROUGH 2106 01:11:42,462 --> 01:11:43,696 THIS, AND ON ONE OF THE SLIDES 2107 01:11:43,696 --> 01:11:45,632 YOU SHOWED SECOND OR THIRD, WAS 2108 01:11:45,632 --> 01:11:46,166 THE 2017 PLAN. 2109 01:11:46,166 --> 01:11:46,533 >> YES. 2110 01:11:46,533 --> 01:11:49,836 >> SO I WONDER IF PART OF THIS 2111 01:11:49,836 --> 01:11:51,571 ENTIRE PROCESS IS ACTUALLY JUST 2112 01:11:51,571 --> 01:11:53,673 GOING TO THE '17 PLAN AND SAYING 2113 01:11:53,673 --> 01:11:55,208 HOW DID WE DO ON THAT, MEETING 2114 01:11:55,208 --> 01:11:56,709 OUR GOALS, WERE THERE THINGS IN 2115 01:11:56,709 --> 01:11:58,044 HERE THAT WERE USEFUL TO US, 2116 01:11:58,044 --> 01:11:59,579 WERE THERE THINGS THAT WERE -- 2117 01:11:59,579 --> 01:12:01,014 DID THIS REALLY HELP US BECAUSE 2118 01:12:01,014 --> 01:12:02,415 IT SEEMS LIKE THERE'S NO BETTER 2119 01:12:02,415 --> 01:12:04,150 MODEL FOR FINDING WHAT WORKS AND 2120 01:12:04,150 --> 01:12:06,252 DOESN'T WORK IN MAKING A 2121 01:12:06,252 --> 01:12:06,953 STRATEGIC PLAN IS WHAT HAPPENED 2122 01:12:06,953 --> 01:12:07,387 BEFORE. 2123 01:12:07,387 --> 01:12:08,188 SO IS THAT PART OF IT? 2124 01:12:08,188 --> 01:12:08,955 >> ABSOLUTELY. 2125 01:12:08,955 --> 01:12:10,256 THAT WAS OUR FIRST STEP. 2126 01:12:10,256 --> 01:12:11,758 STEP ONE WAS REVISITING THE 2127 01:12:11,758 --> 01:12:12,725 2017 -- AND ACTUALLY I 2128 01:12:12,725 --> 01:12:16,463 APPRECIATE YOU SAYING THAT. 2129 01:12:16,463 --> 01:12:18,298 STEP ONE, IT TOOK ACTUALLY A 2130 01:12:18,298 --> 01:12:19,299 COUPLE MONTHS TO EVEN GET THE 2131 01:12:19,299 --> 01:12:21,067 INITIAL SKELETON DRAFT WHICH WAS 2132 01:12:21,067 --> 01:12:22,569 REVIEWING OUR PREVIOUS EFFORTS, 2133 01:12:22,569 --> 01:12:24,437 IN ADDITION REVIEWING OTHER 2134 01:12:24,437 --> 01:12:25,972 INSTITUTES, TO TAKE AS FAR AS A 2135 01:12:25,972 --> 01:12:27,807 STRUCTURAL IS CONCERNED AND AS 2136 01:12:27,807 --> 01:12:29,576 WELL AS LOOKING AT OAR, MAKING 2137 01:12:29,576 --> 01:12:30,877 SURE WE'RE IN ALIGNMENT WITH A 2138 01:12:30,877 --> 01:12:32,512 WHOLE BUNCH OF OTHER STRATEGIC 2139 01:12:32,512 --> 01:12:35,148 PLANS ACROSS THE INSTITUTE, BUT 2140 01:12:35,148 --> 01:12:36,349 YOU'RE ABSOLUTELY RIGHT, STEP 2141 01:12:36,349 --> 01:12:37,750 ONE WAS TAKING A LOOK AT THE 2142 01:12:37,750 --> 01:12:38,551 FIRST STRATEGIC PLAN, WORKING 2143 01:12:38,551 --> 01:12:40,186 THROUGH THAT AND SEEING HOW THAT 2144 01:12:40,186 --> 01:12:41,721 WAS ORGANIZED, AND AGREED, 2145 01:12:41,721 --> 01:12:43,156 TAKING A LOOK AT EITHER 2146 01:12:43,156 --> 01:12:44,023 SUCCESSES THERE OR WHERE WE 2147 01:12:44,023 --> 01:12:45,291 BUILD ON, ABSOLUTELY. 2148 01:12:45,291 --> 01:12:46,292 >> ARE THERE ANY SPECIFIC 2149 01:12:46,292 --> 01:12:48,061 EXAMPLES OF WHAT WORKED OR 2150 01:12:48,061 --> 01:12:48,495 THINGS WE DID? 2151 01:12:48,495 --> 01:12:52,432 I MEAN, DID YOU CALL OUT -- I 2152 01:12:52,432 --> 01:12:54,067 REALLY DON'T REMEMBER, DID YOU 2153 01:12:54,067 --> 01:13:01,207 CALL OUT LONG-ACTING 2154 01:13:01,207 --> 01:13:01,541 IMPLANTABLES? 2155 01:13:01,541 --> 01:13:02,609 I ACTUALLY THINK THAT JUST 2156 01:13:02,609 --> 01:13:04,677 ENCOURAGES THE FIELD QUITE 2157 01:13:04,677 --> 01:13:05,979 FRANKLY SAYING WE SET UP A GOAL 2158 01:13:05,979 --> 01:13:07,113 FIVE YEARS AGO AND IT WORKED. 2159 01:13:07,113 --> 01:13:08,948 >> WE DEFINITELY CALLED OUT 2160 01:13:08,948 --> 01:13:10,049 LONG-ACTING FOR TREATMENT AND 2161 01:13:10,049 --> 01:13:10,683 PREVENTION. 2162 01:13:10,683 --> 01:13:14,721 WE ALSO SAID BY 2024-2025, WE'D 2163 01:13:14,721 --> 01:13:18,658 HAVE A CURE THAT IN A 2164 01:13:18,658 --> 01:13:19,526 SIGNIFICANT AMOUNT OF POPULATION 2165 01:13:19,526 --> 01:13:21,628 WOULD BE PRETTY FUNCTIONAL. 2166 01:13:21,628 --> 01:13:23,496 NOT THERE. 2167 01:13:23,496 --> 01:13:25,665 AND WE'D HAVE A VACCINE THAT WAS 2168 01:13:25,665 --> 01:13:28,401 AT LEAST 60 TO 70% EFFECTIVE. 2169 01:13:28,401 --> 01:13:33,006 SO YOU HAVE TO TAKE BIG SWINGS, 2170 01:13:33,006 --> 01:13:34,641 AND THAT'S THE KIND OF THING 2171 01:13:34,641 --> 01:13:37,810 THAT WE DID. 2172 01:13:37,810 --> 01:13:39,012 ADDITIONALLY, ON THE TREATMENT 2173 01:13:39,012 --> 01:13:41,447 ACROSS THE LIFESPAN, EARLY IN 2174 01:13:41,447 --> 01:13:43,049 THE PLAN, WE TALKED ABOUT THE 2175 01:13:43,049 --> 01:13:48,087 NEED TO GET THE BEST APT 2176 01:13:48,087 --> 01:13:49,055 ANTIRETROVIRALS APPROVED FOR 2177 01:13:49,055 --> 01:13:51,391 ACROSS THE LI LIFESPAN. 2178 01:13:51,391 --> 01:13:52,725 THAT'S AN AREA THAT IMPAACT 2179 01:13:52,725 --> 01:13:54,027 NETWORK HAS EXCELLED WITH AND 2180 01:13:54,027 --> 01:13:54,794 WILL CONTINUE TO DO SO. 2181 01:13:54,794 --> 01:14:01,134 SO I WOULD SAY IF WE'RE BATTING 2182 01:14:01,134 --> 01:14:02,902 BETWEEN 4- AND 500, SO IN 2183 01:14:02,902 --> 01:14:04,204 BASEBALL, THAT'S PRETTY GOOD. 2184 01:14:04,204 --> 01:14:05,738 IN LIFE, IT'S NOT GOOD ENOUGH. 2185 01:14:05,738 --> 01:14:08,808 SO AGAIN, MANY OF THESE RESEARCH 2186 01:14:08,808 --> 01:14:10,777 QUESTIONS ARE -- THERE'S SO MUCH 2187 01:14:10,777 --> 01:14:11,744 INUNKNOWN THAT WE STILL NEED, 2188 01:14:11,744 --> 01:14:12,645 AND THAT'S WHY WE NEED TO BE 2189 01:14:12,645 --> 01:14:14,047 ABLE TO CONTINUE TO SUPPORT THE 2190 01:14:14,047 --> 01:14:21,287 BASIC SCIENCE. 2191 01:14:21,287 --> 01:14:23,189 >> REUBEN. 2192 01:14:23,189 --> 01:14:25,058 >> SUPER. 2193 01:14:25,058 --> 01:14:26,359 LOTS TO UNPACK AND DISCUSS 2194 01:14:26,359 --> 01:14:27,894 THERE. 2195 01:14:27,894 --> 01:14:29,629 2017, THAT WAS PREPANDEMIC, SO 2196 01:14:29,629 --> 01:14:32,498 WAS THERE ANYTHING IN THIS ON 2197 01:14:32,498 --> 01:14:33,700 PANDEMIC PREPAREDNESS? 2198 01:14:33,700 --> 01:14:35,335 I THINK OUR VIEWS ON THAT HAVE 2199 01:14:35,335 --> 01:14:37,070 CHANGED CONSIDERABLY, SINCE 2200 01:14:37,070 --> 01:14:37,303 2017. 2201 01:14:37,303 --> 01:14:39,706 I DIDN'T SEE THAT WORD IN THERE 2202 01:14:39,706 --> 01:14:39,939 REALLY. 2203 01:14:39,939 --> 01:14:42,875 >> IT WAS BIOPREPAREDNESS IS THE 2204 01:14:42,875 --> 01:14:43,243 FIFTH PRIORITY. 2205 01:14:43,243 --> 01:14:45,378 WE DID THAT BECAUSE IT BOTH 2206 01:14:45,378 --> 01:14:47,480 INCLUDES BIODEFENSE AND ACADEMIC 2207 01:14:47,480 --> 01:14:49,549 PREPAREDNESS, JUST FROM A 2208 01:14:49,549 --> 01:14:50,650 LOGISTICAL STANDPOINT, THEY MADE 2209 01:14:50,650 --> 01:14:52,185 SENSE BECAUSE OF THE NATURE AND 2210 01:14:52,185 --> 01:14:57,457 OVERLAP OF THEM, BUT PANDEMIC 2211 01:14:57,457 --> 01:14:58,858 PREPAREDNESS IS A SPECIFIC FACET 2212 01:14:58,858 --> 01:15:00,727 AND ALMOST AN ENTIRE PRIORITY OF 2213 01:15:00,727 --> 01:15:01,127 ITS OWN. 2214 01:15:01,127 --> 01:15:03,062 >> SO I WANT TO MAYBE CHALLENGE 2215 01:15:03,062 --> 01:15:03,930 THE GROUP A LITTLE BIT TOO. 2216 01:15:03,930 --> 01:15:05,331 I THINK EVERYONE HERE PROBABLY 2217 01:15:05,331 --> 01:15:07,767 WOULD SUPPORT DARWINIAN 2218 01:15:07,767 --> 01:15:09,502 EVOLUTION, YOU KNOW AND THE 2219 01:15:09,502 --> 01:15:10,169 FITTEST SURVIVE. 2220 01:15:10,169 --> 01:15:11,571 WAS I NOT LOUD ENOUGH? 2221 01:15:11,571 --> 01:15:13,539 EVERYONE HERE MIGHT SUPPORT 2222 01:15:13,539 --> 01:15:15,408 DARWINIAN EVOLUTION AND WE SEE 2223 01:15:15,408 --> 01:15:16,943 RAPIDLY EVOLVING VIRUSES AND 2224 01:15:16,943 --> 01:15:18,911 RESISTANCE AND THINGS LIKE THAT. 2225 01:15:18,911 --> 01:15:21,214 SO I THINK WITHIN HIV RESEARCH, 2226 01:15:21,214 --> 01:15:23,716 THERE'S TREMENDOUS ADVANCES AND 2227 01:15:23,716 --> 01:15:24,584 COLLABORATIONS, I THINK RICH WAS 2228 01:15:24,584 --> 01:15:25,585 REFERRING TO THINGS LIKE THAT 2229 01:15:25,585 --> 01:15:27,553 WHERE WE DO WORK ACROSS AND 2230 01:15:27,553 --> 01:15:29,722 COLLABORATE REALLY, REALLY WELL, 2231 01:15:29,722 --> 01:15:31,691 BUT WHAT IF WE JUST LET EVERYONE 2232 01:15:31,691 --> 01:15:32,792 COLLABORATE ON DIFFERENT 2233 01:15:32,792 --> 01:15:33,893 PROBLEMS AND MAYBE MORE NEW 2234 01:15:33,893 --> 01:15:34,994 PEOPLE WOULD COME TO THE FIELD 2235 01:15:34,994 --> 01:15:36,396 AND MORE OF THESE HARD PROBLEMS 2236 01:15:36,396 --> 01:15:39,899 LIKE VACCINE WOULD GET SOLVED OR 2237 01:15:39,899 --> 01:15:42,769 CURE, RIGHT? 2238 01:15:42,769 --> 01:15:44,404 IN WHICH CASE THERE WOULDN'T BE 2239 01:15:44,404 --> 01:15:45,805 ANYTHING PROTECTED AND IT WOULD 2240 01:15:45,805 --> 01:15:47,240 JUST OPEN UP FOR ALL BASIC 2241 01:15:47,240 --> 01:15:48,474 SCIENTISTS TO GO AFTER THESE 2242 01:15:48,474 --> 01:15:49,676 PROBLEMS AND THEN MAYBE THERE 2243 01:15:49,676 --> 01:15:51,177 WOULD BE MORE INNOVATIVE THINGS 2244 01:15:51,177 --> 01:15:53,379 TO TRANSLATE. 2245 01:15:53,379 --> 01:15:56,115 SO WHAT'S STOP WHAT 2246 01:15:56,115 --> 01:15:57,917 >> SO WHAT'S STOPPING SOMEBODY 2247 01:15:57,917 --> 01:16:02,021 FROM WORKING, PUTTING A GRANT 2248 01:16:02,021 --> 01:16:04,324 IN? 2249 01:16:04,324 --> 01:16:05,425 IT'S NOT JUST WHAT YOU CHOOSE TO 2250 01:16:05,425 --> 01:16:06,025 WORK ON. 2251 01:16:06,025 --> 01:16:07,727 >> SO WITH SUCH A LARGE 2252 01:16:07,727 --> 01:16:09,796 PROPORTION WORKING ON ONE VIRUS, 2253 01:16:09,796 --> 01:16:11,664 THERE'S A LOT LESS WORKING ON 2254 01:16:11,664 --> 01:16:12,198 OTHERS. 2255 01:16:12,198 --> 01:16:14,067 WE'VE SIEB SCENE ALL THE 2256 01:16:14,067 --> 01:16:15,268 INNOVATION COME OUT OF HIV THAT 2257 01:16:15,268 --> 01:16:17,470 WE MIGHT NOT HAVE ACHIEVED HAD 2258 01:16:17,470 --> 01:16:19,339 THERE NOT BEEN THAT DEDICATED 2259 01:16:19,339 --> 01:16:19,872 EVERYTHING. 2260 01:16:19,872 --> 01:16:22,709 BUT IF IT WAS AN EQUALLY 2261 01:16:22,709 --> 01:16:24,143 DEDICATED EFFORT ON OTHER VIRUS, 2262 01:16:24,143 --> 01:16:25,411 THERE COULD BE OTHER SURPRISE 2263 01:16:25,411 --> 01:16:26,713 THERE IS THAT COULD COME BACK 2264 01:16:26,713 --> 01:16:28,414 AND HELP ON HIV RESEARCH. 2265 01:16:28,414 --> 01:16:30,850 JUST A THOUGHT. 2266 01:16:30,850 --> 01:16:35,088 >> AGAIN, WHAT IS -- BACK TO 2267 01:16:35,088 --> 01:16:36,422 SWIM LANES, WHAT IS THE 2268 01:16:36,422 --> 01:16:38,725 RESPONSIBILITY OF DAIDS, WHAT IS 2269 01:16:38,725 --> 01:16:41,127 THE RESPONSIBILITY OF DMID, 2270 01:16:41,127 --> 01:16:42,428 TALKING ABOUT A LURE KNOWLEDGE 2271 01:16:42,428 --> 01:16:44,964 CAL VIRUS, WHAT'S THE 2272 01:16:44,964 --> 01:16:45,631 RESPONSIBILITY OF NINDS? 2273 01:16:45,631 --> 01:16:46,933 I THINK PART OF THE PROBLEM IS 2274 01:16:46,933 --> 01:16:50,336 THAT WE ARE DRIVEN BY THE WAY 2275 01:16:50,336 --> 01:16:52,205 THE FUNDS ARE APPROPRIATED BY 2276 01:16:52,205 --> 01:16:53,406 THE CONGRESS. 2277 01:16:53,406 --> 01:16:55,808 AND TO A CERTAIN EXTENT, THAT 2278 01:16:55,808 --> 01:16:58,878 LIMITS THE DEGRIE DEGREE OF 2279 01:16:58,878 --> 01:16:59,245 FLEXIBILITY. 2280 01:16:59,245 --> 01:17:01,147 AND THAT'S ONE OF THE REASONS WE 2281 01:17:01,147 --> 01:17:02,915 PUSH VERY HARD TO EXPAND THE 2282 01:17:02,915 --> 01:17:06,953 DEFINITION OF CO-MORBID ITS AND 2283 01:17:06,953 --> 01:17:08,588 COINFECTIONS, BECAUSE THAT'S A 2284 01:17:08,588 --> 01:17:09,789 WAY TO BLOW SOME OF THAT OPEN. 2285 01:17:09,789 --> 01:17:12,859 >> I TOTALLY AGREE WITH THAT, 2286 01:17:12,859 --> 01:17:14,060 AND THAT'S THE TRICKY PART THAT 2287 01:17:14,060 --> 01:17:18,464 I DON'T HAVE A SOLUTION TO. 2288 01:17:18,464 --> 01:17:19,999 >> I JUST WANTED TO COMMENT THAT 2289 01:17:19,999 --> 01:17:21,534 I THINK ONE OF THE OTHER -- ONE 2290 01:17:21,534 --> 01:17:23,169 OF THE CHALLENGES IS THAT IN 2291 01:17:23,169 --> 01:17:26,773 THIS MOMENT, THERE IS SO MUCH 2292 01:17:26,773 --> 01:17:28,641 UNCERTAINTY ABOUT THE FUTURE AND 2293 01:17:28,641 --> 01:17:31,244 THE BUDGETS, THE FACT THAT THE 2294 01:17:31,244 --> 01:17:34,213 BUDGETS ARE SO TIGHT, I THINK 2295 01:17:34,213 --> 01:17:36,048 THAT DRIVES SOME COMMENTS LIKE 2296 01:17:36,048 --> 01:17:36,315 THESE. 2297 01:17:36,315 --> 01:17:38,384 SO I'M SURE THIS IS SOMETHING 2298 01:17:38,384 --> 01:17:40,553 EVERYBODY IN THIS ROOM FULLY IS 2299 01:17:40,553 --> 01:17:45,191 AWARE OF, IF THERE WAS REALLY 2300 01:17:45,191 --> 01:17:47,126 ENOUGH MONEY IN THIS COUNTRY TO 2301 01:17:47,126 --> 01:17:48,895 FUND ALL OF THE BIOMEDICAL 2302 01:17:48,895 --> 01:17:50,329 RESEARCH THAT NEEDED TO BE DONE, 2303 01:17:50,329 --> 01:17:51,431 THEN WE WOULDN'T BE HAVING THIS 2304 01:17:51,431 --> 01:17:52,532 CONVERSATION AT ALL. 2305 01:17:52,532 --> 01:17:53,266 THERE JUST ISN'T. 2306 01:17:53,266 --> 01:17:54,367 SO IT DOESN'T MEAN THAT YOU 2307 01:17:54,367 --> 01:17:57,904 LEVEL DOWN, RIGHT? 2308 01:17:57,904 --> 01:18:00,406 IT THEANS -- AND WE ALL HAVE TO 2309 01:18:00,406 --> 01:18:02,175 VOTE. 2310 01:18:02,175 --> 01:18:05,111 >> WHEN YOU SEND OUT AN RFI, 2311 01:18:05,111 --> 01:18:06,345 YOU'RE GOING TO GET RESPONSES 2312 01:18:06,345 --> 01:18:07,079 FROM DIFFERENT PEOPLE WITH 2313 01:18:07,079 --> 01:18:09,282 DIFFERENT PURVIEW AND DIFFERENT 2314 01:18:09,282 --> 01:18:10,149 ADVOCACY GROUPS AND THINGS LIKE 2315 01:18:10,149 --> 01:18:10,817 THAT. 2316 01:18:10,817 --> 01:18:11,918 AND A LOT OF CASES THEY WENT 2317 01:18:11,918 --> 01:18:13,453 RIGHT DOWN THE LINE AND 2318 01:18:13,453 --> 01:18:15,087 RESPONDED TO EACH PRIORITY 2319 01:18:15,087 --> 01:18:15,521 INDIVIDUALLY. 2320 01:18:15,521 --> 01:18:17,490 SO IF YOU WERE NOT AN HIV/AIDS 2321 01:18:17,490 --> 01:18:19,358 RESEARCHER AND YOU GET TO THE 2322 01:18:19,358 --> 01:18:21,127 HIV/AIDS PRIORITY, YOUR COMMENTS 2323 01:18:21,127 --> 01:18:22,862 ARE PROBABLY GOING TO BE GEARED 2324 01:18:22,862 --> 01:18:23,963 MORE TOWARDS SPREADING THE 2325 01:18:23,963 --> 01:18:26,032 WEALTH AND SHARING THOSE 2326 01:18:26,032 --> 01:18:27,667 RESOURCES WITH SOMEONE WITH YOUR 2327 01:18:27,667 --> 01:18:28,801 AREA OF INTEREST. 2328 01:18:28,801 --> 01:18:30,470 AND I MEAN, THAT IS PART OF 2329 01:18:30,470 --> 01:18:32,205 THEIR INTEREST TO DO SO. 2330 01:18:32,205 --> 01:18:34,841 HOWEVER, YOU KNOW, IN AN EFFORT 2331 01:18:34,841 --> 01:18:35,475 OF TRANSPARENCY TO SHARE THAT 2332 01:18:35,475 --> 01:18:37,143 WITH YOU, THAT IS ALSO PART OF 2333 01:18:37,143 --> 01:18:38,678 THE PROCESS WHEN YOU GET THESE 2334 01:18:38,678 --> 01:18:40,313 RFIs TO ALSO UNDERSTAND, WHICH 2335 01:18:40,313 --> 01:18:41,414 IS ONE OF THE REASONS WHY I 2336 01:18:41,414 --> 01:18:43,182 TRIED TO LAY THAT EARLIER, IS TO 2337 01:18:43,182 --> 01:18:47,320 SAY WHEN WE PUT THAT'S OUT, 2338 01:18:47,320 --> 01:18:50,089 WRITE DOWN EACH PRIORITY AND 2339 01:18:50,089 --> 01:18:51,457 GAVE INPUT ON EVERY SINGLE ONE 2340 01:18:51,457 --> 01:18:52,525 OF THEM AS WELL. 2341 01:18:52,525 --> 01:18:54,594 >> SO JUST ON THAT POINT, SO I 2342 01:18:54,594 --> 01:18:57,196 MEAN, YOU SHOWED THERE WAS ABOUT 2343 01:18:57,196 --> 01:18:58,898 63 RESPONDED IN THIS CYCLE. 2344 01:18:58,898 --> 01:19:00,299 >> YES. 2345 01:19:00,299 --> 01:19:04,370 >> IT SOUNDED LIKE HALF ARE 2346 01:19:04,370 --> 01:19:04,670 HIV-RELATED. 2347 01:19:04,670 --> 01:19:06,472 >> THAT'S ANOTHER GOOD POINT, 2348 01:19:06,472 --> 01:19:10,076 THE RESPONSES EITHER TOUCHED ON 2349 01:19:10,076 --> 01:19:10,276 IT -- 2350 01:19:10,276 --> 01:19:13,913 >> THE 2017 TIMELINE, WHAT WERE 2351 01:19:13,913 --> 01:19:15,181 THE NUMBERS -- 2352 01:19:15,181 --> 01:19:19,819 >> I'M NOT SURE THERE WAS AN RFI 2353 01:19:19,819 --> 01:19:21,153 ON THAT ONE AT THE TIME. 2354 01:19:21,153 --> 01:19:25,191 I DO NOT BELIEVE WE DID THIS PRO 2355 01:19:25,191 --> 01:19:35,601 SET PROCESS. 2356 01:19:35,601 --> 01:19:38,671 >> JUST A COMMENT, KUDOS FOR 2357 01:19:38,671 --> 01:19:43,276 DOING THIS PROCESS. 2358 01:19:43,276 --> 01:19:44,343 I EL 2359 01:19:44,343 --> 01:19:46,879 >> OBVIOUSLY WE'RE NOT ALL GOING 2360 01:19:46,879 --> 01:19:49,916 TO AGREE WITH EVERYTHING WE -- 2361 01:19:49,916 --> 01:19:50,816 >> THANK YOU VERY MUCH, AND 2362 01:19:50,816 --> 01:19:51,617 THANK YOU ALL FOR YOUR COMMENTS. 2363 01:19:51,617 --> 01:19:56,422 >> THANK YOU VERY MUCH. 2364 01:19:56,422 --> 01:19:59,358 OKAY. 2365 01:19:59,358 --> 01:20:00,793 CARL IS GOING TO STEP BACK TO 2366 01:20:00,793 --> 01:20:02,862 THE FRONT AND TALK ABOUT FUTURE 2367 01:20:02,862 --> 01:20:04,230 DIRECTION OF THE CLINICAL TRIALS 2368 01:20:04,230 --> 01:20:14,407 NETWORKS. 2369 01:20:17,410 --> 01:20:21,581 >> I'M GOING TO TAKE A LITTLE 2370 01:20:21,581 --> 01:20:22,882 BIT LONGER WITH A LITTLE BIT 2371 01:20:22,882 --> 01:20:24,116 MORE GRANULARITY THAN I NORMALLY 2372 01:20:24,116 --> 01:20:26,852 DO. 2373 01:20:26,852 --> 01:20:28,955 AND I THINK IT'S IMPORTANT IN 2374 01:20:28,955 --> 01:20:31,223 PART BASED ON THE WAY WE'VE BEEN 2375 01:20:31,223 --> 01:20:34,093 THINKING ABOUT THIS, BUT ALSO 2376 01:20:34,093 --> 01:20:36,596 YOU'LL SEE A LOT OF THIS 2377 01:20:36,596 --> 01:20:38,898 PREVIOUS CONVERSATION ABOUT 2378 01:20:38,898 --> 01:20:39,999 COLLABORATION AND FUTURE 2379 01:20:39,999 --> 01:20:42,668 DIRECTIONS REFLECTED IN THE 2380 01:20:42,668 --> 01:20:45,805 SLIDES TODAY. 2381 01:20:45,805 --> 01:20:47,340 THIS IS ORGANIZED NOT BY 2382 01:20:47,340 --> 01:20:50,409 NETWORK. 2383 01:20:50,409 --> 01:20:51,944 I DO NOT HAVE A BUCKET THAT SAYS 2384 01:20:51,944 --> 01:20:54,580 IMPACT, A BUCKET THAT SAYS ACTG, 2385 01:20:54,580 --> 01:20:55,982 OR PTN OR VTN. 2386 01:20:55,982 --> 01:20:58,517 IT IS ORGANIZED BY FUNCTIONAL 2387 01:20:58,517 --> 01:20:59,952 RESEARCH AREAS. 2388 01:20:59,952 --> 01:21:03,990 SO WHEN I SAY THINGS LIKE 2389 01:21:03,990 --> 01:21:05,791 GETTING THE BEST ANTIRETROVIRALS 2390 01:21:05,791 --> 01:21:10,563 ACROSS THE LIFESPAN, THE PEOPLE 2391 01:21:10,563 --> 01:21:11,464 AT IMPACT, THEY'RE JUST GOING TO 2392 01:21:11,464 --> 01:21:12,531 HAVE TO TRUST ME. 2393 01:21:12,531 --> 01:21:14,533 AND TALK ABOUT CURE ACROSS THE 2394 01:21:14,533 --> 01:21:16,502 LIFESPAN, IT NEEDS TO BE 2395 01:21:16,502 --> 01:21:18,471 REFLECTED THAT YOU'RE NOT GOING 2396 01:21:18,471 --> 01:21:20,006 TO SEE INDIVIDUAL NETWORKS 2397 01:21:20,006 --> 01:21:25,511 NECESSARILY CALLED OUT. 2398 01:21:25,511 --> 01:21:27,113 WITH THAT SAID, WE ARE IN A 2399 01:21:27,113 --> 01:21:29,148 PROCESS SIMILAR TO A STRATEGIC 2400 01:21:29,148 --> 01:21:32,385 PLAN WHERE EVERY SEVEN YEARS, WE 2401 01:21:32,385 --> 01:21:33,819 COMPETITIVELY REVIEW THE NETWORK 2402 01:21:33,819 --> 01:21:34,553 ACTIVITIES. 2403 01:21:34,553 --> 01:21:36,889 WE ARE LITERALLY HALFWAY THROUGH 2404 01:21:36,889 --> 01:21:39,425 THE SEVEN-YEAR GRANT CYCLE. 2405 01:21:39,425 --> 01:21:42,361 SO WHAT WE ARE DOING IS TAKING A 2406 01:21:42,361 --> 01:21:46,365 PAUSE, LOOKING AT WHERE WE ARE 2407 01:21:46,365 --> 01:21:48,034 AS A RESEARCH ENTERPRISE, WHERE 2408 01:21:48,034 --> 01:21:50,703 WE ARE WITH OUR FUNDING, AND 2409 01:21:50,703 --> 01:21:52,805 THINKING ABOUT WAYS WE COULD BE 2410 01:21:52,805 --> 01:21:53,039 BETTER. 2411 01:21:53,039 --> 01:21:55,808 WHERE DO WE NEED TO BE? 2412 01:21:55,808 --> 01:21:57,543 NOT NECESSARILY WHEN WE MAKE THE 2413 01:21:57,543 --> 01:21:59,645 NEXT SET OF AWARDS, BUT CAN WE 2414 01:21:59,645 --> 01:22:01,280 THINK ABOUT A VERY 2415 01:22:01,280 --> 01:22:03,249 FORWARD-LOOKING AGENDA THAT GETS 2416 01:22:03,249 --> 01:22:05,651 US TO WHERE WE ARE THINKING AS A 2417 01:22:05,651 --> 01:22:07,653 GROUP OF SCIENTISTS, WHERE WE 2418 01:22:07,653 --> 01:22:09,722 WANT THE CLINICAL RESEARCH THAT 2419 01:22:09,722 --> 01:22:13,025 WE ARE SEEKING TO DRIVE, TO 2420 01:22:13,025 --> 01:22:14,760 CARRY US THROUGH TO THE NEXT 2421 01:22:14,760 --> 01:22:18,264 NETWORK RENEWAL IN 2034. 2422 01:22:18,264 --> 01:22:22,435 SO A 10-YEAR CYCLE. 2423 01:22:22,435 --> 01:22:23,903 THREE YEARS LEFT IN THIS CYCLE, 2424 01:22:23,903 --> 01:22:26,505 SEVEN IN THE NEXT. 2425 01:22:26,505 --> 01:22:28,040 SO WE'RE GOING TO BE FIVE YEARS 2426 01:22:28,040 --> 01:22:32,111 BEYOND THE NIAID STRATEGIC PLAN. 2427 01:22:32,111 --> 01:22:33,312 SO WHERE WE ARE IN THE PROCESS 2428 01:22:33,312 --> 01:22:36,282 IS WE ARE IN PLANNING MODE NOW 2429 01:22:36,282 --> 01:22:41,987 AND THROUGH PART OF 2025. 2430 01:22:41,987 --> 01:22:50,296 IN 2026, COMPLETION, IN 2027 WE 2431 01:22:50,296 --> 01:22:52,131 WILL MAKE AWARDS, AND IN THIS 2432 01:22:52,131 --> 01:22:53,666 PERIOD BETWEEN NOW AND THE TIME 2433 01:22:53,666 --> 01:22:54,767 OF AWARDS, WE HAVE THE 2434 01:22:54,767 --> 01:22:56,869 FLEXIBILITY TO ADAPT, TAKE NEW 2435 01:22:56,869 --> 01:22:58,070 IDEAS AND REALLY MAKE SURE THAT 2436 01:22:58,070 --> 01:23:02,341 WE ARE PUTTING FORWARD THE MOST 2437 01:23:02,341 --> 01:23:05,177 SORT OF VISIONARY PATH FOR US 2438 01:23:05,177 --> 01:23:06,512 AND THE ACTIVITY THAT WE ARE 2439 01:23:06,512 --> 01:23:10,015 SEEKING TO FOSTER TO IMPROVE THE 2440 01:23:10,015 --> 01:23:12,985 LIFE OF PEOPLE LIVING WITH HIV 2441 01:23:12,985 --> 01:23:17,890 AND IMPROVE PREVENTION OF HIV 2442 01:23:17,890 --> 01:23:20,826 FOR ALL. 2443 01:23:20,826 --> 01:23:22,294 SO WHERE WE ARE, WE'RE NOW IN 2444 01:23:22,294 --> 01:23:25,464 THE AREA OF -- WE LAUNCHED IN 2445 01:23:25,464 --> 01:23:27,767 THE SPRING WITH A STRATEGIC 2446 01:23:27,767 --> 01:23:28,901 WORKING GROUP MEETING WHERE ALL 2447 01:23:28,901 --> 01:23:33,172 THE NETWORKS CAME IN AND WERE 2448 01:23:33,172 --> 01:23:34,607 ABLE TO BASICALLY MAKE A 2449 01:23:34,607 --> 01:23:36,008 PRESENTATION THAT WAS PRETTY 2450 01:23:36,008 --> 01:23:38,144 DETAILED ABOUT WHERE THEY 2451 01:23:38,144 --> 01:23:39,345 THOUGHT THEIR RESEARCH AGENDA 2452 01:23:39,345 --> 01:23:39,779 SHOULD GO. 2453 01:23:39,779 --> 01:23:43,048 SO THAT GAVE US A BASELINE. 2454 01:23:43,048 --> 01:23:45,084 OVER THE SUMMER, UNTIL DECEMBER, 2455 01:23:45,084 --> 01:23:46,919 WE WILL CONTINUE TO GET INPUT 2456 01:23:46,919 --> 01:23:49,655 FROM STAKEHOLDERS, INVESTIGATORS 2457 01:23:49,655 --> 01:23:50,222 COMMUNITY. 2458 01:23:50,222 --> 01:23:52,224 WE'VE HAD WEBINARS, WE ARE IN 2459 01:23:52,224 --> 01:23:54,693 THE PROCESS OF DEVELOPING BLOG 2460 01:23:54,693 --> 01:23:56,562 POSTS ON SPECIFIC TOPICS, 2461 01:23:56,562 --> 01:23:59,865 THEMATIC DISCUSSION DISCUSSIONSN 2462 01:23:59,865 --> 01:24:00,199 FEEDBACK. 2463 01:24:00,199 --> 01:24:01,867 TOWN HALLS MAY BE NECESSARY. 2464 01:24:01,867 --> 01:24:02,868 TODAY WE ARE HERE FOR A 2465 01:24:02,868 --> 01:24:03,936 PRELIMINARY DISCUSSION ABOUT 2466 01:24:03,936 --> 01:24:06,238 IDEAS THAT WE HAVE, AND WE WILL 2467 01:24:06,238 --> 01:24:08,007 CONTINUE TO DO THIS WITH OTHER 2468 01:24:08,007 --> 01:24:11,210 ADVISORY COMMITTEES, AND WE GET 2469 01:24:11,210 --> 01:24:14,146 TO JANUARY, WE WILL COME BACK 2470 01:24:14,146 --> 01:24:15,681 WITH MORE OF A FINAL STRUCTURE. 2471 01:24:15,681 --> 01:24:18,217 SO FOR TODAY, THIS IS THE 2472 01:24:18,217 --> 01:24:19,118 PRELIMINARY DISCUSSION WITH 2473 01:24:19,118 --> 01:24:21,487 ARAC. 2474 01:24:21,487 --> 01:24:25,324 SO WE HAVE A WEBSITE THAT'S UP 2475 01:24:25,324 --> 01:24:26,992 THAT IS GOING TO BECOME THE HOME 2476 01:24:26,992 --> 01:24:28,294 OF ALL THE BLOG POST, THE HOME 2477 01:24:28,294 --> 01:24:30,830 OF THE FEEDBACK WE'VE RECEIVED, 2478 01:24:30,830 --> 01:24:32,598 AND ALSO THERE WILL BE A PLACE 2479 01:24:32,598 --> 01:24:35,801 WHERE PEOPLE CAN WRITE DIRECTLY 2480 01:24:35,801 --> 01:24:37,002 WITH ADDITIONAL COMMENTS AND 2481 01:24:37,002 --> 01:24:40,272 IDEAS THEY WILL BE MONITORED AND 2482 01:24:40,272 --> 01:24:41,006 READ. 2483 01:24:41,006 --> 01:24:43,008 WHAT WE WOULD PLAN TO DO WITH 2484 01:24:43,008 --> 01:24:46,178 THE FEEDBACK AND THE COMMENTS 2485 01:24:46,178 --> 01:24:50,115 THAT WE GET, WHETHER IT'S IN A 2486 01:24:50,115 --> 01:24:53,018 WEBINAR OR THROUGH THE WEBSITE, 2487 01:24:53,018 --> 01:24:54,954 IS DEVELOP A SERIES OF FAQs. 2488 01:24:54,954 --> 01:24:57,156 BECAUSE THERE ARE THEMES THAT 2489 01:24:57,156 --> 01:24:58,157 EMERGE WHEN YOU LOOK AT THE 2490 01:24:58,157 --> 01:24:58,924 TOTALITY OF THE DATA. 2491 01:24:58,924 --> 01:25:00,793 CAN WE THEN BUNDLE THESE AND 2492 01:25:00,793 --> 01:25:02,995 GIVE A RESPONSE TO KEEP THE 2493 01:25:02,995 --> 01:25:04,530 DIALOGUE GOING WITH PEOPLE THAT 2494 01:25:04,530 --> 01:25:06,632 ARE INTERESTED IN PROVIDING 2495 01:25:06,632 --> 01:25:08,167 FEEDBACK. 2496 01:25:08,167 --> 01:25:10,669 SO THAT'S WHERE WE'RE AT TODAY 2497 01:25:10,669 --> 01:25:12,938 IN TERMS OF CONTINUING TO 2498 01:25:12,938 --> 01:25:14,039 SOLICIT OUTREACH FOR 2499 01:25:14,039 --> 01:25:15,040 STAKEHOLDERS. 2500 01:25:15,040 --> 01:25:16,575 HERE ARE THE TWO MOST RECENT 2501 01:25:16,575 --> 01:25:18,744 ONES WE'VE HAD. 2502 01:25:18,744 --> 01:25:21,413 WE HAD ONE FOCUSED SPECIFICALLY 2503 01:25:21,413 --> 01:25:24,917 ON SCIENTIFIC PRIORITIES IN MAY, 2504 01:25:24,917 --> 01:25:26,552 WITH COMMUNITY AND STAKEHOLDER 2505 01:25:26,552 --> 01:25:28,220 INPUT, AND THEN JUST LAST WEEK, 2506 01:25:28,220 --> 01:25:30,723 WE HAD ONE ON THE STRUCTURE AND 2507 01:25:30,723 --> 01:25:33,125 FUNCTION OF CTUs AND CRSs. 2508 01:25:33,125 --> 01:25:35,127 A LOT OF DISCUSSION ABOUT 2509 01:25:35,127 --> 01:25:36,896 IMPLEMENTATION SCIENCE AND HOW 2510 01:25:36,896 --> 01:25:39,164 TO FOSTER THE RIGHT TYPE OF 2511 01:25:39,164 --> 01:25:41,367 SITES TO ENGAGE IN 2512 01:25:41,367 --> 01:25:43,936 IMPLEMENTATION SCIENCE. 2513 01:25:43,936 --> 01:25:46,639 HANK IS PROVING TO INCREDIBLY 2514 01:25:46,639 --> 01:25:49,942 VALUABLE AS A CONVENING GROUP, 2515 01:25:49,942 --> 01:25:51,510 HANC, BECAUSE THEY HAVE A DEGREE 2516 01:25:51,510 --> 01:25:52,978 OF RECOGNITION IN COMMUNITY FOR 2517 01:25:52,978 --> 01:25:56,315 THESE KINDS OF THINGS. 2518 01:25:56,315 --> 01:25:57,616 WE'RE ALSO MORE THAN HAPPY TO 2519 01:25:57,616 --> 01:25:58,984 COME TALK TO INDIVIDUAL GROUPS 2520 01:25:58,984 --> 01:26:02,621 AND ORGANIZATIONS. 2521 01:26:02,621 --> 01:26:05,925 I'VE BEEN SCHEDULED INTO EVERY 2522 01:26:05,925 --> 01:26:07,326 NETWORK MEETING TO COME IN AND 2523 01:26:07,326 --> 01:26:08,961 TALK ABOUT THE STRATEGIC VIEW 2524 01:26:08,961 --> 01:26:12,398 ABOUT WHERE WE'RE GOING. 2525 01:26:12,398 --> 01:26:13,799 IMPACT IS AT THE END OF THE 2526 01:26:13,799 --> 01:26:16,535 MONTH. 2527 01:26:16,535 --> 01:26:20,272 SO AS WE THINK ABOUT THIS, IN 2528 01:26:20,272 --> 01:26:22,141 ADDITION TO BEING WITH STRATEGIC 2529 01:26:22,141 --> 01:26:23,475 ABOUT WHERE WE WANT TO GO, WHAT 2530 01:26:23,475 --> 01:26:26,512 DO WE NEED TO FOCUS ON AS 2531 01:26:26,512 --> 01:26:28,981 SCIENTIFIC LEADERS THAT WE CAN 2532 01:26:28,981 --> 01:26:31,250 ACCOMPLISH IN THE REMAINDER OF 2533 01:26:31,250 --> 01:26:34,553 THIS CURRENT GRANT CYCLE? 2534 01:26:34,553 --> 01:26:37,022 WHERE ARE THE OPPORTUNITIES THAT 2535 01:26:37,022 --> 01:26:39,091 HAVE EMERGED THAT ARE MAYBE NOT 2536 01:26:39,091 --> 01:26:40,859 BIG ENOUGH TO BECOME AN ELEMENT 2537 01:26:40,859 --> 01:26:44,897 IN THE NEW AWARD BUT WHERE WE 2538 01:26:44,897 --> 01:26:46,332 CAN MAKE GAINS. 2539 01:26:46,332 --> 01:26:47,766 WHAT ADJUSTMENTS DO WE NEED TO 2540 01:26:47,766 --> 01:26:51,704 MAKE IN THE STRUCTURE AND 2541 01:26:51,704 --> 01:26:53,238 SCIENTIFIC DIRECTION NOW AND 2542 01:26:53,238 --> 01:26:56,442 THROUGH THE NEW AWARDS THAT WILL 2543 01:26:56,442 --> 01:27:00,579 HELP ACCELERATE THE PACE OF 2544 01:27:00,579 --> 01:27:02,448 DISCOVERY, AND HOW DO WE WORK TO 2545 01:27:02,448 --> 01:27:04,450 BUILD IMPLEMENTATION SCIENCE 2546 01:27:04,450 --> 01:27:06,318 NEEDS AND RESEARCH INTO OUR 2547 01:27:06,318 --> 01:27:07,853 IMPLEMENTATION INTO OUR PLANS? 2548 01:27:07,853 --> 01:27:09,688 SO I'LL JUST GO BACK AND SAY 2549 01:27:09,688 --> 01:27:14,460 THERE'S AN OVERALL THEME THAT 2550 01:27:14,460 --> 01:27:15,227 WILL EMERGE FROM THE PREAN 2551 01:27:15,227 --> 01:27:17,396 TAITION. 2552 01:27:17,396 --> 01:27:18,397 FROM THE 2553 01:27:18,397 --> 01:27:19,732 PRESENTATION TODAY AND IT COMES 2554 01:27:19,732 --> 01:27:21,033 DOWN TO EXPANDED COLLABORATIONS. 2555 01:27:21,033 --> 01:27:22,835 WHAT YOU SAW FROM WHAT NICHOLAS 2556 01:27:22,835 --> 01:27:26,538 PRESENTED IS THERE IS A NEED TO 2557 01:27:26,538 --> 01:27:28,507 BE SIGNIFICANTLY MORE 2558 01:27:28,507 --> 01:27:29,274 INTERDISCIPLINARY THAN WE 2559 01:27:29,274 --> 01:27:30,709 CURRENTLY ARE. 2560 01:27:30,709 --> 01:27:33,579 WE HAVE WORKED VERY HARD TO 2561 01:27:33,579 --> 01:27:35,047 BUILD RELATIONSHIPS WITH 2562 01:27:35,047 --> 01:27:35,447 INSTITUTES. 2563 01:27:35,447 --> 01:27:39,385 SOME ARE VERY RECEPTIVE TO THOSE 2564 01:27:39,385 --> 01:27:41,620 OPPORTUNITIES, AND SOME ARE 2565 01:27:41,620 --> 01:27:43,689 RELATIVELY RESISTANT. 2566 01:27:43,689 --> 01:27:45,090 AS YOU'VE SEEN TODAY IN MY 2567 01:27:45,090 --> 01:27:48,927 PRESENTATION AND WITH DR. -- 2568 01:27:48,927 --> 01:27:53,665 WHAT DR. MARAZZTSO SHOWED, 2569 01:27:53,665 --> 01:27:55,034 THERE'S NEW LEADERSHIP COMING IN 2570 01:27:55,034 --> 01:27:56,869 TO THE OFFICE OF AIDS RESEARCH 2571 01:27:56,869 --> 01:27:58,737 AND THERE'S NEW LEADERSHIP 2572 01:27:58,737 --> 01:28:00,606 ACROSS THE NIH WITH DR. MONICA 2573 01:28:00,606 --> 01:28:00,939 BERTAGNOLLI. 2574 01:28:00,939 --> 01:28:02,441 SO WE ARE GOING TO WORK 2575 01:28:02,441 --> 01:28:03,709 EXTREMELY HARD AT HELPING TO 2576 01:28:03,709 --> 01:28:06,979 CREATE BETTER OPPORTUNITIES TO 2577 01:28:06,979 --> 01:28:08,847 BUILD THOSE KINDS OF BRIDGES SO 2578 01:28:08,847 --> 01:28:12,284 WE'RE NOT TAKING THE MONEY AND 2579 01:28:12,284 --> 01:28:13,685 SHIFTING IT OFF TO SOMETHING 2580 01:28:13,685 --> 01:28:15,888 THAT IS NOT RELEVANT TO US BUT 2581 01:28:15,888 --> 01:28:19,124 CAN WE BRING IN THE EXPERTISE, 2582 01:28:19,124 --> 01:28:23,262 BECAUSE WE'RE NOT CARDIOLOGISTS, 2583 01:28:23,262 --> 01:28:26,665 WE'RE NOT EXPERTS IN KIDNEY 2584 01:28:26,665 --> 01:28:27,633 DISEASE OR LIVER DISEASE, BUT 2585 01:28:27,633 --> 01:28:30,536 WHAT WE NEED IS THE EXPERTISE TO 2586 01:28:30,536 --> 01:28:32,471 HELP US DEAL WITH THE 2587 01:28:32,471 --> 01:28:35,441 COINFECTIONS AND COMORBIDITIES 2588 01:28:35,441 --> 01:28:36,442 ASSOCIATED WITH HIV, 2589 01:28:36,442 --> 01:28:38,310 PARTICULARLY THE COMORBIDITIES. 2590 01:28:38,310 --> 01:28:41,146 THE BEST EXAMPLE OF THAT THAT 2591 01:28:41,146 --> 01:28:42,881 WILL WE'VE BEEN QUITE SUCCESSFUL 2592 01:28:42,881 --> 01:28:44,216 WITH IS THE REPRIEVE TRIAL, BUT 2593 01:28:44,216 --> 01:28:45,918 THAT WAS NOT EASY. 2594 01:28:45,918 --> 01:28:49,955 THAT REQUIRED THE GROUP TO WRITE 2595 01:28:49,955 --> 01:28:51,824 A GRANT. 2596 01:28:51,824 --> 01:28:53,225 ART WAS A PARTNER. 2597 01:28:53,225 --> 01:28:55,828 WE GOT TO A GOOD PLACE, BUT IT 2598 01:28:55,828 --> 01:28:57,896 TOOK A TREMENDOUS AMOUNT OF 2599 01:28:57,896 --> 01:29:01,700 ENERGY AND EFFORT TO GET US TO 2600 01:29:01,700 --> 01:29:03,168 WHERE WE ENDED UP. 2601 01:29:03,168 --> 01:29:08,207 THAT SAID, THERE WAS SUCCESS AND 2602 01:29:08,207 --> 01:29:10,642 CAN WE BUILD ON SUCCESS BUT USE 2603 01:29:10,642 --> 01:29:11,743 ALTERNATIVE MODELS TO GET THOSE 2604 01:29:11,743 --> 01:29:13,912 KINDS OF IDEAS BUILT AND BOUGHT 2605 01:29:13,912 --> 01:29:15,714 INTO AT THE MULTI-INSTITUTE 2606 01:29:15,714 --> 01:29:20,052 LEVEL SO THAT WE CAN MOVE OUR 2607 01:29:20,052 --> 01:29:20,552 IDEAS FORWARD. 2608 01:29:20,552 --> 01:29:21,720 SO YOU ALL KNOW THE NETWORK 2609 01:29:21,720 --> 01:29:22,254 STRUCTURE. 2610 01:29:22,254 --> 01:29:26,892 THAT'S WHAT WE HAVE RIGHT NOW, 2611 01:29:26,892 --> 01:29:27,559 FOUR LEADERSHIP GROUPS 2612 01:29:27,559 --> 01:29:28,560 ASSOCIATED WITH THE GREEN, 2613 01:29:28,560 --> 01:29:30,529 LEADERSHIP AND OPERATIONS 2614 01:29:30,529 --> 01:29:35,100 CENTER, EACH HAS ASSOCIATED DATA 2615 01:29:35,100 --> 01:29:36,702 CENTER AND STATISTICAL CENTER. 2616 01:29:36,702 --> 01:29:39,738 THERE'S LAB CENTERS. 2617 01:29:39,738 --> 01:29:41,273 BUT IN ADDITION TO THAT, YOU ARE 2618 01:29:41,273 --> 01:29:45,244 PROBABLY AWARE THAT THERE IS 2619 01:29:45,244 --> 01:29:46,445 NETWORK OVERSIGHT ACTIVITIES. 2620 01:29:46,445 --> 01:29:47,546 THERE'S ALSO COMMUNITY 2621 01:29:47,546 --> 01:29:48,747 ENGAGEMENT EFFORTS THAT ARE 2622 01:29:48,747 --> 01:29:49,181 ONGOING. 2623 01:29:49,181 --> 01:29:51,183 AND THEN THERE'S NETWORK 2624 01:29:51,183 --> 01:29:54,019 COORDINATION ACROSS THE TOP. 2625 01:29:54,019 --> 01:29:56,221 THE CTUs AND CRSs ARE THERE 2626 01:29:56,221 --> 01:30:01,059 SHOWN AT THE BOTTOM. 2627 01:30:01,059 --> 01:30:06,098 SO IN TERMS OF THE CURRENT 2628 01:30:06,098 --> 01:30:09,401 APPROACH TO SITE INSIGHT 2629 01:30:09,401 --> 01:30:11,103 OVERSIGHT, THERE'S ESSENTIALLY 2630 01:30:11,103 --> 01:30:14,139 THREE FLAVORS OF CRSs OF 2631 01:30:14,139 --> 01:30:15,874 CLINICAL RESEARCH SITES THAT ARE 2632 01:30:15,874 --> 01:30:16,542 EITHER ASSOCIATED OR NOT 2633 01:30:16,542 --> 01:30:17,576 ASSOCIATED WITH THE CLINICAL 2634 01:30:17,576 --> 01:30:17,876 TRIALS UNIT. 2635 01:30:17,876 --> 01:30:19,211 SO IN SOME WAYS IF YOU THINK OF 2636 01:30:19,211 --> 01:30:21,613 A MOTHERSHIP, A CLINICAL TRIALS 2637 01:30:21,613 --> 01:30:23,282 UNIT IS THE MOTHERSHIP, IT 2638 01:30:23,282 --> 01:30:24,049 PROVIDES ADMINISTRATIVE 2639 01:30:24,049 --> 01:30:25,484 CAPACITY, SHARED RESOURCES, 2640 01:30:25,484 --> 01:30:27,486 MENTORING AND OVERSIGHT, AND 2641 01:30:27,486 --> 01:30:32,090 THERE ARE PLENTY OF CRSs/C 2642 01:30:32,090 --> 01:30:33,625 TUs THAT HAVE AFFILIATED 2643 01:30:33,625 --> 01:30:34,893 CLINICAL RESEARCH SITES THAT ARE 2644 01:30:34,893 --> 01:30:36,962 ALIGNED WITH THEM AND EACH ONE 2645 01:30:36,962 --> 01:30:40,132 CAN MAKE SCIENTIFIC 2646 01:30:40,132 --> 01:30:40,999 CONTRIBUTIONS IN IMPLEMENT 2647 01:30:40,999 --> 01:30:42,901 TRIALS AND MANY ARE ALIGNED WITH 2648 01:30:42,901 --> 01:30:44,570 SPECIFIC NETWORK AND NETWORK 2649 01:30:44,570 --> 01:30:44,970 ACTIVITIES. 2650 01:30:44,970 --> 01:30:46,305 WE ALSO HAVE THE ABILITY TO 2651 01:30:46,305 --> 01:30:48,640 BRING IN PROTOCOL-SPECIFIC SITES 2652 01:30:48,640 --> 01:30:51,710 IF WE DO NOT HAVE THE CAPACITY 2653 01:30:51,710 --> 01:30:53,445 OR THE EXPERTISE AT THE CURRENT 2654 01:30:53,445 --> 01:30:55,847 SITES TO PERFORM THE RESEARCH 2655 01:30:55,847 --> 01:30:57,649 THAT IS PUT FORWARD THROUGH THE 2656 01:30:57,649 --> 01:30:59,518 CLINICAL TRIAL THAT THE NETWORK 2657 01:30:59,518 --> 01:31:03,021 IS PROVIDING. 2658 01:31:03,021 --> 01:31:04,022 THIRD, THERE'S ALSO THE ABILITY 2659 01:31:04,022 --> 01:31:06,358 TO BRING IN TRULY 2660 01:31:06,358 --> 01:31:07,659 PROTOCOL-SPECIFIC SITES AS SHORT 2661 01:31:07,659 --> 01:31:08,760 TERM IMPLEMENTERS. 2662 01:31:08,760 --> 01:31:11,163 WE SEE A COMBINATION OF THESE 2663 01:31:11,163 --> 01:31:17,669 TYPES OF SITES, CRS, PROTOCOL 2664 01:31:17,669 --> 01:31:19,304 SPECIFIC SITES ASSOCIATED WITH 2665 01:31:19,304 --> 01:31:20,505 CTUs, AS WELL AS 2666 01:31:20,505 --> 01:31:21,974 PROTOCOL-SPECIFIC SITES THAT ARE 2667 01:31:21,974 --> 01:31:23,709 BRAND NEW AS BEING ESSENTIAL 2668 01:31:23,709 --> 01:31:27,212 TOOLS THAT WE CAN MIX AND MATCH 2669 01:31:27,212 --> 01:31:28,947 AS WE MOVE FORWARD FOR 2670 01:31:28,947 --> 01:31:29,548 IMPLEMENTATION SCIENCE. 2671 01:31:29,548 --> 01:31:32,718 FOR EXAMPLE, THERE'S A PTN 2672 01:31:32,718 --> 01:31:35,254 PROTOCOL CALLED 096 WHICH IS 2673 01:31:35,254 --> 01:31:39,691 LOOKING AT ACCESS TO 2674 01:31:39,691 --> 01:31:41,326 ANTIRETROVIRALS UP TAKE FOR ART 2675 01:31:41,326 --> 01:31:43,962 AND PREVENTION METHODOLOGIES IN 2676 01:31:43,962 --> 01:31:44,830 THE SOUTH. 2677 01:31:44,830 --> 01:31:47,399 THERE'S NOT A SINK EL SITE THAT 2678 01:31:47,399 --> 01:31:49,034 IS ASSOCIATED WITH THE NETWORK 2679 01:31:49,034 --> 01:31:50,669 FACILITY, THEY'RE ALL IN CLINICS 2680 01:31:50,669 --> 01:31:51,770 IN CITIES. 2681 01:31:51,770 --> 01:31:53,939 SO THIS IS A BIG DEPARTURE, AND 2682 01:31:53,939 --> 01:31:56,074 THOSE WOULD BE EXAMPLES OF 2683 01:31:56,074 --> 01:31:58,443 PROTOCOL-SPECIFIC SITES. 2684 01:31:58,443 --> 01:32:00,178 WE HAVE A PROTOCOL WORKING IN 2685 01:32:00,178 --> 01:32:00,812 BARBERSHOPS. 2686 01:32:00,812 --> 01:32:03,148 YOU WOULDN'T SEE A BARBER SHOP 2687 01:32:03,148 --> 01:32:04,549 AFFILIATED WITH A CTU, BUT IF 2688 01:32:04,549 --> 01:32:06,318 YOU'RE GOING TO REACH COMMUNITY, 2689 01:32:06,318 --> 01:32:08,754 YOU'RE GOING TO NEED TO GO TO 2690 01:32:08,754 --> 01:32:09,755 PLACES WHERE COMMUNITY 2691 01:32:09,755 --> 01:32:10,756 CONGREGATES AND WE'RE GOING TO 2692 01:32:10,756 --> 01:32:12,624 NEED TO BE FLEXIBLE ABOUT BEING 2693 01:32:12,624 --> 01:32:15,894 ABLE TO ADD THOSE KINDS OF 2694 01:32:15,894 --> 01:32:18,764 PROTOCOL-SPECIFIC SITES. 2695 01:32:18,764 --> 01:32:20,666 SO TO STATE THE OBVIOUS, WE ARE 2696 01:32:20,666 --> 01:32:23,068 GOING TO MAINTAIN THE FOUR 2697 01:32:23,068 --> 01:32:25,270 LEADERSHIP GROUPS. 2698 01:32:25,270 --> 01:32:28,340 THE OVERARCHING THEMES OF THIS 2699 01:32:28,340 --> 01:32:31,343 RENEWAL WILL BE INNOVATION AND 2700 01:32:31,343 --> 01:32:31,910 COLLABORATION. 2701 01:32:31,910 --> 01:32:34,646 THE INNOVATION CAN COME IN AS WE 2702 01:32:34,646 --> 01:32:36,315 MOVE FORWARD, WHAT ARE THE 2703 01:32:36,315 --> 01:32:37,082 PRODUCTS WE'RE BRINGING IN? 2704 01:32:37,082 --> 01:32:38,517 THAT'S A FORM OF INNOVATION. 2705 01:32:38,517 --> 01:32:39,918 BUT ANOTHER WAY OF THINKING 2706 01:32:39,918 --> 01:32:41,186 ABOUT INNOVATION IS CLINICAL 2707 01:32:41,186 --> 01:32:42,387 TRIAL DESIGN. 2708 01:32:42,387 --> 01:32:46,191 WE REALLY HAVE TO SOLVE THE 2709 01:32:46,191 --> 01:32:47,726 QUESTIONS ABOUT ACTIVE 2710 01:32:47,726 --> 01:32:49,628 COMPARATOR GROUPS, THE NOTION OF 2711 01:32:49,628 --> 01:32:55,100 WHEN IS A PLACEBO REASONABLE AND 2712 01:32:55,100 --> 01:32:56,435 ETHICAL, BUT THIS ALL WILL NEED 2713 01:32:56,435 --> 01:32:59,004 TO BE WORKED OUT IN A WAY THAT 2714 01:32:59,004 --> 01:33:00,505 FACILITATE THE RESEARCH AND 2715 01:33:00,505 --> 01:33:02,474 DOESN'T MAKE IT SO EVERY TRIAL 2716 01:33:02,474 --> 01:33:05,310 WE DO THAT REQUIRES AN ACTIVE 2717 01:33:05,310 --> 01:33:08,013 CONTROL ARM REQUIRES 60,000 2718 01:33:08,013 --> 01:33:08,347 PARTICIPANTS. 2719 01:33:08,347 --> 01:33:09,548 I THINK THAT'S THE CHALLENGE WE 2720 01:33:09,548 --> 01:33:14,686 FACE AS WE MOVE FORWARD. 2721 01:33:14,686 --> 01:33:16,588 IN THE PAST CYCLE WE'RE 2722 01:33:16,588 --> 01:33:17,255 COMPLETING, WE'RE PARTWAY 2723 01:33:17,255 --> 01:33:19,424 THROUGH NOW, WE'RE SEEING MANY 2724 01:33:19,424 --> 01:33:20,559 GROUNDBREAKING STUDIES THAT 2725 01:33:20,559 --> 01:33:21,426 STARTED FROM THESE DLAB RANGE OF 2726 01:33:21,426 --> 01:33:23,395 MOTIONS WITH OTHER NETWORKS. 2727 01:33:23,395 --> 01:33:24,496 OTHER NETWORKS AND OTHER PARTS 2728 01:33:24,496 --> 01:33:25,063 OF NIH. 2729 01:33:25,063 --> 01:33:27,733 SO I THINK THAT WE REALLY NEED 2730 01:33:27,733 --> 01:33:31,002 TO HAVE A WAY OF HAVING A BETTER 2731 01:33:31,002 --> 01:33:33,638 DIALOGUE ACROSS THE NIH ON THE 2732 01:33:33,638 --> 01:33:36,742 RESEARCH THAT IS GOING TO BE 2733 01:33:36,742 --> 01:33:38,377 REALLY CRITICAL TO HELP IMPROVE 2734 01:33:38,377 --> 01:33:41,980 THE HEALTH OF PEOPLE LIVING WITH 2735 01:33:41,980 --> 01:33:45,484 HIV. 2736 01:33:45,484 --> 01:33:47,052 SO ACROSS ALL THESE AREAS OF HIV 2737 01:33:47,052 --> 01:33:49,354 SCIENCE WE WILL REALLY NEED TO 2738 01:33:49,354 --> 01:33:50,155 EXPEDITE COLLABORATION TO 2739 01:33:50,155 --> 01:33:51,456 ADDRESS THE HIGHEST PRIORITY 2740 01:33:51,456 --> 01:33:51,757 QUESTIONS. 2741 01:33:51,757 --> 01:33:52,624 SO I'M GOING TO GO THROUGH A 2742 01:33:52,624 --> 01:33:57,496 LITTLE BIT ABOUT EACH OF THESE 2743 01:33:57,496 --> 01:33:58,864 AREAS, AND YOU'LL SEE ON SEVERAL 2744 01:33:58,864 --> 01:33:59,631 OF THE SLIDES THE NETWORKS THAT 2745 01:33:59,631 --> 01:34:01,800 ARE PRIMARILY RESPONSIBLE FOR 2746 01:34:01,800 --> 01:34:03,769 THESE AS WE GO FORWARD. 2747 01:34:03,769 --> 01:34:05,570 SO FOR HIV PREVENTION, WE WANT 2748 01:34:05,570 --> 01:34:08,874 TO CONTINUE TO SUPPORT 2749 01:34:08,874 --> 01:34:10,308 BIOMEDICAL RESEARCH ON 2750 01:34:10,308 --> 01:34:10,909 PREVENTION INTERVENTIONS THAT 2751 01:34:10,909 --> 01:34:12,511 CAN CHANGE THE PRACTICE OF 2752 01:34:12,511 --> 01:34:13,412 MEDICINE AND REDUCE HIV 2753 01:34:13,412 --> 01:34:15,147 INCIDENCE. 2754 01:34:15,147 --> 01:34:17,249 AS BACKGROUND, AS YOU ARE ALL 2755 01:34:17,249 --> 01:34:20,886 AWARE, WE HAVE MADE TREMENDOUS 2756 01:34:20,886 --> 01:34:22,754 PROGRESS THROUGH ORAL PREP, 2757 01:34:22,754 --> 01:34:25,490 THROUGH INJECTABLE PREP, THERE'S 2758 01:34:25,490 --> 01:34:26,358 ACTIVITIES AND WORK THAT NEEDS 2759 01:34:26,358 --> 01:34:30,462 TO BE DONE WITH POST EXPOSURE 2760 01:34:30,462 --> 01:34:32,864 PROPHYLAXIS, AND U EQUALS U HAS 2761 01:34:32,864 --> 01:34:36,401 BECOME THE COIN OF THE REALM. 2762 01:34:36,401 --> 01:34:39,137 FOR CERTAIN TYPES OF MTPs, 2763 01:34:39,137 --> 01:34:40,672 ESPECIALLY ONES RELATED TO 2764 01:34:40,672 --> 01:34:41,706 CONTRACEPTION, THERE'S ACTIVITY 2765 01:34:41,706 --> 01:34:42,274 HERE THAT WILL BE QUITE 2766 01:34:42,274 --> 01:34:43,108 IMPORTANT. 2767 01:34:43,108 --> 01:34:46,111 SO IN TERMS OF PARTNERS, 2768 01:34:46,111 --> 01:34:46,778 OBVIOUSLY THERE'S COMMUNITY, 2769 01:34:46,778 --> 01:34:48,580 WE'VE HAD REALLY GOOD 2770 01:34:48,580 --> 01:34:50,315 PARTNERSHIPS WITH THE BILL AND 2771 01:34:50,315 --> 01:34:52,617 MELINDA GATES FOUNDATION, OTHER 2772 01:34:52,617 --> 01:34:53,919 INSTITUTES AT NIH, AND AS WE 2773 01:34:53,919 --> 01:34:56,288 LOOK AT IMPLEMENTATION SCIENCE 2774 01:34:56,288 --> 01:34:57,722 MOVING FORWARD, IT IS REALLY 2775 01:34:57,722 --> 01:34:58,890 ESSENTIAL THAT WE THINK ABOUT 2776 01:34:58,890 --> 01:35:01,460 THE OTHER PART OF THE FEDERAL 2777 01:35:01,460 --> 01:35:03,328 GOVERNMENT, WHERE WE CAN BUILD 2778 01:35:03,328 --> 01:35:04,863 THESE TYPES OF COLLABORATIONS TO 2779 01:35:04,863 --> 01:35:07,365 LOOK AT IMPLEMENTATION. 2780 01:35:07,365 --> 01:35:12,471 WITH CDC, WITH HRSA, FOR OPIOID 2781 01:35:12,471 --> 01:35:14,105 SUBSTANCE USE AND OTHER FORMS OF 2782 01:35:14,105 --> 01:35:17,876 DRUG USE, SAMHSA, PEPFAR AND 2783 01:35:17,876 --> 01:35:19,644 USAID WILL BE CRITICAL PARTNERS. 2784 01:35:19,644 --> 01:35:22,147 THERE'S ALSO INTERNATIONAL 2785 01:35:22,147 --> 01:35:23,348 GOVERNMENTS, PARTNERS WE NEED TO 2786 01:35:23,348 --> 01:35:28,220 WORK ON, WORK WITH, AND INDUSTRY 2787 01:35:28,220 --> 01:35:29,588 REMAINS AN ESSENTIAL ELEMENT OF 2788 01:35:29,588 --> 01:35:32,724 MANY OF THE ACTIVITY THAT WE 2789 01:35:32,724 --> 01:35:34,593 ENGAGE IN BECAUSE WE ARE NOT A 2790 01:35:34,593 --> 01:35:35,026 DRUG COMPANY. 2791 01:35:35,026 --> 01:35:36,461 WE ARE NOT GOING TO GET IN THE 2792 01:35:36,461 --> 01:35:39,631 BUSINESS OF MAKING CHEMICALS FOR 2793 01:35:39,631 --> 01:35:42,300 USE IN EFFICACY TRIALS OR 2794 01:35:42,300 --> 01:35:44,803 PROVING THE CONCEPT THAT A DRUG 2795 01:35:44,803 --> 01:35:46,238 WORKS BECAUSE AT THE END OF THE 2796 01:35:46,238 --> 01:35:48,807 DAY, THERE HAS TO BE A WAY OF 2797 01:35:48,807 --> 01:35:50,775 TAKING THOSE ACTIVE MOLECULES 2798 01:35:50,775 --> 01:35:56,248 AND TAKING THEM TO SCALE. 2799 01:35:56,248 --> 01:35:57,249 TO A POINT WHERE THEY ARE 2800 01:35:57,249 --> 01:36:03,321 ACCESSIBLE AND USABLE BY OTHERS. 2801 01:36:03,321 --> 01:36:05,957 I THINK THE PARTNERSHIPS WE'VE 2802 01:36:05,957 --> 01:36:09,394 HAD WITH VIV, CABOTEGRAVIR ARE 2803 01:36:09,394 --> 01:36:10,061 REALLY GOOD. 2804 01:36:10,061 --> 01:36:11,596 THE CHALLENGE WITH THAT STUDY IS 2805 01:36:11,596 --> 01:36:13,131 WE FINISHED EARLY, SO WE DID NOT 2806 01:36:13,131 --> 01:36:14,699 HAVE THE CHANCE TO FINISH ALL OF 2807 01:36:14,699 --> 01:36:17,636 THE NECESSARY DEVELOPMENT STEPS, 2808 01:36:17,636 --> 01:36:19,404 BUT WE COULD DO BETTER. 2809 01:36:19,404 --> 01:36:24,042 AND IN SOME WAYS, WE'RE MA MAKIG 2810 01:36:24,042 --> 01:36:26,044 OUR FIRST AND SOMETIMES SECOND 2811 01:36:26,044 --> 01:36:27,345 OR THIRD PANCAKE, BUT AS WE GO 2812 01:36:27,345 --> 01:36:29,481 FORWARD, WE WILL ADD THESE 2813 01:36:29,481 --> 01:36:31,116 ELEMENTS INTO THE MIX EARLIER IN 2814 01:36:31,116 --> 01:36:33,084 THE FUTURE SO WE'RE NOT WAITING 2815 01:36:33,084 --> 01:36:36,087 UNTIL WE'RE PARTWAY THROUGH THE 2816 01:36:36,087 --> 01:36:37,088 EFFICACY TRIALS TO START 2817 01:36:37,088 --> 01:36:41,226 THINKING ABOUT IMPLEMENTATION. 2818 01:36:41,226 --> 01:36:43,094 WE TRIED, WE WEREN'T AS 2819 01:36:43,094 --> 01:36:44,362 AGGRESSIVE AND AFORCEFUL AS WE 2820 01:36:44,362 --> 01:36:45,564 COULD OR SHOULD HAVE BEEN AND I 2821 01:36:45,564 --> 01:36:46,765 THINK WE'LL DO BETTER IN THE 2822 01:36:46,765 --> 01:36:48,700 FUTURE. 2823 01:36:48,700 --> 01:36:49,901 WE REALLY NEED TO ADVANCE NEW 2824 01:36:49,901 --> 01:36:52,070 WAYS TO REDUCE VERTICAL 2825 01:36:52,070 --> 01:36:52,737 TRANSMISSION, AND TO WHAT I 2826 01:36:52,737 --> 01:36:54,773 THINK ABOUT THIS IS A FORM OF 2827 01:36:54,773 --> 01:36:57,042 SOME VERY FOCUSED CLINICAL 2828 01:36:57,042 --> 01:36:59,477 TRIALS ON NEW STRATEGIES BUT 2829 01:36:59,477 --> 01:37:00,845 REALLY INTEGRATED WITH 2830 01:37:00,845 --> 01:37:01,780 COORDINATED IMPLEMENTATION 2831 01:37:01,780 --> 01:37:02,714 SCIENCE. 2832 01:37:02,714 --> 01:37:07,852 SO WE GET THESE IDEAS TO 2833 01:37:07,852 --> 01:37:10,388 PREGNANT PEOPLE AS QUICKLY AS 2834 01:37:10,388 --> 01:37:12,190 POSSIBLE IN A COORDINATED WAY, 2835 01:37:12,190 --> 01:37:15,026 WHERE WE'RE ALSO THINKING ABOUT 2836 01:37:15,026 --> 01:37:17,529 PREGNANT PEOPLE LIVING WITH HIV 2837 01:37:17,529 --> 01:37:19,197 AND PEOPLE WHO ARE AT RISK OF 2838 01:37:19,197 --> 01:37:21,666 HIV SO THAT WE ARE DOING 2839 01:37:21,666 --> 01:37:24,502 VIRTUALLY EVERYTHING WE CAN TO 2840 01:37:24,502 --> 01:37:32,811 SLOW DOWN, PREVENT VERTICAL 2841 01:37:32,811 --> 01:37:33,311 TRANSMISSION. 2842 01:37:33,311 --> 01:37:34,846 SO IN ADDITION TO THAT, WE HAVE 2843 01:37:34,846 --> 01:37:35,714 TO THINK ABOUT THE INFANTS THAT 2844 01:37:35,714 --> 01:37:41,119 ARE BORN THAT ARE PAIR PERINATY 2845 01:37:41,119 --> 01:37:41,386 INFECTED. 2846 01:37:41,386 --> 01:37:43,088 WE NEED TO BE ABLE TO TAKE 2847 01:37:43,088 --> 01:37:44,189 CHILDREN AT THAT TIME AND GET 2848 01:37:44,189 --> 01:37:45,790 THEM ON TO ANY RETROVIRAL 2849 01:37:45,790 --> 01:37:49,194 THERAPY AND USE A P1115-LIKE 2850 01:37:49,194 --> 01:37:53,131 SYSTEM TO ENGAGE IN GETTING 2851 01:37:53,131 --> 01:37:54,499 THOSE BABIES ON THERAPY AS 2852 01:37:54,499 --> 01:37:58,003 QUICKLY AS POSSIBLE SO THAT WE 2853 01:37:58,003 --> 01:38:01,940 ARE DOING EVERYTHING WE CAN TO 2854 01:38:01,940 --> 01:38:04,676 FURTHER REDUCE DEVELOPMENT OF 2855 01:38:04,676 --> 01:38:08,780 AIDS IN THAT POPULATION. 2856 01:38:08,780 --> 01:38:10,215 ADDITIONALLY, WE WOULD THEN HAVE 2857 01:38:10,215 --> 01:38:12,684 A COHORT THAT WOULD BE ELIGIBLE 2858 01:38:12,684 --> 01:38:13,451 TO PARTICIPATE IN CURE STUDIES 2859 01:38:13,451 --> 01:38:15,086 IN THE FUTURE, AND THERE'S A LOT 2860 01:38:15,086 --> 01:38:18,790 OF EXCITEMENT IN CURE WITH IDEAS 2861 01:38:18,790 --> 01:38:25,530 THAT ARE GOING FORWARD. 2862 01:38:25,530 --> 01:38:29,801 I SAID EARLIER CHOICE IS A GOAL, 2863 01:38:29,801 --> 01:38:30,902 PREVENTION METHODS BEST NEED TO 2864 01:38:30,902 --> 01:38:32,904 BE DIRECTED AT VULNERABLE 2865 01:38:32,904 --> 01:38:34,439 PREVENTION METHODS BEST NEED TO 2866 01:38:34,439 --> 01:38:37,842 BE DIRECTED -- DOMESTICALLY AND 2867 01:38:37,842 --> 01:38:40,845 PARTNERSHIP AND THE PARTNERSHIPS 2868 01:38:40,845 --> 01:38:42,380 WE BUILD -- IT WILL BE REALLY 2869 01:38:42,380 --> 01:38:44,149 IMPORTANT TO HELP UNDERSTAND 2870 01:38:44,149 --> 01:38:45,483 UPTAKE AND ADHERENCE AND MAKING 2871 01:38:45,483 --> 01:38:48,019 SURE WE ARE LACKING AT EFFICIENT 2872 01:38:48,019 --> 01:38:49,587 AND COST-EFFECTIVE DELIVERY 2873 01:38:49,587 --> 01:38:51,189 METHODS THAT ARE IMPLEMENTABLE 2874 01:38:51,189 --> 01:38:52,457 AND THAT'S WHERE THE 2875 01:38:52,457 --> 01:38:54,225 PARTNERSHIPS WITH THE LIKES OF 2876 01:38:54,225 --> 01:38:59,898 HRSA, SAMHSA, CDC AND PEPFAR 2877 01:38:59,898 --> 01:39:01,733 WILL BE ABSOLUTELY ESSENTIAL. 2878 01:39:01,733 --> 01:39:03,134 BECAUSE YOU DON'T WANT AN 2879 01:39:03,134 --> 01:39:04,769 ACADEMIC GROUP DOING YOUR 2880 01:39:04,769 --> 01:39:05,370 IMPLEMENTATION SCIENCE UNLESS 2881 01:39:05,370 --> 01:39:09,340 THEY ARE A PARTNER WITH AN 2882 01:39:09,340 --> 01:39:09,841 IMPLEMENTER. 2883 01:39:09,841 --> 01:39:10,975 BECAUSE THE IMPLEMENTERS WILL 2884 01:39:10,975 --> 01:39:12,277 HAVE TO LIVE WITH WHATEVER WE 2885 01:39:12,277 --> 01:39:14,212 PRODUCE, AND I THINK THAT'S WHY 2886 01:39:14,212 --> 01:39:15,213 GIVING PEOPLE SKIN IN THE GAME 2887 01:39:15,213 --> 01:39:17,282 WILL BE CRITICAL AS WE MOVE 2888 01:39:17,282 --> 01:39:18,883 FORWARD IN THAT SPACE. 2889 01:39:18,883 --> 01:39:23,154 MOVING ON TO VACCINES THE 2890 01:39:23,154 --> 01:39:24,122 DIVISION REMAINS COMMITTED TO 2891 01:39:24,122 --> 01:39:27,358 WORKING ON A SAFE, EFFECTIVE AND 2892 01:39:27,358 --> 01:39:28,326 DURABLE HIV VACCINE. 2893 01:39:28,326 --> 01:39:30,628 WHAT WE ARE SEEKING NOW ARE WAYS 2894 01:39:30,628 --> 01:39:34,365 OF DEVELOPING VACCINES THAT CAN 2895 01:39:34,365 --> 01:39:37,035 TRIGGER THE PRODUCTION OF BROAD 2896 01:39:37,035 --> 01:39:38,169 NEUTRALIZING AND BODIES AS WELL 2897 01:39:38,169 --> 01:39:40,105 AS MOVING TOWARDS ENHANCED CELL 2898 01:39:40,105 --> 01:39:44,209 MEDIATED RESPONSES THAT WILL 2899 01:39:44,209 --> 01:39:45,410 ELIMINATE INFECTED CELLS. 2900 01:39:45,410 --> 01:39:47,245 I THINK THE PARTNERSHIP OF THOSE 2901 01:39:47,245 --> 01:39:48,613 TWO GOING FORWARD IS ESSENTIAL. 2902 01:39:48,613 --> 01:39:52,383 AT THE SAME TIME, YOU SAW TED'S 2903 01:39:52,383 --> 01:39:54,152 TALK TODAY, TED PIERSON TALKED 2904 01:39:54,152 --> 01:39:56,521 ABOUT THE WORK ON THE FUSION 2905 01:39:56,521 --> 01:39:56,755 PEPTIDE. 2906 01:39:56,755 --> 01:39:58,490 HE REALLY UNDERSOLD THAT. 2907 01:39:58,490 --> 01:39:59,924 THAT STUFF LOOKS REALLY GOOD AND 2908 01:39:59,924 --> 01:40:01,659 THAT COMBINED WITH SOME OF THE 2909 01:40:01,659 --> 01:40:03,795 THINGS THAT THE LIKES OF BART 2910 01:40:03,795 --> 01:40:06,331 AND LEO AT THE HUTCH AND DENNIS 2911 01:40:06,331 --> 01:40:08,299 AND HIS TEAM ARE DOING REALLY 2912 01:40:08,299 --> 01:40:09,467 GIVES ME HOPE. 2913 01:40:09,467 --> 01:40:10,969 NOW I AM ONE OF THE MOST 2914 01:40:10,969 --> 01:40:12,070 OPTIMISTIC PEOPLE YOU'LL EVER 2915 01:40:12,070 --> 01:40:13,071 MEET. 2916 01:40:13,071 --> 01:40:15,573 AND I STILL THINK SAFE EFFECTIVE 2917 01:40:15,573 --> 01:40:18,643 AND DI DURABLE HIV VACCINE IS ON 2918 01:40:18,643 --> 01:40:21,312 THE HORIZON. 2919 01:40:21,312 --> 01:40:23,181 NOT OVER THE HORIZON, ON THE 2920 01:40:23,181 --> 01:40:23,615 HORIZON. 2921 01:40:23,615 --> 01:40:30,155 SO THE CHALLENGES REMAIN, HOW DO 2922 01:40:30,155 --> 01:40:31,623 WE GET A MOLECULE FROM THE LAB 2923 01:40:31,623 --> 01:40:32,090 INTO THE ARM. 2924 01:40:32,090 --> 01:40:35,493 THIS GETS BACK TO GNP 2925 01:40:35,493 --> 01:40:36,361 MANUFACTURING PROCESSES AND WE 2926 01:40:36,361 --> 01:40:39,397 DO ENGAGE IN SOME OF THAT FOR A 2927 01:40:39,397 --> 01:40:41,132 SCALE RELATED TO PHASE 1 AND 2A 2928 01:40:41,132 --> 01:40:45,603 BUT THEN PARTNERSHIPS ARE 2929 01:40:45,603 --> 01:40:46,571 ULTIMATELY NEEDED. 2930 01:40:46,571 --> 01:40:48,006 WE'RE CURRENTLY WORKING WITH 2931 01:40:48,006 --> 01:40:49,040 MODERNA. 2932 01:40:49,040 --> 01:40:52,210 WERE WORKING WITH VIR AND THAT'S 2933 01:40:52,210 --> 01:40:53,545 A SAD STORY FOR CONVERSATIONS 2934 01:40:53,545 --> 01:40:53,978 OVER A BEER. 2935 01:40:53,978 --> 01:40:55,547 WE HAVE PARTNERSHIPS WITH THE 2936 01:40:55,547 --> 01:41:00,919 VACCINE CENTER, BILL AND MELINDA 2937 01:41:00,919 --> 01:41:02,620 GATES, NIH INSTITUTES AND 2938 01:41:02,620 --> 01:41:03,121 PHARMACEUTICAL PARTNERS. 2939 01:41:03,121 --> 01:41:05,023 BUT REALLY IT IS ABOUT 2940 01:41:05,023 --> 01:41:07,425 CONTINUING REALLY STRONG BASIC 2941 01:41:07,425 --> 01:41:09,460 SCIENCE SO WE CAN MAKE 2942 01:41:09,460 --> 01:41:10,228 ADDITIONAL DISCOVERIES, LIKE 2943 01:41:10,228 --> 01:41:12,864 WHAT IS THE STORY WITH CMC IN 2944 01:41:12,864 --> 01:41:19,704 DRIVING THE H -- THAT'S A 2945 01:41:19,704 --> 01:41:20,805 PLATFORM THAT DOESN'T 2946 01:41:20,805 --> 01:41:21,906 NECESSARILY REQUIRE A VIRUS TO 2947 01:41:21,906 --> 01:41:23,308 DELIVER THE ANTIGENS. 2948 01:41:23,308 --> 01:41:26,878 ADDITIONALLY, WITH REA WE REALLO 2949 01:41:26,878 --> 01:41:29,013 EXPAND THE WORK ON VACCINES FOR 2950 01:41:29,013 --> 01:41:30,982 OTHER COMORBIDITIES, 2951 01:41:30,982 --> 01:41:31,649 PARTICULARLY TUBERCULOSIS, AND 2952 01:41:31,649 --> 01:41:33,585 THIS REMAINS A GOAL FOR VACCINE 2953 01:41:33,585 --> 01:41:35,653 RESEARCH AS WELL. 2954 01:41:35,653 --> 01:41:39,057 MOVING ON TO THERAPEUTICS, 2955 01:41:39,057 --> 01:41:41,492 REALLY WHAT WE ARE ABOUT IS 2956 01:41:41,492 --> 01:41:42,961 ADVANCING THERAPEUTIC STRATEGIES 2957 01:41:42,961 --> 01:41:45,396 TO TREAT HIV AND HIV ASSOCIATED 2958 01:41:45,396 --> 01:41:46,798 COINFECTIONS AND COMORBIDITIES 2959 01:41:46,798 --> 01:41:50,869 ACROSS THE LIFESPAN. 2960 01:41:50,869 --> 01:41:51,736 THERAPEUTICS RESEARCH WILL SEEK 2961 01:41:51,736 --> 01:41:54,372 TO PROVIDE TO ALL PEOPLE LIVING 2962 01:41:54,372 --> 01:41:56,708 WITH AIDS/HIV MEANS TO ACHIEVE A 2963 01:41:56,708 --> 01:42:00,211 HEALTHY LIFESPAN AND A BRIDGE TO 2964 01:42:00,211 --> 01:42:00,979 A CURE. 2965 01:42:00,979 --> 01:42:03,181 SO WHEN YOU HEAR THE PEOPLE AT 2966 01:42:03,181 --> 01:42:05,550 THE ACTG, PARTICULARLY JUDY TALK 2967 01:42:05,550 --> 01:42:08,486 ABOUT THIS, SHE TALKS ABOUT THE 2968 01:42:08,486 --> 01:42:08,820 FOURTH 95. 2969 01:42:08,820 --> 01:42:11,723 AND IF WE THINK ABOUT THE THIRD 2970 01:42:11,723 --> 01:42:14,692 95 BEING VIRALLY SUPPRESSED, THE 2971 01:42:14,692 --> 01:42:19,731 FOURTH 95 IS LIVING A NORMAL 2972 01:42:19,731 --> 01:42:21,666 LIFESPAN WITHOUT COMORBIDITIES, 2973 01:42:21,666 --> 01:42:24,035 WITH THE COMORBIDITIES THAT I 2974 01:42:24,035 --> 01:42:26,571 SUPPOSE YOU'RE GENETICALLY 2975 01:42:26,571 --> 01:42:27,939 PROGRAMMED FOR, IF YOU'RE 2976 01:42:27,939 --> 01:42:28,806 PROGRAMMED GENETICALLY FOR HEART 2977 01:42:28,806 --> 01:42:30,041 DISEASE, YOU'RE GOING TO GET IT, 2978 01:42:30,041 --> 01:42:34,012 BUT WE CAN -- WE NEED TO DEAL 2979 01:42:34,012 --> 01:42:36,414 WITH COMORBIDITIES THAT ARE 2980 01:42:36,414 --> 01:42:38,182 EXACERBATED BY LIVING WITH HIV. 2981 01:42:38,182 --> 01:42:40,318 THAT LAS TO BE OUR TARGET, AND 2982 01:42:40,318 --> 01:42:44,155 THAT NEEDS TO BE -- THIS IS 2983 01:42:44,155 --> 01:42:46,891 WHERE THE CALL TO THE OTHER 2984 01:42:46,891 --> 01:42:49,694 INSTITUTES TO COME AND JOIN US 2985 01:42:49,694 --> 01:42:50,895 IN A WAY OF ADDRESSING THESE 2986 01:42:50,895 --> 01:42:52,664 DISEASES THAT ARE WITHIN THEIR 2987 01:42:52,664 --> 01:42:54,732 PURVIEW, BUT ARE EXACERBATED BY 2988 01:42:54,732 --> 01:42:55,233 HIV. 2989 01:42:55,233 --> 01:42:57,101 AND THAT PARTNERSHIP DOESN'T 2990 01:42:57,101 --> 01:42:58,636 MEAN THAT THEY PAY THE FREIGHT. 2991 01:42:58,636 --> 01:43:00,605 IT A PARTNERSHIP WHERE THEY 2992 01:43:00,605 --> 01:43:01,973 PROVIDE SCIENTIFIC INPUT, AND WE 2993 01:43:01,973 --> 01:43:04,175 CAN THEN PARTNER TO GET THIS 2994 01:43:04,175 --> 01:43:07,011 KIND OF WORK DONE. 2995 01:43:07,011 --> 01:43:09,814 A GOOD EXAMPLE OF THAT WAS THE 2996 01:43:09,814 --> 01:43:11,582 SLIM LIVER STUDY THAT WAS JUST 2997 01:43:11,582 --> 01:43:15,520 DONE BY NIAID, WHERE HE TOOK 2998 01:43:15,520 --> 01:43:17,789 SEMAGLUTIDE AND TREATED FATTY 2999 01:43:17,789 --> 01:43:22,593 LIVER DISEASE AND IT WAS IS KIND 3000 01:43:22,593 --> 01:43:24,362 OF MAGICAL HOW IT MELTED THE 3001 01:43:24,362 --> 01:43:25,096 FATTY LIVER. 3002 01:43:25,096 --> 01:43:31,369 I THINK THOSE KINDS OF 3003 01:43:31,369 --> 01:43:32,570 RELATIVELY SMALL BUT IMPACTFUL 3004 01:43:32,570 --> 01:43:36,007 TRIALS THAT TOOK FOREVER TO GET 3005 01:43:36,007 --> 01:43:37,141 OPEN FOR A VARIETY OF REASONS 3006 01:43:37,141 --> 01:43:39,978 WILL CONTINUE TO BE THE KIND OF 3007 01:43:39,978 --> 01:43:42,947 TOOLS THAT WE NEED TO SEE HOW 3008 01:43:42,947 --> 01:43:45,984 THESE NEW DRUGS THAT HAVE IMPACT 3009 01:43:45,984 --> 01:43:47,719 ON METABOLIC PATHWAYS CAN BE 3010 01:43:47,719 --> 01:43:49,687 USED IN HIV. 3011 01:43:49,687 --> 01:43:52,623 AS WE MOVE FORWARD. 3012 01:43:52,623 --> 01:43:54,826 THE PARTNERS AREN'T THAT 3013 01:43:54,826 --> 01:43:55,793 DIFFERENT FOR EVERYTHING ELSE WE 3014 01:43:55,793 --> 01:43:58,429 DO. 3015 01:43:58,429 --> 01:44:00,765 BUT THE INSTITUTES AT NIH WILL 3016 01:44:00,765 --> 01:44:01,432 BE ABSOLUTELY CRITICAL AS WE 3017 01:44:01,432 --> 01:44:08,239 MOVE FORWARD. 3018 01:44:08,239 --> 01:44:09,974 SO IN TERMS OF CHALLENGES AND 3019 01:44:09,974 --> 01:44:11,142 FUTURE DIRECTS, WE REALLY NEED 3020 01:44:11,142 --> 01:44:12,777 TO BE ABLE TO WORK WITH 3021 01:44:12,777 --> 01:44:13,678 DEVELOPING BETTER REGIMENS THAT 3022 01:44:13,678 --> 01:44:16,681 ARE SAFER AND EASIER TO 3023 01:44:16,681 --> 01:44:18,783 TOLERATE, LONG-ACTING REGIMENS 3024 01:44:18,783 --> 01:44:22,153 THAT DON'T NECESSARILY HAVE A 3025 01:44:22,153 --> 01:44:24,622 SIGNIFICANT RISK OF RESISTANCE 3026 01:44:24,622 --> 01:44:26,157 THE WAY RILPIVIRINE DOES, SO 3027 01:44:26,157 --> 01:44:29,227 WE'RE HOPEFUL THAT MERCK HAS 3028 01:44:29,227 --> 01:44:32,263 SOME LONG-ACTING AGENTS COMING 3029 01:44:32,263 --> 01:44:37,635 FORWARD, WE HAVE LEN, MAYBE, 3030 01:44:37,635 --> 01:44:40,238 JUST MAYBE IF THE MOON GETS 3031 01:44:40,238 --> 01:44:44,809 RIGHT, GILEAD AND VEVE CAN GET 3032 01:44:44,809 --> 01:44:45,910 TOGETHER AND FIGURE OUT HOW TO 3033 01:44:45,910 --> 01:44:46,944 SPEAK TO EACH OTHER. 3034 01:44:46,944 --> 01:44:48,813 WE'LL SEE HOW THAT GOES. 3035 01:44:48,813 --> 01:44:50,181 BUT WE REALLY WILL NEED TO 3036 01:44:50,181 --> 01:44:52,283 CONTINUE TO WORK ON DEVELOPING 3037 01:44:52,283 --> 01:44:53,684 LONG-ACTING AND SUSTAINED 3038 01:44:53,684 --> 01:44:56,087 RELEASE FOR GLOBAL USE. 3039 01:44:56,087 --> 01:45:00,425 WHAT WOULD REALLY HELP IS IF WE 3040 01:45:00,425 --> 01:45:02,527 HAD ACCESS TO ASSAYS. 3041 01:45:02,527 --> 01:45:04,262 THINK ABOUT THE NUMBER OF COVID 3042 01:45:04,262 --> 01:45:05,563 TESTS, WE'VE ALL TAKEN 3043 01:45:05,563 --> 01:45:07,065 COLLECTIVELY IN THIS ROOM OVER 3044 01:45:07,065 --> 01:45:08,599 THE PAST THREE OR FOUR YEARS, IF 3045 01:45:08,599 --> 01:45:11,002 WE HAD A POINT OF CARE 3046 01:45:11,002 --> 01:45:12,303 DIAGNOSTIC OR A HAND-BASED 3047 01:45:12,303 --> 01:45:14,172 DIAGNOSTIC THAT COULD GIVE YOU 3048 01:45:14,172 --> 01:45:15,773 VIRAL LOAD, I MEAN, THAT WOULD 3049 01:45:15,773 --> 01:45:17,742 BE SUCH A HUGE STEP FORWARD FOR 3050 01:45:17,742 --> 01:45:21,512 CURE AS WELL AS FOR HIV THEIR 3051 01:45:21,512 --> 01:45:22,046 TICS. 3052 01:45:22,046 --> 01:45:24,315 WE HAVE TOOLS COMING FORWARD TO 3053 01:45:24,315 --> 01:45:27,718 MONITOR ADHERENCE THROUGH HAIR 3054 01:45:27,718 --> 01:45:30,988 AND URINE. 3055 01:45:30,988 --> 01:45:32,957 WE REALLY NEED TO CONTINUE TO 3056 01:45:32,957 --> 01:45:35,426 IMPROVE THERAPEUTIC OPTIONS FOR 3057 01:45:35,426 --> 01:45:37,295 PREGNANT PEOPLE AND FOR CHILDREN 3058 01:45:37,295 --> 01:45:40,465 SO THEY GET TO A PLACE THAT 3059 01:45:40,465 --> 01:45:43,167 THEY'RE ON PAR WITH NON-PREGNANT 3060 01:45:43,167 --> 01:45:45,136 ADULTS, AND REALLY SEEK TO 3061 01:45:45,136 --> 01:45:48,106 OPTIMIZE LONG-ACTING FOR 3062 01:45:48,106 --> 01:45:48,406 PEDIATRICS. 3063 01:45:48,406 --> 01:45:51,342 THAT WOULD BE SUCH A GAME 3064 01:45:51,342 --> 01:45:52,009 CHANGER, PARTICULARLY WHEN YOU 3065 01:45:52,009 --> 01:45:57,148 GET INTO ADOLESCENCE. 3066 01:45:57,148 --> 01:45:58,015 WHERE YOU HAVE KIDS THAT JUST 3067 01:45:58,015 --> 01:45:59,317 DON'T WANT TO TAKE THEIR MEDS 3068 01:45:59,317 --> 01:46:04,122 ANYMORE. 3069 01:46:04,122 --> 01:46:05,523 WE NEED TO REALLY THINK 3070 01:46:05,523 --> 01:46:07,625 CAREFULLY ABOUT HOW WE USE 3071 01:46:07,625 --> 01:46:08,159 BNABs. 3072 01:46:08,159 --> 01:46:09,727 THIS GENERATION OF BNABs THAT 3073 01:46:09,727 --> 01:46:14,031 WE CURRENTLY HAVE, BUT BNABs 3074 01:46:14,031 --> 01:46:15,233 LIKE THE ONES TED SHOWED TODAY, 3075 01:46:15,233 --> 01:46:16,834 THERE ARE MORE OF THESE IN THE 3076 01:46:16,834 --> 01:46:18,803 PIPELINE THAT WILL REALLY 3077 01:46:18,803 --> 01:46:22,640 NEUTRALIZE 95, 97, 99% OF ALL 3078 01:46:22,640 --> 01:46:24,375 VIRUSES CIRCULATING. 3079 01:46:24,375 --> 01:46:26,444 CD4IG REMAINS THE GOLD STANDARD. 3080 01:46:26,444 --> 01:46:27,879 WE NEED TO BE ABLE TO FIGURE OUT 3081 01:46:27,879 --> 01:46:31,015 HOW TO USE CD4IG AND THAT WILL 3082 01:46:31,015 --> 01:46:33,117 PROBABLY REQUIRE GENE THERAPY TO 3083 01:46:33,117 --> 01:46:37,255 GET US TO THAT POINT. 3084 01:46:37,255 --> 01:46:38,656 THROUGH BEHAVIORAL AND SOCIAL 3085 01:46:38,656 --> 01:46:39,857 SCIENCE, UNDERSTAND ADHERENCE 3086 01:46:39,857 --> 01:46:41,492 CHALLENGES AND HOW BEST TO 3087 01:46:41,492 --> 01:46:43,361 MANAGE THOSE, AND IMPROVE 3088 01:46:43,361 --> 01:46:44,662 IMPLEMENTATION AT SCALE THROUGH 3089 01:46:44,662 --> 01:46:48,299 PARTNERSHIPS. 3090 01:46:48,299 --> 01:46:49,700 UNDER CURE, REALLY, THIS IS 3091 01:46:49,700 --> 01:46:51,135 ABOUT UNDERSTANDING -- I THINK 3092 01:46:51,135 --> 01:46:52,537 THERE'S A STRONG BASIC SCIENCE 3093 01:46:52,537 --> 01:46:52,904 COMPONENT HERE. 3094 01:46:52,904 --> 01:46:54,138 WE REALLY NEED TO UNDERSTAND 3095 01:46:54,138 --> 01:46:57,441 WHAT THE BIOLOGY IS ASSOCIATED 3096 01:46:57,441 --> 01:47:00,144 WITH MAINTAINING THE RESERVOIR 3097 01:47:00,144 --> 01:47:03,414 IN THE STRUCTURE OF WHERE THAT 3098 01:47:03,414 --> 01:47:05,516 LATENT CD4 CELL, WHAT ARE THE 3099 01:47:05,516 --> 01:47:06,918 SURROUNDING STROMA THAT KEEP 3100 01:47:06,918 --> 01:47:08,986 THAT CELL NOURISHED AND KEEP IT 3101 01:47:08,986 --> 01:47:10,388 ALIVE AND KEEP IT EITHER 3102 01:47:10,388 --> 01:47:12,356 PROTECTED FROM T CELLS OR KEEP 3103 01:47:12,356 --> 01:47:14,525 IT IN A STATE THAT MAKES IT EASY 3104 01:47:14,525 --> 01:47:17,595 FOR TO ACTIVATE AND RESPOND. 3105 01:47:17,595 --> 01:47:22,266 SO THE RESERVOIR ISN'T JUST ONE 3106 01:47:22,266 --> 01:47:24,769 CELL, IT ISN'T AN ENVIRONMENT, 3107 01:47:24,769 --> 01:47:27,538 THE WAY CANCER IS NOT A SINGLE 3108 01:47:27,538 --> 01:47:28,773 CELL BUT IT IS IN THE TISSUE AND 3109 01:47:28,773 --> 01:47:30,575 THE WAY THE CANCER EXPLOITS THE 3110 01:47:30,575 --> 01:47:32,076 TISSUE TO ITS OWN BENEFIT. 3111 01:47:32,076 --> 01:47:34,045 WE REALLY NEED TO UNDERSTAND, 3112 01:47:34,045 --> 01:47:35,046 THAT'S NOT A GOAL OF THE 3113 01:47:35,046 --> 01:47:35,479 NETWORK. 3114 01:47:35,479 --> 01:47:36,914 THE GOAL OF THE NETWORK IS TO 3115 01:47:36,914 --> 01:47:38,649 REALLY COME UP WITH STRATEGIES 3116 01:47:38,649 --> 01:47:41,485 THAT WILL UNDERSTAND THE BIOLOGY 3117 01:47:41,485 --> 01:47:43,454 AND DEVELOP WAYS OF ERADICATING 3118 01:47:43,454 --> 01:47:47,058 THE REPLICATION CONFIDENT 3119 01:47:47,058 --> 01:47:48,693 RESERVOIR AND/OR CONTROL REBOUND 3120 01:47:48,693 --> 01:47:51,429 IN THE ABSENCE OF ANTIRETROVIRAL 3121 01:47:51,429 --> 01:47:52,496 THERAPY. 3122 01:47:52,496 --> 01:47:55,132 AND HERE THE PEDS GROUP WITH 3123 01:47:55,132 --> 01:47:56,734 P1115 HAS REALLY BEEN AT THE 3124 01:47:56,734 --> 01:47:59,036 CUTTING EDGE WITH GETTING A 3125 01:47:59,036 --> 01:48:02,540 COHORT TO APPOINT WHERE THEY 3126 01:48:02,540 --> 01:48:04,442 COULD UNDERGO A SUBSTANTIAL 3127 01:48:04,442 --> 01:48:06,544 EXPLORATION OF STRUCTURED 3128 01:48:06,544 --> 01:48:08,946 TREATMENT INTERRUPTIONS IN 3129 01:48:08,946 --> 01:48:09,380 CHILDREN. 3130 01:48:09,380 --> 01:48:14,952 MAYBE WE LOST EVERYBODY ONLINE, 3131 01:48:14,952 --> 01:48:17,021 BUT -- DID WE LOSE THE ZOOM 3132 01:48:17,021 --> 01:48:17,455 LINK? 3133 01:48:17,455 --> 01:48:17,989 NO? 3134 01:48:17,989 --> 01:48:18,856 I'LL KEEP GOING THEN. 3135 01:48:18,856 --> 01:48:21,492 BUT REALLY, THIS IS A CHALLENGE 3136 01:48:21,492 --> 01:48:25,763 FOR US AS WE GO FORWARD. 3137 01:48:25,763 --> 01:48:27,965 AND IMPACT ON ACTG WILL BE THE 3138 01:48:27,965 --> 01:48:29,333 LEAD, BUT REALLY THIS IS GOING 3139 01:48:29,333 --> 01:48:30,434 TO REQUIRE THE COLLABORATORIES 3140 01:48:30,434 --> 01:48:31,636 AND OTHER GROUPS TO BE 3141 01:48:31,636 --> 01:48:33,371 CONTINUING TO DEVELOP REALLY 3142 01:48:33,371 --> 01:48:36,641 NOVEL STRATEGIES THAT CAN MOVE 3143 01:48:36,641 --> 01:48:38,809 FORWARD INTO ADVANCED CLINICAL 3144 01:48:38,809 --> 01:48:43,948 STUDIES. 3145 01:48:43,948 --> 01:48:47,652 SOSO I TALKED ABOUT THE NEED TO 3146 01:48:47,652 --> 01:48:49,420 REALLY IDENTIFY AND CHARACTERIZE 3147 01:48:49,420 --> 01:48:50,488 RESERVOIRS, WE NEED TO DEVELOP 3148 01:48:50,488 --> 01:48:51,122 STRATEGIES. 3149 01:48:51,122 --> 01:48:52,757 WE NEED TO THINK ABOUT MODIFYING 3150 01:48:52,757 --> 01:48:54,191 BNABs SO THEY HAVE THE 3151 01:48:54,191 --> 01:48:55,126 APPROPRIATE FC FUNCTIONS AS WELL 3152 01:48:55,126 --> 01:49:00,931 AS OTHER LEVELS OF ABILITY TO 3153 01:49:00,931 --> 01:49:02,133 NEUTRALIZE VIRUS BECAUSE RIGHT 3154 01:49:02,133 --> 01:49:04,402 NOW, EVEN THE BEST COCKTAIL DOES 3155 01:49:04,402 --> 01:49:07,505 NOT NEUTRALIZE ALL THREE -- 3156 01:49:07,505 --> 01:49:08,472 ANTIBODIES DO NOT NEUTRALIZE ALL 3157 01:49:08,472 --> 01:49:10,675 THE VIRUSES, SO WHY WOULD YOU 3158 01:49:10,675 --> 01:49:14,578 START WITH A -- FROM A 3159 01:49:14,578 --> 01:49:17,214 PERSPECTIVE OF THAT YOU'RE UNDER 3160 01:49:17,214 --> 01:49:18,849 100%, WE HAVE DRUGS THAT ARE 3161 01:49:18,849 --> 01:49:20,284 UNDER 100% EFFECTIVE AT BLOCKING 3162 01:49:20,284 --> 01:49:20,718 VIRUS. 3163 01:49:20,718 --> 01:49:22,320 WHY WOULD WE START GIVING 3164 01:49:22,320 --> 01:49:23,187 ANTIBODIES TO PEOPLE IF WE 3165 01:49:23,187 --> 01:49:24,188 ALREADY KNOW THAT THERE'S GOING 3166 01:49:24,188 --> 01:49:26,223 TO BE RESISTANCE THAT WILL 3167 01:49:26,223 --> 01:49:29,293 EMERGE OR THAT THERE WILL BE A 3168 01:49:29,293 --> 01:49:30,961 UNBOUND FRACTION THAT WILL NOT 3169 01:49:30,961 --> 01:49:34,999 BE NEUTRALIZED BY THOSE 3170 01:49:34,999 --> 01:49:35,299 ANTIBODIES. 3171 01:49:35,299 --> 01:49:39,704 AND WE NEED TO ALSO DO SOME WORK 3172 01:49:39,704 --> 01:49:41,238 IN TAILORING CURATIVE STRATEGIES 3173 01:49:41,238 --> 01:49:42,273 AT THE INDIVIDUAL LEVEL, JUST TO 3174 01:49:42,273 --> 01:49:43,307 SEE WHAT WILL WORK AND WHAT 3175 01:49:43,307 --> 01:49:45,843 WON'T. 3176 01:49:45,843 --> 01:49:47,144 WE NEED TO DEVELOP A PIPELINE, 3177 01:49:47,144 --> 01:49:50,348 CONTINUE TO DEVELOP A PIPELINE, 3178 01:49:50,348 --> 01:49:50,848 IN ADVANCE. 3179 01:49:50,848 --> 01:49:52,116 THESE COMBINATIONS OF STRATEGIES 3180 01:49:52,116 --> 01:49:54,151 AS THEY COME ALONG INTO ADULTS 3181 01:49:54,151 --> 01:49:56,854 AND CHILDREN AS RAPIDLY AS 3182 01:49:56,854 --> 01:49:58,022 FEASIBLE. 3183 01:49:58,022 --> 01:49:59,590 AND ALSO FOCUS ON THE EQUITY 3184 01:49:59,590 --> 01:50:00,791 QUESTION HERE. 3185 01:50:00,791 --> 01:50:04,061 HOW CAN WE MAKE SURE THAT THE 3186 01:50:04,061 --> 01:50:06,664 POPULATIONS MOST IN NEED HAVE 3187 01:50:06,664 --> 01:50:09,200 EQUAL ACCESS, NOT JUST BASED ON 3188 01:50:09,200 --> 01:50:10,601 GEOGRAPHY BUT ALSO BASED ON 3189 01:50:10,601 --> 01:50:12,636 LIFESPAN. 3190 01:50:12,636 --> 01:50:14,739 AND WE NEED TO ALSO THEN AS I 3191 01:50:14,739 --> 01:50:18,109 WAS SAYING BEFORE, LINK CURE TO 3192 01:50:18,109 --> 01:50:19,543 PREVENTION OF VERTICAL 3193 01:50:19,543 --> 01:50:20,211 TRANSMISSION ACTIVITIES. 3194 01:50:20,211 --> 01:50:22,413 I THINK THIS IS GOING TO BE A 3195 01:50:22,413 --> 01:50:25,015 REALLY IMPORTANT ACTIVITY FOR US 3196 01:50:25,015 --> 01:50:26,784 GOING FORWARD TO USE THE TOOLS 3197 01:50:26,784 --> 01:50:31,355 AND TECHNOLOGIES OF HIV 3198 01:50:31,355 --> 01:50:35,526 PREVENTION TO CREATE A WAY OF 3199 01:50:35,526 --> 01:50:36,494 SIGNIFICANTLY REDUCING THE 3200 01:50:36,494 --> 01:50:39,330 NUMBER OF BABIES BORN WITH HIV, 3201 01:50:39,330 --> 01:50:41,399 BUT THEN MAKE SURE THAT WE DO 3202 01:50:41,399 --> 01:50:44,135 OUR BEST TO TAKE THOSE CHILDREN, 3203 01:50:44,135 --> 01:50:48,172 GET THEM ON ANTIRETRO VIRAL 3204 01:50:48,172 --> 01:50:50,574 THERAPY, THROUGH THE CARES 3205 01:50:50,574 --> 01:50:51,776 SYSTEMS, MAINTAIN THEM IN CARE 3206 01:50:51,776 --> 01:50:55,613 BUT ALSO, IF APPROPRIATE, OFFER 3207 01:50:55,613 --> 01:50:56,914 THOSE PARENTS THE OPPORTUNITY 3208 01:50:56,914 --> 01:50:57,982 FOR RESEARCH TO HELP THEIR 3209 01:50:57,982 --> 01:50:58,249 CHILDREN. 3210 01:50:58,249 --> 01:51:00,284 SO WITH THAT, I'LL PAUSE. 3211 01:51:00,284 --> 01:51:03,654 THAT WAS REALLY GRANULAR, AND I 3212 01:51:03,654 --> 01:51:05,623 REALIZE I TALKED A HECK OF A LOT 3213 01:51:05,623 --> 01:51:06,824 LONGER TO YOU THAN I NORMALLY 3214 01:51:06,824 --> 01:51:08,526 DO, BUT I THOUGHT IT WAS 3215 01:51:08,526 --> 01:51:09,326 IMPORTANT FOR YOU TO SEE SOME OF 3216 01:51:09,326 --> 01:51:10,861 THE BACKGROUND THAT WE'RE 3217 01:51:10,861 --> 01:51:13,697 THINKING ABOUT IN TERMS OF 3218 01:51:13,697 --> 01:51:15,466 STRATEGIES AND APPROACHES AS WE 3219 01:51:15,466 --> 01:51:17,735 GO FORWARD. 3220 01:51:17,735 --> 01:51:19,303 SO QUESTIONS, PLEASE. 3221 01:51:19,303 --> 01:51:21,672 >> SHOULD WE START ONLINE AND 3222 01:51:21,672 --> 01:51:23,974 SEE IF THERE'S ANYONE ON ZOOM 3223 01:51:23,974 --> 01:51:31,081 WITH A QUESTION? 3224 01:51:31,081 --> 01:51:32,483 OKAY. 3225 01:51:32,483 --> 01:51:33,584 LET'S JUST COME AROUND. 3226 01:51:33,584 --> 01:51:34,685 I THINK THERE WILL BE LOTS OF 3227 01:51:34,685 --> 01:51:40,257 QUESTIONS. 3228 01:51:40,257 --> 01:51:43,227 FLEURN 3229 01:51:43,227 --> 01:51:45,496 >> SO THANKS, CARL. 3230 01:51:45,496 --> 01:51:47,131 I APPRECIATED THE GRANULARITY, 3231 01:51:47,131 --> 01:51:48,866 AND I FEEL LIKE YOU HAVE THE 3232 01:51:48,866 --> 01:51:50,301 HARDEST TIME SLOTS TODAY, RIGHT 3233 01:51:50,301 --> 01:51:51,068 AFTER LUNCH AND AT THE END OF 3234 01:51:51,068 --> 01:51:53,804 THE DAY. 3235 01:51:53,804 --> 01:51:55,372 WHAT I WANTED TO ASK ABOUT WAS 3236 01:51:55,372 --> 01:51:55,873 TWO THINGS. 3237 01:51:55,873 --> 01:51:59,376 IT SOUNDS LIKE FROM THE 2017 3238 01:51:59,376 --> 01:52:01,679 PLAN, ONE LESSON THAT YOU HAVE 3239 01:52:01,679 --> 01:52:03,547 LEARNED IS THINKING ABOUT MAYBE 3240 01:52:03,547 --> 01:52:05,583 SOME OF THOSE TARGETS WERE 3241 01:52:05,583 --> 01:52:08,319 AMBITIOUS BECAUSE WE DIDN'T 3242 01:52:08,319 --> 01:52:10,087 FULLY UNDERSTAND THE 3243 01:52:10,087 --> 01:52:11,455 FOUNDATIONAL ELEMENTS WE NEEDED 3244 01:52:11,455 --> 01:52:12,456 TO UNDERSTAND SO IT'S GOING BACK 3245 01:52:12,456 --> 01:52:13,891 TO BASICS IN SOME WAYS. 3246 01:52:13,891 --> 01:52:16,393 SO I JUST WANTED TO CONFIRM IF 3247 01:52:16,393 --> 01:52:17,895 THAT'S RIGHT, IF I'M GETTING IT. 3248 01:52:17,895 --> 01:52:19,964 AND THE SECOND THING WAS WITH 3249 01:52:19,964 --> 01:52:21,632 HIV CURE RESEARCH, YOU TALKED 3250 01:52:21,632 --> 01:52:23,133 ABOUT GOING IN TO CHILDREN AS 3251 01:52:23,133 --> 01:52:26,403 RAPIDLY AS FEASIBLE. 3252 01:52:26,403 --> 01:52:28,372 OBVIOUSLY WITH VERY EARLY 3253 01:52:28,372 --> 01:52:29,707 ANTIRETROVIRAL THERAPY THAT MADE 3254 01:52:29,707 --> 01:52:30,908 SENSE AND THAT WAS IMPORTANT, I 3255 01:52:30,908 --> 01:52:33,277 THINK THERE'S THIS QUESTION 3256 01:52:33,277 --> 01:52:35,145 ABOUT WHEN IT IS ETHICALLY 3257 01:52:35,145 --> 01:52:36,146 ACCEPTABLE TO TEST SOME OF THESE 3258 01:52:36,146 --> 01:52:38,582 CURE STRATEGIES IN CHILDREN, 3259 01:52:38,582 --> 01:52:41,252 GIVEN SOME OF THEM ARE QUITE 3260 01:52:41,252 --> 01:52:43,554 TOXIC AND HAVE ART, SO I'M 3261 01:52:43,554 --> 01:52:44,555 CURIOUS WHAT YOU THINK ABOUT 3262 01:52:44,555 --> 01:52:45,055 THAT. 3263 01:52:45,055 --> 01:52:48,259 IS IT THE RIGHT TIME OR IS THERE 3264 01:52:48,259 --> 01:52:49,894 STILL SOME NEED FOR TESTING OR 3265 01:52:49,894 --> 01:52:50,761 ARE THERE CERTAIN APPROACHES 3266 01:52:50,761 --> 01:52:53,597 THAT YOU THINK MIGHT BE KIND OF 3267 01:52:53,597 --> 01:52:55,332 READY TO BRING IN TO YOUNGER 3268 01:52:55,332 --> 01:52:56,534 POPULATIONS NOW? 3269 01:52:56,534 --> 01:53:03,374 >> SO THINK THE PEW TEE OF BEAUF 3270 01:53:03,374 --> 01:53:05,109 WORKING WITH IMPACT IS THEY 3271 01:53:05,109 --> 01:53:07,177 REALLY GOOD AT CONSULTATION, AND 3272 01:53:07,177 --> 01:53:08,279 THINK THE VISION OF FEASIBILITY 3273 01:53:08,279 --> 01:53:10,347 HAS TO TAKE INTO ACCOUNT THE 3274 01:53:10,347 --> 01:53:11,448 SAFETY COMPONENT OF THAT. 3275 01:53:11,448 --> 01:53:15,920 BUT THE IDEA IS, LET'S THINK IN 3276 01:53:15,920 --> 01:53:21,191 A WAY THAT WE'RE -- WE HAVE A 3277 01:53:21,191 --> 01:53:22,826 GOAL, AND I WOULD LIKE TO THINK 3278 01:53:22,826 --> 01:53:25,563 ABOUT WE'RE NOT PROTECTING 3279 01:53:25,563 --> 01:53:26,630 PEOPLE FROM RESEARCHMENT I 3280 01:53:26,630 --> 01:53:29,800 REALLY WOULD LIKE TO GET AWAY 3281 01:53:29,800 --> 01:53:31,569 FROM THAT PARADIGM, BUT WE'RE 3282 01:53:31,569 --> 01:53:33,203 ENGAGING PEOPLE IN THE 3283 01:53:33,203 --> 01:53:34,838 OPPORTUNITY OF RESEARCH, WE'RE 3284 01:53:34,838 --> 01:53:38,042 PROVIDING THE APPROPRIATE 3285 01:53:38,042 --> 01:53:39,243 EDUCATION TO THE PROVIDER, TO 3286 01:53:39,243 --> 01:53:42,813 THE PERSON GIVING THE INFORMED 3287 01:53:42,813 --> 01:53:45,883 CONSENT. 3288 01:53:45,883 --> 01:53:47,418 SO THE PARENT OR PERSON OFFERING 3289 01:53:47,418 --> 01:53:51,722 THE REBEINGOFFERED THE RESEARCHE 3290 01:53:51,722 --> 01:53:52,389 THEIR DECISION. 3291 01:53:52,389 --> 01:53:54,291 THAT'S WHAT I MEAN BY FEASIBLE. 3292 01:53:54,291 --> 01:53:55,960 I THINK THE MORE WE CAN GET TO 3293 01:53:55,960 --> 01:53:56,794 THE SENSE OF WE'RE NOT 3294 01:53:56,794 --> 01:53:58,329 PROTECTING YOU FROM RESEARCH, 3295 01:53:58,329 --> 01:54:00,731 WHETHER IT'S THE SPECIAL 3296 01:54:00,731 --> 01:54:02,366 POPULATION -- I MEAN, JEANIE 3297 01:54:02,366 --> 01:54:04,668 TALKED ABOUT IT TODAY, IN 3298 01:54:04,668 --> 01:54:06,837 PREGNANCY, CAN WE EXPAND THE 3299 01:54:06,837 --> 01:54:08,672 TYPES OF STUDIES WE'RE DOING IN 3300 01:54:08,672 --> 01:54:09,239 PREGNANCY? 3301 01:54:09,239 --> 01:54:11,408 YES, THERE WILL BE DRUGS THAT 3302 01:54:11,408 --> 01:54:14,678 HAVE NO BUSINESS GOING IN TO 3303 01:54:14,678 --> 01:54:16,447 PREGNANT PEOPLE OR INTO 3304 01:54:16,447 --> 01:54:17,314 CHILDREN, BECAUSE THEY DON'T 3305 01:54:17,314 --> 01:54:19,283 HAVE A SAFETY PROFILE. 3306 01:54:19,283 --> 01:54:20,918 BUT ONCE THERE'S A SAFETY 3307 01:54:20,918 --> 01:54:24,722 PROFILE ASSOCIATED WITH THAT 3308 01:54:24,722 --> 01:54:26,490 DRUG, WE NEED TO HAVE THE 3309 01:54:26,490 --> 01:54:27,391 CONVERSATION. 3310 01:54:27,391 --> 01:54:31,962 ULTIMATELY THE FDA IS GU GOING O 3311 01:54:31,962 --> 01:54:34,898 HAVE A SAY IN THIS TOO. 3312 01:54:34,898 --> 01:54:36,900 >> I THINK I AGREE WITH YOU 3313 01:54:36,900 --> 01:54:38,836 COMPLETELY ABOUT THE IDEA OF 3314 01:54:38,836 --> 01:54:41,905 PROTECTING PEOPLE THROUGH 3315 01:54:41,905 --> 01:54:44,341 RESEARCH AS APPROPRIATE, AND AS 3316 01:54:44,341 --> 01:54:45,309 ANNIE AND COLLEAGUES HAVE 3317 01:54:45,309 --> 01:54:46,710 ARGUED, AND I THINK A LOT OF THE 3318 01:54:46,710 --> 01:54:48,245 TERMINOLOGY THEY USE IS SORT OF 3319 01:54:48,245 --> 01:54:49,113 RESPONSIBLE INCLUSION, RIGHT, 3320 01:54:49,113 --> 01:54:53,050 THAT YOU THINK ABOUT HOW DO YOU 3321 01:54:53,050 --> 01:54:55,119 BRING PEOPLE IN WHEN IT'S RIGHT, 3322 01:54:55,119 --> 01:54:56,553 AND WITH PREGNANT PEOPLE IN 3323 01:54:56,553 --> 01:54:57,421 PARTICULAR, THEY ARE MAKING 3324 01:54:57,421 --> 01:54:58,722 THEIR OWN DECISIONS IN MANY 3325 01:54:58,722 --> 01:55:00,691 WAYS, SO THEY ARE -- THE IDEA OF 3326 01:55:00,691 --> 01:55:01,892 THEM AS VULNERABLE DOESN'T 3327 01:55:01,892 --> 01:55:02,626 REALLY MAKE SENSE. 3328 01:55:02,626 --> 01:55:05,029 SO I'M COMPLETELY ON BOARD 3329 01:55:05,029 --> 01:55:05,462 THERE. 3330 01:55:05,462 --> 01:55:08,098 I THINK WHEN IT COMES TO 3331 01:55:08,098 --> 01:55:09,833 PEDIATRIC RESEARCH, PART OF THE 3332 01:55:09,833 --> 01:55:12,670 CHALLENGE IS WE HAVE THIS RE 3333 01:55:12,670 --> 01:55:14,338 REGULATORY SYSTEM AND WE HAVE 3334 01:55:14,338 --> 01:55:15,439 PROXY CONSENT WHERE SOMEBODY 3335 01:55:15,439 --> 01:55:16,607 ELSE IS MAKING DECISIONS FOR 3336 01:55:16,607 --> 01:55:16,874 CHILDREN. 3337 01:55:16,874 --> 01:55:18,108 SO I THINK YOU'RE ABSOLUTELY 3338 01:55:18,108 --> 01:55:19,243 RIGHT TO BE LOOKING FORWARD TO 3339 01:55:19,243 --> 01:55:22,079 WHEN THE TIME IS RIGHT TO OFFER 3340 01:55:22,079 --> 01:55:23,280 THOSE OPPORTUNITIES TO CHILDREN 3341 01:55:23,280 --> 01:55:24,715 BUT WE STILL HAVE TO DO IT 3342 01:55:24,715 --> 01:55:28,752 WITHIN THE RISK/BENEFIT RATIOS 3343 01:55:28,752 --> 01:55:30,087 THAT HAVE BEEN DETERMINED TO BE 3344 01:55:30,087 --> 01:55:31,355 APPROPRIATE FOR KIDS WHEN 3345 01:55:31,355 --> 01:55:32,623 THEY'RE NOT THE ONES MAKING -- 3346 01:55:32,623 --> 01:55:33,991 >> THAT'S ONE OF THE THINGS I 3347 01:55:33,991 --> 01:55:39,263 REALLY LOVED ABOUT P1115, IS THE 3348 01:55:39,263 --> 01:55:42,199 GOAL WAS GET THE NEWBORN ON THE 3349 01:55:42,199 --> 01:55:44,501 BEST DRUGS, THE BEST 3350 01:55:44,501 --> 01:55:46,904 ANTIRETROVIRALS AS SOON AS 3351 01:55:46,904 --> 01:55:47,871 POSSIBLE. 3352 01:55:47,871 --> 01:55:48,305 THAT'S CARE. 3353 01:55:48,305 --> 01:55:49,606 AND THAT'S APPROPRIATE. 3354 01:55:49,606 --> 01:55:52,676 BUT THEN AS THAT CHILD GROW, 3355 01:55:52,676 --> 01:55:55,946 YOU'VE DONE SOMETHING TO CHECK 3356 01:55:55,946 --> 01:55:57,715 THE EXPANSION OF THE RESERVOIR 3357 01:55:57,715 --> 01:56:00,451 HOPEFULLY, AS LONG AS THEY STAY 3358 01:56:00,451 --> 01:56:03,821 VIRALLY SUPPRESSED, AND THE WAY 3359 01:56:03,821 --> 01:56:04,922 DR. PRASAD SET THAT WHOLE STUDY 3360 01:56:04,922 --> 01:56:06,223 UP WAS A SERIES OF GATES. 3361 01:56:06,223 --> 01:56:09,093 BUT WITH BETTER DRUGS, MORE KIDS 3362 01:56:09,093 --> 01:56:10,360 WILL FLOW THROUGH THOSE GATES 3363 01:56:10,360 --> 01:56:12,930 AND GET TO A POINT WHERE THE 3364 01:56:12,930 --> 01:56:17,835 PARENTS CAN GET COMFORTABLE WITH 3365 01:56:17,835 --> 01:56:19,036 THIS KIND OF AN APPROACH. 3366 01:56:19,036 --> 01:56:20,170 SO THAT'S THE KIND OF -- AND 3367 01:56:20,170 --> 01:56:23,307 THAT'S WHY I THINK THIS LINKAGE 3368 01:56:23,307 --> 01:56:27,010 TO DELIVERY OF -- THROUGH 3369 01:56:27,010 --> 01:56:28,979 IMPLEMENTATION SCIENCE, BETTER 3370 01:56:28,979 --> 01:56:30,614 PREVENTION AND TREATMENT 3371 01:56:30,614 --> 01:56:33,250 STRATEGIES TO PREGNANT PEOPLE, 3372 01:56:33,250 --> 01:56:34,451 WHETHER THEY'RE LIVING WITH HIV 3373 01:56:34,451 --> 01:56:35,953 OR VULNERABLE TO HIV WILL BE 3374 01:56:35,953 --> 01:56:37,121 REALLY AN IMPORTANT WAY OF 3375 01:56:37,121 --> 01:56:41,892 KEEPING THE EDUCATION GOING FOR 3376 01:56:41,892 --> 01:56:43,093 THESE FAMILIES AS THEY GO 3377 01:56:43,093 --> 01:56:48,999 FORWARD. 3378 01:56:48,999 --> 01:56:52,803 >> RAVI? 3379 01:56:52,803 --> 01:56:54,671 >> THANK YOU I WOULD AGREE THE 3380 01:56:54,671 --> 01:56:55,539 GRANULARITY WAS HELPFUL. 3381 01:56:55,539 --> 01:56:57,241 IT WAS GREAT THAT YOU FOCUSED ON 3382 01:56:57,241 --> 01:56:58,842 THIS OPPORTUNITY FOR PREGNANT 3383 01:56:58,842 --> 01:57:01,011 PEOPLE AND PREVENTION STRATEGIES 3384 01:57:01,011 --> 01:57:05,516 TO THEN FEED A CURE AGENDA, 3385 01:57:05,516 --> 01:57:07,217 WITHIN THAT POPULATION, BUT THEN 3386 01:57:07,217 --> 01:57:08,118 I THINK THERE'S ALSO AN 3387 01:57:08,118 --> 01:57:09,553 OPPORTUNITY TO CONTINUE 3388 01:57:09,553 --> 01:57:15,025 SYNERGIES AMONG ADULTS OR NOT 3389 01:57:15,025 --> 01:57:17,528 PERINATAL -- PERINATALLY 3390 01:57:17,528 --> 01:57:18,729 ACQUIRED SITUATIONS WHERE THE 3391 01:57:18,729 --> 01:57:22,099 PREVENTION NETWORKS AND THEIR 3392 01:57:22,099 --> 01:57:24,868 FAILURES FOR LACK OF A BETTER 3393 01:57:24,868 --> 01:57:26,703 WORD HAVING SMALL RESERVOIRS 3394 01:57:26,703 --> 01:57:31,642 POTENTIALLY AS YOU KNOW, CURRENT 3395 01:57:31,642 --> 01:57:36,346 ACTGHPGN COLLABORATION AND THAT 3396 01:57:36,346 --> 01:57:38,115 CAN BE BROKERED IN A WAY THAT 3397 01:57:38,115 --> 01:57:40,617 WILL FEED THE CURE AGENDA MORE 3398 01:57:40,617 --> 01:57:40,984 COLLABORATIVELY? 3399 01:57:40,984 --> 01:57:42,252 >> I REALLY LIKE THAT IDEA, 3400 01:57:42,252 --> 01:57:43,787 BEING ABLE TO CAPTURE PEOPLE -- 3401 01:57:43,787 --> 01:57:46,757 CAPTURE IS THE WRONG WORD -- 3402 01:57:46,757 --> 01:57:56,266 IDENTIFY PEOPLE THAT ARE NEWLY 3403 01:57:56,266 --> 01:57:59,303 CONVERTED IS AN IDEAL GOAL. 3404 01:57:59,303 --> 01:58:00,737 GOOD LOOK WITH THAT WITH YOUR 3405 01:58:00,737 --> 01:58:00,904 CAB. 3406 01:58:00,904 --> 01:58:02,172 >> MORE ABOUT THAT LATER. 3407 01:58:02,172 --> 01:58:04,007 >> BUT I ALSO DON'T WANT TO POKE 3408 01:58:04,007 --> 01:58:05,342 A BEAR THAT'S BEEN ADDRESSED 3409 01:58:05,342 --> 01:58:06,410 NUMEROUS TIMES IN THIS AND 3410 01:58:06,410 --> 01:58:07,644 PROBABLY OTHER SETTINGS BUT WHAT 3411 01:58:07,644 --> 01:58:09,479 IS THE CURRENT THINKING OF THE 3412 01:58:09,479 --> 01:58:10,914 DIVISION IN TERMS OF PREVENTION 3413 01:58:10,914 --> 01:58:12,983 PRODUCTS THAT DON'T OFFER 3414 01:58:12,983 --> 01:58:18,689 SYSTEMIC AND ONLY COMPARTMENTAL 3415 01:58:18,689 --> 01:58:21,625 OBLIGATION MOVING FORWARD, 3416 01:58:21,625 --> 01:58:22,626 PARTICULARLY AS WE SORT OF 3417 01:58:22,626 --> 01:58:24,261 INCORPORATE A PERHAPS EXPANDED 3418 01:58:24,261 --> 01:58:25,028 LENS ABOUT CHOICE? 3419 01:58:25,028 --> 01:58:28,398 >> WELL, WE ARE MOVING FORWARD 3420 01:58:28,398 --> 01:58:31,268 WITH A RECTAL DOUCHE, I THINK 3421 01:58:31,268 --> 01:58:32,669 THAT WILL BE AN IMPORTANT STUDY 3422 01:58:32,669 --> 01:58:41,211 TO SEE HOW TRULY EMBRACED SAID 3423 01:58:41,211 --> 01:58:42,980 PRODUCT IS, ARE THERE BE A 3424 01:58:42,980 --> 01:58:44,615 COMPANY WOULD'S WILLING TO BACK 3425 01:58:44,615 --> 01:58:46,683 TO TAKE IT FORWARD. 3426 01:58:46,683 --> 01:58:48,318 I THINK THE ISSUE REALLY COMES 3427 01:58:48,318 --> 01:58:50,220 DOWN TO HOW YOU GET A PRODUCT 3428 01:58:50,220 --> 01:58:53,924 LIKE THE LOGISTICS ON GETTING A 3429 01:58:53,924 --> 01:58:57,194 PRODUCT LIKE THAT APPROVED OR 3430 01:58:57,194 --> 01:58:57,961 FORMIDABLE. 3431 01:58:57,961 --> 01:59:01,231 IF YOUR COMPARATOR GROUP IS 3432 01:59:01,231 --> 01:59:05,068 EITHER INJECTABLE CABOTEGRAVIR, 3433 01:59:05,068 --> 01:59:06,169 OR LEN. 3434 01:59:06,169 --> 01:59:08,672 SO, I MEAN, WHAT YOU WENT 3435 01:59:08,672 --> 01:59:13,377 THROUGH IS AN ACTIVE CONTROL, 3436 01:59:13,377 --> 01:59:14,678 BUT YOU ALL DID IT RIGHT. 3437 01:59:14,678 --> 01:59:17,214 YOU ACTUALLY PROVIDED 3438 01:59:17,214 --> 01:59:21,451 APPROPRIATE COUNSELING TO THE 3439 01:59:21,451 --> 01:59:24,755 PEOPLE WHO WERE IN BOTH ARMS SO 3440 01:59:24,755 --> 01:59:25,956 THAT THEY KNEW THEY SHOULD BE 3441 01:59:25,956 --> 01:59:29,226 TAKING THEIR MEDICATIONS. 3442 01:59:29,226 --> 01:59:33,297 AND THE STUDIES DEMONSTRATED 3443 01:59:33,297 --> 01:59:39,503 RELATIVELY GOOD EFFECTIVENESS OF 3444 01:59:39,503 --> 01:59:42,339 ORAL TDFFTC BUT THE INJECTABLE 3445 01:59:42,339 --> 01:59:45,542 WAS STILL BETTER FOR BOTH 3446 01:59:45,542 --> 01:59:46,176 STUDIES. 3447 01:59:46,176 --> 01:59:49,913 I REALLY -- I DESPAIR ABOUT 3448 01:59:49,913 --> 01:59:51,882 BRINGING FORWARD SOMETHING THAT 3449 01:59:51,882 --> 01:59:56,920 ISN'T -- DOESN'T PROTECT AT THE 3450 01:59:56,920 --> 01:59:57,554 SAME LEVEL. 3451 01:59:57,554 --> 02:00:00,090 I MEAN, WE HAVE CONDOMS. 3452 02:00:00,090 --> 02:00:02,059 AND CONDOMS WOULD BE GREAT FOR 3453 02:00:02,059 --> 02:00:04,127 PREVENTING ALL STIs, BUT THEY 3454 02:00:04,127 --> 02:00:05,963 HAVE AN EFFECTIVENESS RANGE OF 3455 02:00:05,963 --> 02:00:10,500 ZERO TO 100, RIGHT? 3456 02:00:10,500 --> 02:00:13,203 SO IF YOU THEN THROW INTO THAT A 3457 02:00:13,203 --> 02:00:18,575 TOPICAL, IT'S LIKE I DON'T SEE 3458 02:00:18,575 --> 02:00:19,876 THE POINT, FRANKLY. 3459 02:00:19,876 --> 02:00:21,311 ONE OTHER THING IS, WHAT SHOULD 3460 02:00:21,311 --> 02:00:22,646 THE FEDERAL GOVERNMENT SPEND ITS 3461 02:00:22,646 --> 02:00:25,882 MONEY ON? 3462 02:00:25,882 --> 02:00:29,186 AND I THINK CHOICE THAT IS 3463 02:00:29,186 --> 02:00:30,587 EFFECTIVE WOULD BE THE IDEAL 3464 02:00:30,587 --> 02:00:33,757 THING TO SPEND OUR MONEY ON. 3465 02:00:33,757 --> 02:00:35,859 I'LL JUST LEAVE IT AT THAT. 3466 02:00:35,859 --> 02:00:37,160 SO THERE'S -- I'M SURE WE'LL 3467 02:00:37,160 --> 02:00:38,261 HAVE MORE DISCUSSIONS ABOUT 3468 02:00:38,261 --> 02:00:46,269 THIS. 3469 02:00:46,269 --> 02:00:46,903 >> THANKS. 3470 02:00:46,903 --> 02:00:47,904 WE'RE GOING TO KEEP GOING AROUND 3471 02:00:47,904 --> 02:00:48,572 THE ROOM. 3472 02:00:48,572 --> 02:00:49,873 OKAY. 3473 02:00:49,873 --> 02:00:52,042 >> CARL, YOU HAD A SLIDE THAT 3474 02:00:52,042 --> 02:00:54,244 TALKED ABOUT PARTNERSHIPS AND 3475 02:00:54,244 --> 02:00:57,848 PREVENTION, HAD A LOT OF PRIVATE 3476 02:00:57,848 --> 02:00:59,316 NGOs, SO FORTH, YOU HAD U.S. 3477 02:00:59,316 --> 02:01:01,585 GOVERNMENT ORGANIZATIONS, 3478 02:01:01,585 --> 02:01:03,420 PEPFAR, USAID, CDC. 3479 02:01:03,420 --> 02:01:06,923 I THOUGHT A GLARING ABSENCE 3480 02:01:06,923 --> 02:01:10,994 THERE WAS FDA, SO I'M WONDERING 3481 02:01:10,994 --> 02:01:12,629 WHETHER FIRST OF ALL THAT'S 3482 02:01:12,629 --> 02:01:13,730 INTENTIONAL, WHETHER THE FDA 3483 02:01:13,730 --> 02:01:15,699 NEEDS TO BE KEPT AT ARM'S LENGTH 3484 02:01:15,699 --> 02:01:17,367 BECAUSE OF THEIR UNIQUE ROLE, 3485 02:01:17,367 --> 02:01:19,870 WHETHER THEY'RE NOT -- I MEAN, 3486 02:01:19,870 --> 02:01:22,172 FDA IS BY NO MEANS MONOLITHIC. 3487 02:01:22,172 --> 02:01:24,908 THERE'S A TREMENDOUS DIFFERENCE 3488 02:01:24,908 --> 02:01:28,412 IN PHILOSOPHY BETWEEN A QUITE 3489 02:01:28,412 --> 02:01:30,047 FORWARD LOOKING DIAGNOSTIC 3490 02:01:30,047 --> 02:01:31,348 BRANCH BOTH OF WHICH ARE 3491 02:01:31,348 --> 02:01:32,649 INCREDIBLY IMPORTANT HERE, SO 3492 02:01:32,649 --> 02:01:34,618 JUST THOUGHTS ABOUT THAT IN 3493 02:01:34,618 --> 02:01:34,851 GENERAL. 3494 02:01:34,851 --> 02:01:39,322 >> SO I WILL ADMIT THAT THAT WAS 3495 02:01:39,322 --> 02:01:41,191 A GLARING OMISSION, BECAUSE THE 3496 02:01:41,191 --> 02:01:47,964 ROLE I SEE FOR FDA IS ONE OF AN 3497 02:01:47,964 --> 02:01:50,067 ADVISORY OR REGULATORY BODY THAT 3498 02:01:50,067 --> 02:01:50,700 BASICALLY LOOKS AT THE WORK 3499 02:01:50,700 --> 02:01:52,235 THAT'S GOING ON AND PASSES 3500 02:01:52,235 --> 02:01:52,769 JUDGMENT ON IT. 3501 02:01:52,769 --> 02:01:56,073 I DON'T SEE THAT AS A 3502 02:01:56,073 --> 02:01:58,809 COLLABORATIVE EVENT. 3503 02:01:58,809 --> 02:02:01,545 ALTHOUGH I THINK THERE ARE 3504 02:02:01,545 --> 02:02:04,714 OPPORTUNITIES WHERE WE COULD 3505 02:02:04,714 --> 02:02:06,583 ENGAGE THEM IN WAYS THAT MAYBE 3506 02:02:06,583 --> 02:02:10,620 I'M NOT THINKING AS WELL AS I 3507 02:02:10,620 --> 02:02:11,388 SHOULD ABOUT THIS. 3508 02:02:11,388 --> 02:02:12,722 >> I'D JUST ENCOURAGE YOU TO 3509 02:02:12,722 --> 02:02:14,558 THINK ABOUT THAT. 3510 02:02:14,558 --> 02:02:16,293 AGAIN, BEING FAIRLY CLOSE TO THE 3511 02:02:16,293 --> 02:02:18,495 DIAGNOSTIC SIDE WHERE I'D SAY 3512 02:02:18,495 --> 02:02:20,063 YOU KIND OF FEEL LIKE YOU'RE 3513 02:02:20,063 --> 02:02:22,566 SHOUTING INTO THE WIND VERSUS 3514 02:02:22,566 --> 02:02:24,201 THE -- THANK YOU -- VERSUS THE 3515 02:02:24,201 --> 02:02:26,837 THERAPEUTIC BRANCH THAT ACTUALLY 3516 02:02:26,837 --> 02:02:27,938 COMES TO CONFERENCES AND SAYS IF 3517 02:02:27,938 --> 02:02:29,339 YOU WANT TO HAVE A GENE THERAPY 3518 02:02:29,339 --> 02:02:30,740 APPROVED, THIS IS WHAT WE THINK 3519 02:02:30,740 --> 02:02:32,409 YOU NEED TO SHOW, THAT'S 3520 02:02:32,409 --> 02:02:33,510 INCREDIBLY USEFUL TO THE FIELD. 3521 02:02:33,510 --> 02:02:34,077 >> AGREED. 3522 02:02:34,077 --> 02:02:35,679 >> AND ACTUALLY, GETTING A SENSE 3523 02:02:35,679 --> 02:02:40,383 THAT THEY'RE LISTENING IS VERY 3524 02:02:40,383 --> 02:02:41,184 ENCOURAGING TO THE FIELD AS 3525 02:02:41,184 --> 02:02:41,384 WELL. 3526 02:02:41,384 --> 02:02:44,354 SO I THINK IT'S WORTH THINKING 3527 02:02:44,354 --> 02:02:47,290 ABOUT HOW THE INDEPENDENCE OF 3528 02:02:47,290 --> 02:02:49,159 THAT ULTIMATE JUDGMENT CAN BE 3529 02:02:49,159 --> 02:02:52,329 MAINTAINED, BUT STILL THE ENTIRE 3530 02:02:52,329 --> 02:02:53,430 ENTERPRISE BE FACILITATED. 3531 02:02:53,430 --> 02:02:55,632 BECAUSE I THINK THAT'S 3532 02:02:55,632 --> 02:02:55,932 EVERYBODY -- 3533 02:02:55,932 --> 02:02:57,033 >> I TAKE YOUR POINT AND I WILL 3534 02:02:57,033 --> 02:03:00,103 ADD THE FDA TO MY SLIDES. 3535 02:03:00,103 --> 02:03:00,770 THANK YOU. 3536 02:03:00,770 --> 02:03:01,838 THAT'S A REALLY IMPORTANT POINT. 3537 02:03:01,838 --> 02:03:03,173 >> CARL, I WAS JUST GOING TO ADD 3538 02:03:03,173 --> 02:03:04,708 THAT WE DO HAVE PARTNERSHIPS 3539 02:03:04,708 --> 02:03:06,476 WITH THE FDA IN CERTAIN 3540 02:03:06,476 --> 02:03:09,513 CIRCUMSTANCES WHERE THEY NEED 3541 02:03:09,513 --> 02:03:11,281 OUR HELP AND VICE VERSA SO THEY 3542 02:03:11,281 --> 02:03:16,753 CAME ACTUALLY TO THE ACTG FOR 3543 02:03:16,753 --> 02:03:19,356 HELP WITH -- IN THE STOMP TRIAL 3544 02:03:19,356 --> 02:03:20,790 AND THEN WE ALSO CONSULTED WITH 3545 02:03:20,790 --> 02:03:23,093 THEM VERY REGULARLY ON ACTIVE 3546 02:03:23,093 --> 02:03:24,628 2 DURING THE COVID PANDEMIC TO 3547 02:03:24,628 --> 02:03:27,130 GET THEIR EVOLVING ADVICE ON 3548 02:03:27,130 --> 02:03:28,031 CLINICAL END POINTS IN THAT 3549 02:03:28,031 --> 02:03:30,100 TRIAL, AND I THINK IN THE PAST 3550 02:03:30,100 --> 02:03:33,069 THEY'VE HAD REALLY VALUABLE 3551 02:03:33,069 --> 02:03:38,208 INPUT ON DESIGN ADVICE, WHEN 3552 02:03:38,208 --> 02:03:40,410 WE'RE TALKING ABOUT 3553 02:03:40,410 --> 02:03:41,845 COUNTERFACTUALS AND ALTERNATIVES 3554 02:03:41,845 --> 02:03:42,712 TO PLACEBOS. 3555 02:03:42,712 --> 02:03:46,850 SO IT'S A DIFFERENT TYPE OF 3556 02:03:46,850 --> 02:03:48,385 PARTNERSHIP, PARTNERS WHO ARE 3557 02:03:48,385 --> 02:03:49,452 BRINGING INTERVENTIONS, 3558 02:03:49,452 --> 02:03:50,587 DEVELOPING IN THE CASE OF 3559 02:03:50,587 --> 02:03:53,657 COMPANIES, BUT THEY ARE VALUABLE 3560 02:03:53,657 --> 02:04:00,363 PARTNERS. 3561 02:04:00,363 --> 02:04:01,898 >> ANY ADDITIONAL QUESTIONS? 3562 02:04:01,898 --> 02:04:05,502 CARL? 3563 02:04:05,502 --> 02:04:08,338 >> SO IF YOU HAVE THOUGHTS THAT 3564 02:04:08,338 --> 02:04:09,873 OCCUR TO YOU AND YOU WANT TO 3565 02:04:09,873 --> 02:04:13,476 WRITE, YOU CAN WRITE DIRECTLY TO 3566 02:04:13,476 --> 02:04:15,145 ME, OR YOU CAN PUT THEM IN ON 3567 02:04:15,145 --> 02:04:15,912 THE WEBSITE. 3568 02:04:15,912 --> 02:04:17,847 I'D LOVE YOUR FEEDBACK, AND THIS 3569 02:04:17,847 --> 02:04:20,383 REMAINS A WORK IN PROGRESS. 3570 02:04:20,383 --> 02:04:24,221 AND YOU'LL SEE A VERSION OF THIS 3571 02:04:24,221 --> 02:04:25,622 PROBABLY IN MORE TRUNCATED FORM 3572 02:04:25,622 --> 02:04:29,359 IN JANUARY AS WE GET READY TO 3573 02:04:29,359 --> 02:04:32,295 ASK YOUR APPROVAL FOR THE SIZE 3574 02:04:32,295 --> 02:04:33,930 AND SCOPE OF WHAT WE'RE MOVING 3575 02:04:33,930 --> 02:04:35,599 FORWARD WITH THE NETWORK. 3576 02:04:35,599 --> 02:04:38,768 SO THANK YOU. 3577 02:04:38,768 --> 02:04:40,937 >> THANK YOU. 3578 02:04:40,937 --> 02:04:42,372 AND I'LL REMIND EVERYONE THE 3579 02:04:42,372 --> 02:04:44,874 NEXT MEETING IS JANUARY 27TH. 3580 02:04:44,874 --> 02:04:48,044 IT WILL BE VIRTUAL AS CARL 3581 02:04:48,044 --> 02:04:49,813 MENTIONED, AND I THINK WE CAN 3582 02:04:49,813 --> 02:04:50,680 ADJOURN THE MEETING. 3583 02:04:50,680 --> 02:05:00,991 THANKS, EVERYONE.